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1. Abstract: 
Secondary lymphoid organs (SLOs), including lymph nodes, tonsils and Peyer’s patches, 
contain highly organised microenvironments in which adaptive and innate immune cells 
interact with stromal fibroblasts. It is within these organs that germinal centres (GCs) form; 
structures that function to permit the development of high affinity antigen-specific humoral 
immune responses. Follicular dendritic cells (FDCs) and B cells are the cells primarily 
responsible for driving formation and function of the GC. 
B cells scan FDC stromal cell networks for antigen complement complexes bound to the 
CD21 receptor through the complement component C3dg. CD21 is expressed on both cell 
types, permitting transfer of antigen complexes from B cells to FDCs where it is retained and 
presented permitting antigen-specific B cell activation and initiating a cyclical cycle of 
selection and expansion leading to high affinity antibody selection. Human FDCs are 
reported to express a long isoform of the CD21 receptor (CD21L), whereas B cells express a 
short isoform (CD21S). In this thesis I utilised a flow cytometry-based assay to investigate 
the different potential mechanism of CD21 isoform function in B cells and FDCs; revealing 
that FDC express a significantly higher number of CD21 molecules on their cell surface and 
provide evidence that this may be a mechanism of antigen transfer between the two cells 
types. 
CD21 and the complement pathway, including C3 and its derivatives, have been implicated 
in autoimmune diseases, including Rheumatoid Arthritis (RA). Soluble CD21 (sCD21) 
concentration is consistently decreased within the serum of RA patients compared with age-
matched healthy control samples. Here I show that lower sCD21 concentrations correlate 
with increased disease phenotype. Additionally, I show that sCD21 can block C3dg complex 
binding to peripheral B cells and consequently prevent co-activation through the CD19/CD21 
complex on the surface of B cells. Together these results suggest a role for sCD21 in 
suppressing human immune responses. 
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7. Introduction 
Development of high affinity adaptive immune responses take place within the highly 
organised and specialised secondary lymphoid organs (SLOs) including spleen, Peyer’s 
patches and lymph nodes (LN). These lymph and blood filtration organs provide the 
microenvironment to both drive robust adaptive immune responses including antibody-
mediated (humoral) and cellular mediated immune responses producing cytokines and for 
cytotoxic lymphocytes to help clear and prevent infection as well as accelerating tissue 
repair. It is the unique structure and function of these lymphoid tissues that coordinate the 
dynamics and efficiency of immune responses and control the cellular chorography required 
to drive antigen specific immune responses. Deficiencies in key cell types and proteins 
required for normal formation, structure and function of lymphoid tissues leads to formation 
of chronic inflammatory disease, T cell mediated immunity and humoral deficiency, 
highlighting the critical importance of secondary lymphoid organs in normal health and 
homeostasis of the immune system.  
7.1 Secondary lymphoid organs 
Formation of primary B cell follicles occurs independently of antigen; their main components 
are recirculating B cells that are recruited and retained within a network of follicular dendritic 
cells (FDCs) (Howard et al., 1972). Follicles develop in humans during the second trimester 
of foetal life, and FDCs become apparent within a few days of the formation of B cell clusters 
(Timens et al., 1987). In mice, SLOs development occurs between embryonic days 13.5 and 
18.5, with B cell follicles forming within 72hr during post-natal development with B cells 
initially forming a donut like structure (Randall et al., 2008).  
Secondary follicles contain lymphoid cells that are not actively involved in antigen-driven 
processes. However, once these cells become activated, an enhanced adaptive immune 
response can occur. This can occur as a result of three different mechanisms and, in certain 
circumstances, these may coexist. These are; the formation of germinal centres to select for 
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high affinity B cells, the proliferation of memory B blasts within the follicles and follicular 
proliferation in response to T cell-independent antigens which is independent of germinal 
centre reaction and involves low affinity IgM responses. The focus of this thesis will be on 
the germinal centre reaction and the cells within this structure.  
Within the SLO, there are three main stromal cell populations; follicular dendritic cells 
(FDCs), fibroblast reticular cells (FRCs) and marginal reticular cells (MRCs). FRCs 
contribute to the structure and function of the T-cell zone and MRCs are important for the 
function and structure of the marginal zone (MZ) (den Haan et al., 2012). FDCs are 
important for maintenance of B cell follicle structure, antigen presentation to B cells and 
homeostasis of naïve T cells through the production of survival factors. These cells and 
processes are discussed in more detail below.  
The structure of the lymph node is essential to its proper function. Within the lymph node 
there are three separate regions named the cortex, the paracortex, and the medulla, all 
encompassed in the subcapsular sinus. The outer most layer, the cortex, contains B cells, 
macrophages and follicular cells, arranged into primary follicles. The cortex is the area in 
which B cell follicles are found and in which germinal centre development occurs. The 
paracortex is the second most outer layer, containing T cells, dendritic cells and fibroblast 
reticular cells (FRCs). FRCs support prolonged interactions between the T cells and 
dendritic cells within this compartment and form a conduit network permitting small antigens 
to enter into the paracortex and cortical structures of the LN. The medulla is the inner layer 
of the lymph node and is made from lymphatic tissue named medullary cords. These tissues 
are separated by spaces filled with lymph drained from the medullary sinuses. The vascular 
network of the LN consists of high endothelial venules (HEV), through which T and B cells 
enter the organ from the blood. The lymphatic vessels of the lymph node are lined by 
lymphatic endothelial cells (LECs) (Burrell et al., 2011).  
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Figure 7. 1: Structure of the human Lymph node 
 
 
 
 
 
 
 
 
 
Lymph node structure is essential to its function. The cortex contains B cell follicles and the 
paracortex contains B cells, dendritic cells and Fibroblast reticular cells. The medulla is the inner 
layer of the lymph node and is made from lymphatic tissue name medullary cords. The vascular 
network of the LN consists of high endothelial venules, as well as other lympathic vessels, 
supplying the organ with nutrients and allowing the movement of cell types in and out of the 
organ. (Figure adapted from 
https://www.open.edu/openlearn/ocw/mod/oucontent/view.php?id=65373&extra=thumbnailfi
gure_idp794560) 
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7.1.2 The structure of the spleen 
The spleen is surrounded by a capsule that extends many projections into the interior to form 
a compartmentalised structure. The spleen has two compartments, the red and the white 
pulp, and a marginal zone that separates the compartments. A network of sinusoids, 
populated by macrophages and red blood cells, makes up the red pulp compartments and 
the white pulp forms a periarteriolar lymphoid sheath (PALS) populated by T cells. In this 
structure, the B cell follicles form next to the PALS. Interestingly, separation of splenic red 
and white pulp occurs before birth in a Lymphotoxin-αβ-independent (LT) manner 
(Vondenhoff et al., 2008). LT is not detected on B cells until 4 days after birth, therefore 
prenatal development of the white pulp of the spleen occurs in the absence of LT. Postnatal 
development, however, involves an influx of T cells and depends on LTαβ expression by B 
cells (Vondenhoff et al., 2008). The outer boundary of the white pulp is defined by the 
marginal sinus and its associated with a layer of FRC and MOMA-1 staining metallophilic 
macrophages (Burrell et al., 2011).  
7.1.3 The role of Lymphotoxin in Secondary Lymphoid Organ 
development 
Lymphotoxin-β is a member of the TNF family that forms a heteromeric complex with 
Lymphotoxin-α on the cell surface (Browning et al., 1993). It can exist in two forms, a 
secreted homotrimer, LTα3, or a membrane bound heterotrimer, LTα1β2. The membrane 
bound complex is expressed on the surface of activated T and B cells and has a key role in 
B cell follicle formation.  
This molecule, along with other molecules of the same family, has been implemented in the 
induction of lymphoid organ development and has been shown to induce expression of 
adhesion molecules VCAM1, ICAM1, E-selectin and MAdCAM1 by murine endothelial cells 
(Cuff et al., 1998); a potential mechanism leading to LT-dependent organ development. Mice 
deficient in LT have abnormal development of lymphoid organs; animals were shown to have 
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no morphologically detectable lymph nodes or Peyer’s patches, although development of the 
thymus appeared to be normal in this study (De Togni et al., 1994). Histology revealed that 
normal segregation of B and T cells failed to develop within the spleen of these mice. 
Studies have also shown LT-/- mice develop lymph nodes upon treatment with agonist anti-
LTβR antibody; induction of signalling through the LT receptor mediated lymph node genesis 
(Rennert et al., 1998). In contrast, normal mice treated with anti-LTβ lacked lymph nodes, 
further confirming the essential role for LT in SLO development. 
7.1.4 Embryonic SLO formation 
The stromal cells within the SLOs develop as part of a network. During prenatal 
development, retinoic acid induces lymphoid tissue organiser cells to produce CXCL13, 
attracting lymphoid tissue inducer cells (LTi cells) to the sites where lymph nodes are to form 
(van de Pavert et al., 2009). However, this process is not required for SLO development as 
mice deficient for CXCL13 or its receptor CXCR5 have normal lymph node development. 
Signalling induced by LT on LTβR expressed on LTi cells, induces the expression of 
adhesion molecules, along with various chemokines, promoting the clustering of 
haematopoietic cells, leading to the expansion and differentiation of the stromal network 
(Figure 7.2). 
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(Figure adapted from Kranich et al. 2016) Lymphoid tissue organiser cells line blood vessels at 
places where future lymphoid tissues develop. Lymphoid tissue inducer cells (Lti) express 
membrane bound LTαβ and trigger expansion of organiser cells, along with the upregulation of 
CXCL13. Recruitment of T and B cells providing more LT leads to the induction of MRC, FDC and 
FRC precursors.  
Figure 7. 2: Secondary lymphoid organ and FDC development 
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CXCL13 expression by stroma (FDCs and MRCs) induces the homing of B lymphocytes to 
the B cell follicles. CXCL13 acts as a B cell chemoattractant through the CXCR5 receptors 
expressed on the B cell surface. Transfer experiments showed that B cells derived from the 
bone marrow migrate to the follicles due the expression of this receptor (Parrott et al., 1971). 
CXCR5 is not expressed on pre-B cells but is upregulated in development of immature B 
cells in parallel with other B cell maturation markers such as IgD and CD21 (Forster et al., 
1994); this upregulation leads to acquisition of these cells to the B cell follicles (Cyster et al., 
1997). In vitro studies have demonstrated that the level of CXCL13 present in an area 
directly affects CXCR5 expression on B cells (Cyster et al., 1999). The data from this study 
suggested that the CXCL13 gradient within the follicle was steep and was the first 
investigation to suggest that the protein was associated with the membrane processes of the 
follicular stromal cells. Recently our data (under review, 2019) shows that the gradient of 
CXCL13 is mediated by an ectoenzyme CathepsinB which cleaves the heparin binding 
domain off CXCL13 to induce a soluble gradient (Cosgrove et al., under review, 2019). 
Further studies have shown that CXCR5-deficient mice have disorganised germinal centres, 
the same observation was made within CXCL13-/- mice; these results confirm that CXCL13 
is required for recruitment and retention of B cells in an organised structure within the 
secondary lymphoid organs (Voigt et al., 2000). As with SLO development, LT and Tumour 
necrosis factor (TNF) are also required for B cell follicle development; CXCL13 is reduced 
20-fold in mice deficient in LT and 3-4-fold in TNF-deficient mice (Ngo et al., 1999), due to 
the role of these molecules in FDC development and activation, highlighted by the absence 
of FDCs within this model. Therefore, defective formation of B cell follicles in mice deficient 
in LT or TNF can be, in part, attributed to the reduced expression of CXCL13 (Cyster et al., 
2000). In addition to mediating chemoattraction of B cells to the follicle, CXCL13 also 
induces upregulation of LT by B cells; resulting in increased CXCL13 expression due to 
increased FDC activation by the greater concentration of LT available (Ansel et al., 2000). 
These observations were made by using gene-targeted mice, deficient for CXCL13 or 
CXCR5. Wild-type B cell transfer to CXCR5-/- mice showed that LT upregulation only occurs 
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once the cells are within the follicular areas where CXCL13 is present and not in non-
lymphoid organs; showing that B cells upregulate LT as they migrate to B cell follicles in 
response to CXCL13. In further support of these findings, it has been shown that ectopic 
expression of BLC induces B cell-dependent and LT-dependent lymphoid neogenesis 
(Mebius et al., 1997), expression of ectopic CXCL13 in the pancreas likewise lead to neo-
lymphoid tissue genesis (Luther et al., 2000). These data conclude that establishment of a 
positive feedback loop between CXCL13 and LT expression is important in B cell follicle 
development and homeostasis but it is unclear if these processes are simply regulated by 
positioning or as a result of CXCR5 GPCR signalling independent of its role in cellular 
motility.   
7.1.5 FDC development 
While FDCs are essential for the maintenance of B cells within the germinal centre, B cells 
have an essential role in FDC development and maintenance by providing TNF and 
lymphotoxin (LT), showing a mutual dependence of the two cell types within SLOs. LT has 
also been shown to have roles in the development of the SLOs, discussed above. Both TNF 
and lymphotoxin (LT) are essential for the key steps in the differentiation and induction of 
FDC function (Rogni et al., 1994). Pre-FDC development requires LTβR but not TNFR1 
signalling and FDC maturation strictly requires B cells expressing LTαβ (Krautler et al., 
2013). Further to these observations, the disruption of the LT pathway in adult mice leads to 
defects in FDC and GC development, whereas disruption of the TNF pathway does not. 
Disruption of this pathway affects mice during gestation; confirming that both the TNF and 
LT pathways must be functional to allow for mature splenic FDC networks to form (Mackay 
et al., 1997). Studies have also shown that lymphoid organs lacking B cells, TNF or LT are 
devoid of FDCs (Allen et al., 2008), highlighting the essential functions of these factors in 
FDC development. Mice deficient in TNF and LT were also shown to lack polarised B cell 
follicles in the spleen and experiments within the same study revealed that treatment of 
wildtype (wt.) mice with agonists against LT receptor leads to decreased CXCL13 
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expression (Ngo et al., 1999). Together these data show that LT and TNF have a role 
upstream of CXCL13 expression in the process of follicle formation; this role is known to be 
in FDC development which then produce CXCL13, subsequently allowing polarisation of B 
cells within the follicle. Adoptive transfer of functional CD19+ B cells in CD19-deficient mice 
rescued GC formation and FDC activation, further confirming that FDC activation required 
the CD19-dependent upregulation of LT on activated B cells (Myers et al., 2013). In addition 
to the initial generation of FDCs, sustained LT signalling has been shown as essential for 
maintenance of FDCs in a differentiated and functional state (Mackay et al., 1997). 
Transcriptome analysis highlighted down-regulation of key functional genes in FDCs upon 
treatment with anti-LTβR treatment (Huber et al., 2005). For example, clusterin is down-
regulated upon LTβR signalling suppression, suggesting this protein has a role as an FDC-
derived trophic factor for GC B cells.  
Compiling all that is known about FDC development, a three-stage development for FDCs 
has been suggested; LTβR signalling induces the development of FDC precursors in the 
marginal zone, TLR4 signalling induces the development of FDCs in the splenic B cell zone 
and TNFR1 signalling elicits the clustering of FDCs accompanied by lymphoid follicle 
formation (Milicevic et al., 2011). In addition to the initial generation of FDCs, sustained LT 
signalling has been shown as essential for maintenance of FDCs in a differentiated and 
functional state (Mackay et al., 1997). LT has also been shown to cause the upregulation of 
FDC derived CXCL13, highlighting its importance for FDC and GC biology (Aguzzi et al., 
2014). FDC activation has also been shown to increase with immune-complex engagement 
of FcγRIB on the FDC cell surface (Shikh et al., 2006); therefore, as immune-complexes are 
delivered to the GC, FDCs can become more activated, ready to influence the GC response 
in a greater manner (Figure 7.3).  
Interestingly, FDCs can also be generated de novo in nonlymphoid organs during chronic 
inflammatory conditions resulting from autoimmune inflammation and follicular lymphoma 
resulting from a combination of inflammatory signals and the persistent presence of antigen 
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can elicit tissue reorganisation into tertiary lymphoid tissues (TLT’s) containing GCs and fully 
differentiated FDCs (Aloisi et al., 2006). As TLT’s can arise almost anywhere in the body, the 
FDC precursor must possess considerable motility or be ubiquitously present in all tissues. 
In a murine model of chronic inflammation, transgenic overexpression of LT lead to the 
formation of TLT’s in kidneys, which contain fully matured FDCs (Mackay et al., 1997). Upon 
treatment with anti-LTβR, mature FDCs were removed and the kidney was transplanted into 
recipient mice. FDCs reformed within these mice, exclusively derived from cells of the 
transplanted donor mouse. These results further suggested that FDC precursor cells are 
tissue-intrinsic. Consistent with these results, it was recently shown using a mouse model of 
TLT formation in the salivary gland that FDCs arise from mesenchymal progenitors in an IL4 
and TNF dependent process (Nayar et al., 2019).  
FDCs were originally, mistakenly, assumed to be a subset of conventional dendritic cells due 
to their location within lymphoid organs and their dendritic like appearance, however FDCs 
are stromal fibroblasts, unlike conventional dendritic cells, which are hematopoietic in origin. 
The origin of FDCs was controversial for some time; gene expression by FDCs was 
compared with that of follicular stromal cells from the spleen of SCID mice, revealing 90% of 
genes are expressed in these cells from the SCID mice (Wilke et al., 2010) suggesting that 
FDCs develop from the residual network of reticular cells and only minor modification in 
gene expression is sufficient for differentiation of precursor cells into mature FDCs. Recent 
data using fate mapping in mice confirmed the origin of FDCs to be mesenchymal, arising 
from the clonal expansion and differentiation of MRCs (Jarjour et al., 2014). This conclusion 
is further supported by data from Melzi et al., 2016, in which it is shown that MRCs, FDCs 
and sinus lining cells can be infected by BTV (an endotheliotropic virus), suggesting a 
common endothelial progenitor for these cell types, as replication of the virus was not 
identified in the stromal cells of the T cell zone (Melzi et al., 2016). FDCs, FRCs and MRCs 
also share the expression of cell surface markers, LTβR, TNFR1, VCAM1 and ICAM1, 
further indicating they are closely related (Cyster et al., 2000). Studies using reporter genes 
30 
 
have shown that these cells all develop from embryonic splenopancreatic mesenchymal 
cells of the NK2x2.5+Islet+ lineage (Castagnaro et al., 2013). Transplantation of these 
mesenchymal cells into mice led to the generation of all lymphoid stromal subsets (FDCs, 
FRCs and MRCs) and de novo lymphoid tissues. Thus, with the help of specific sets of 
hematopoietic cells, these cells types can differentially develop from a common precursor 
cell. Although cells have been shown to develop from a common precursor, a recent study 
has confirmed that cells are distinct in their gene expression after differentiation. Single-cell 
RNA sequencing performed on isolated mouse pLN CD45- CD31- cells revealed nine 
conserved stromal cell clusters when unsupervised clustering was performed on samples 
(Rodda et al., 2018). 
7.1.6 FDCs as the antigen presenters for B cells 
FDCs have a key role in priming high affinity B cell responses through presenting 
unprocessed antigen to B cells during the germinal centre (GC) reaction. Naïve B cells are 
recruited to germinal centres within the first week following administration of antigen and 
recruitment is complete by the time mature germinal centres have developed (Gray et al., 
1986). The germinal centre reaction initiates through rapid B cell scanning of the FDC 
network leading to antigen specific B cells interacting with cognate antigen complexed with 
the C3dg complement component bound to CD21 on FDCs (Figure 7.3).  
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B cells that carry antigen require T cell help, in order to receive this they must first process this 
antigen into a form that can be presented on an MHC class II molecule, which is then recognised 
by the T cell receptor. The germinal centre is split into the light and dark zone. B cells enter the 
dark zone from the follicle after receiving T cell help. B cells undergo somatic hypermutation (SHM) 
of their B cell receptor and proliferation. A CXCL13 gradient then causes the B cells to migrate to 
the light zone and encounter antigen presented on FDC CD21 membrane receptors. High affinity 
interactions between BCR and antigen lead to class switching, plasma cell and memory cell 
production. Interactions of low affinity lead to B cell apoptosis of the B cell. B cell class switching 
occurs with the help of T follicular helper cells (Tfh cell) which make IL21 and promote class 
switching from IgM antibodies to IgA and IgE, therefore creating a more specific secondary 
immune response.  
Figure 7. 3: The germinal centre reaction 
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Cognate B cells with antigen bound by their BCR migrate to the T-B cell boarder of the GC 
where they can be co-stimulated by T cells through CD40-CD40 ligand (CD40L) signalling. B 
cells present processed antigen on MHCII molecules to T cells, recognised by the α/β T cell 
receptor. Processing of antigen by the B cell occurs through the internalisation of the antigen 
bound BCR using clathrin-dependent, BCR-mediated endocytosis (Natkanski et al., 2013). 
MHCII α and β associate with I chain trimers to form nonamers (Blum et al., 2013). These 
complexes are transported to mature endosomes where the I chain is sequentially 
proteolysed to yield the residual I chain fragment, CLIP. The antigen is processed by various 
proteases in order to form a peptide that is able to bind to the ligand binding site in the 
MHCII molecule within late endosomes upon displacement of the CLIP protein. The 
interaction between internalised BCR/antigen with intracellular MHCII has been observed 
using pulldowns and biotin-labelled antigen (Barroso et al., 2015). Surprisingly, a rare (10%) 
conformation of MHCII is the predominant conformer found in complex with the 
BRC/antigen; this form of MHCII has been shown to be highly effective for T cell activation 
(Busman-Sahay et al., 2011). Therefore, it is thought that this conformation may contribute 
to the efficiency of BCR-meditated antigen presentation. The MHCII/peptide complex is then 
transported to the cell surface, but this process has not been delineated in mechanistic detail 
at present (Adler et al., 2017). T cells are then activated by the antigen presenting B cell 
through two signals; the ligating signal through the TCR, provided by the MHCII/peptide 
complex, and a costimulatory signal, in the form of CD28 ligation by B7 molecules expressed 
on the B cell surface (Healy et al., 1998). These signals result in the increased production of 
IL21, IL10 and IFNγ, which subsequently, along with CD40-CD40L interactions, activate the 
B cells (Margry et al., 2013). CD40 has been show to mediate CXCR4 upregulation on B 
cells (Moir et al., 1999); therefore allowing fully activated B cells to migrate into the dark 
zone of the GC supported the CXCL12 chemokine gradient created by fibroblast within this 
site.  
33 
 
Direct evidence of somatic hypermutation and proliferation of B cells within the light zone 
was obtained by the microdissection of germinal centre cells from sections of mice spleen 
undergoing responses to antigen-protein conjugates (Jacob et al., 1991). The cycles of 
proliferation and hypermutation drive class switching and affinity maturation through cyclical 
migration into the light zone to compete for C3dg-immune complexes on FDCs. B cells with 
high affinity receptor (BCR) are selected for antigen specificity, those with the highest 
specificity are activated under antigen limiting conditions and are the cells that receive help 
from T follicular helper cells. These T cells induce the iterative process of proliferation and 
selection of cells, allowing the process of affinity maturation to proceed over days and 
weeks, resulting in dozens of generations of GC B cells (Crotty et al., 2011). T follicular 
helper cells provide stimulatory signals to GC B cells via multiple pathways, including 
CD40L, IL4, IL21, PD-1 and BAFF. B cell division, somatic hypermutation of immunoglobulin 
genes and engagement of T follicular helper cells are directly proportional to the amount of 
antigen captures and presented on MHCII (Gitlin et al., 2014).  Cells then both continue 
cycling and re-enter the dark zone to undergo further proliferation or exit the GC either as 
specialised antibody secreting plasma cells or long-term memory B cells (Heester et al. 
2014). It is this cyclical process allows the selection of high-affinity antibody producing cells. 
Any cells with a low affinity BCR receives death signals from the FDC, resulting in apoptosis. 
There is a high death rate among the B cells within germinal centres due to this selection by 
FDCs. Analysis revealed that half of the cells undergoing apoptosis are located in the basal 
light zone, 25% in the dark zone and 25% in the basal light zone (Hardie et al., 1993).  
Germinal centre B cells have unique phenotypes, expressing high levels of CD38 and low or 
absent levels of CD44 and CD39 (Ling et al., 1987). The level of surface Ig expressed by 
these cells is lower than that expressed by follicular mantle or marginal zone cells (Liu et al., 
1991). Dark zone B cells are characterised by increased expression of CXCR4 protein and 
mRNA, along with upregulation of cell cycle and somatic hypermutation machinery. Light 
zone B cells however, were shown to upregulate CD86 mRNA (CD28 ligand) and protein 
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and display increased transcription of gene programs essential for antigen presentation 
(Victoria et al., 2010). Cell cycle regulator c-Myc was shown to be transiently expressed in 
subsets of GC B cells in the light zone (Calado et al., 2012). This transient expression was 
suggested to initiate downstream regulators, such as AP4, to mediate multiple rounds of 
division and somatic hypermutation in the dark zone. High expression of transcription factor, 
FOXO1 in B cells found in the dark zone, appears to control formation, organisation and 
gene expression; likely working in concert with Bcl6, a regulator of GC B cell function 
(Nurieva et al., 2009). Additionally, the expression of FOXO1 in the light zone suggests an 
initiation program for dark zone entry established during cognate selection.  
High affinity antibody reactions occur due to class-switching of IgM antibodies to IgG, IgA 
and IgE antibodies in a cytokine dependent process. The majority of IgG and IgA production 
in bone marrow is derived from B cells activated in the spleen and peripheral lymph nodes, 
while a high proportion of the IgA-secreting plasma cells of the lamina propria of the gut 
surfaces are activated in Peyer’s patches, or mesenteric lymph nodes (Hall et al., 1977). As 
the life-span of plasma cells in the bone marrow of rats is around 1 month (Ho et al., 1986), 
there must be continued plasma cell production throughout antibody responses that last 
many months.  
7.1.7 Germinal centres develop within SLO’s 
Antigen and inflammatory signals (adjuvant, pathogen products, damaged/modified self-
proteins, e.g. collagen fragments) can drive formation of Germinal Centres (GCs) within the 
B cell follicle. The function of this unique microenvironment is to stimulate high affinity 
antibody responses. This process can occur in both secondary and tertiary immune 
structures including; lymph nodes, spleen, Peyer’s patches, isolated lymphoid follicles and 
tertiary lymphoid tissues. Studies using mice immunised with (4-hydroxy-3-nitrophenyl)acetyl 
revealed the formation of two anatomically and phenotypically distinct zones within GCs in 
direct response to antigen (Jacob et al., 1991). These zones are termed the light and dark 
zone, due the density of B cells found within each section; this was originally observed using 
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histological sections of SLO tissue, in which B cells were described to reside in two 
compartments (MacLennan et al., 1994). The zones are characterised by the presence of 
CXCL13 expressing FDCs in the light zone and CXCL12 expressing stromal fibroblasts in 
the dark zone (Wang et al., 2011). Immunohistological staining of human tonsil follicles 
indicates that further subdivisions can be made within germinal centres on the basis of 
molecules expressed by their constituent cells. B cells in the dark zone are characterised by 
their expression of the cell cycle-associated nuclear antigen Ki67 (Gerdes et al., 1983). 
Whereas, the light zone contains FDCs; identified by their dendritic processes and 
expression of CD21 and I-CAM1. (Hardie et al., 1993). The outer zone, located immediately 
next to the follicular mantle, contains the greatest concentration of T cells in secondary 
follicles, as well as some B cells and plasmacytes (Hardie et al., 1993). As the B cells that 
give rise to GC structures are initially activated outside the follicle by follicular helper T cells 
in T cells zones, the close proximity of T cells in the follicular mantle is highly important in 
this process.  
Upon challenge with adjuvant-antigen complexes, antigen-specific B cell activation initiates 
rapidly (min to a few hours) (Liu et al., 1991). Naive B cells do not respond to antigen 
localised on FDCs but are activated outside follicles by T cells and subsequently migrate to 
B follicles and form germinal centres (Jacob et al., 1992). Congenital deficiency of CD40 
ligand (Van der Eertwegh et al., 1993) and blocking antibodies against CD40 ligand 
(Kortheuer et al., 1993) are associated with an absence of germinal centres. These findings 
are consistent with a requirement for continued T cell presence to maintain germinal centres.  
It was first demonstrated that germinal centre development is oligoclonal using irradiated 
chimeric mice (Kroese et al., 1987), which was further confirmed in human (Kuppers et al., 
1993) by the analysis of the Ig v-region structure in GC B cells. 72hr after antigen encounter, 
between 104 and 1.5x104 antigen-specific B cells are found in the FDC network of each of 
the follicles within immunised rats (Liu et al., 1991). Thymidine-uptake studies found the cell 
cycle time for GC B cells to be 6-7hrs (Zhang et al., 1988). When the light-zone FDC 
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network becomes filled with B cells, the chemokine gradients generated induce B 
lymphocyte migration to one pole of the network to form the dark zone of the germinal 
centre. The chemokine responsible for this was thought to be solely CXCL12, produced by 
marginal reticular cells, however more recently, CCL21, produced by FRCs, has been shown 
to induce larger and more organised infiltrates (Luther et al., 2019); demonstrated through 
the comparison of CCL19 transgenic mice and mice expressing CCL21. This study 
demonstrated that CCL19 and CCL21 induce invasive infiltrates containing predominantly B 
cells and dendritic cells, whereas CXCL12 recruits mainly B cells, dendritic cells and plasma 
cells. Additionally, CCL21 and CCL19 were shown to induce LT expression on naïve CD4 T 
cells whereas CXCL12 failed to do so.  
Thus the physical organisation of the GC is reflective of and intimately tied to its 
spatiotemporal function (Figure 7.4).  
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Figure 7. 4: The germinal centre structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Adapted from https://doi.org/10.1007/3-540-27806-0_607. Germinal centres are found within B cell 
follicles. They are made of the dark zone and the light zone. Expansion and mutation of B cells 
occurs in the dark zone. In the basal light zone, FDCs reside and helper T cells are found in the 
apical light zone. The light and dark zones are surrounded by the mantle zone.  
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7.2 FDCs 
FDCs were originally identified because of their ability to trap immune complexed antigen in 
B cell follicles and their unique dendritic morphology (Aguzzi et al., 2014). Initial 
experiments, using bone marrow chimeras (Humphrey et al., 1984), indicated that FDCs are 
a stromal, radioresistant cell whose main function is the presentation of C3dg-complexed 
antigen to B cells via the CD21 receptor, to recruit and retain B cells to the GC through 
CXCL13 expression and induce B cell survival or apoptosis of autoreactive B cell clones 
(Figure 7.5).  
One common observation in early studies was, even though these cells were phagocytic and 
endocytosed antigen they encountered, some remained presented extracellularly on the 
surface of cells (Miller et al., 1964). Later electron-microscopy studies revealed that antigen 
was associated with the dendritic processes of these cells and that FDCs formed web-like 
structures (Nossal et al., 1968). In 1978, a study further revealed that FDCs have unique 
cellular structures, including large, irregular nuclei, containing little heterochromatin, and only 
few organelles. FDCs only have small cell bodies, while their cytoplasm extends into many 
filiform dendrites, forming an extensive net-like structure within secondary follicles. It was in 
this report that these cells were officially termed FDCs, after many published studies using 
alternative names, due to their long cytoplasmic processes (Chen et al., 1978). 
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7.2.1 The function and phenotype of FDCs 
 Antigen presentation  
An essential role of FDCs is the recruitment of B cells to the light zone of the GC to 
encounter antigen-complexes presented on the cell surface of FDCs upon CD21 receptors 
which ultimately lead to high-affinity antibody responses; therefore, immune-complex 
trapping is the cardinal function of FDCs. Complement containing immune complexes can 
often be formed very early in responses to pathogen due to the alternative or lectin pathway 
of complement activation. These complexes are transported and deposited on FDCs within 
GC light zones (Heesters et al., 2013). FDCs are described as “dynamic antigen libraries” 
and have the ability to retain this antigen for extended time periods. This presentation of 
antigen is essential to GC maintenance, robust B cell somatic hypermutation and the 
promotion of long-term immune memory (Mandel et al., 1980). GC B cells interact with the 
antigen on the surface of FDCs in order to receive survival signals and undergo affinity 
maturation. Antigen-complexed to C3dg are presented and retained on CD21 receptors, 
highly expressed by FDCs (Liu et al., 1997). FDCs preserve antigen by trapping immune 
complexes in recycling endosomal compartments, thereby protecting the antigen from 
degradation, and periodically cycle the antigen-bound CD21 receptors to the cell surface 
(Heesters et al., 2013). CD21 was shown to be essential for humoral immune function by 
many studies, including those that demonstrated blocking CD21 on murine B cells, using a 
blocking antibody, reduces antibody responses (Qin et al., 1998), as this interaction between 
antigen on FDCs and B cells can no longer occur. The importance of CD21 expression was 
further confirmed in studies which expressed human CD21 in CD21-/- mice increases the 
IgG1 titres in these mice, therefore restoring the GC immune response (Marchbank et al., 
2000). The observation of decreased immune responses is due to the inability of FDCs to 
retain antigen when CD21 is not present (Fischer et al., 1998), therefore indicating this 
function of FDCs is of the upmost importance.  
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 B cell migration and GC organisation  
FDCs also have a role in maintenance of the unique microarchitecture of the GC. Within two 
days of FDC ablation, primary follicles lose their homogeneity and become disorganised; this 
study also showed that the removal of FDCs in mice abrogates the GC response and B cells 
do not undergo class switch recombination or make antigen-specific antibodies (Wang et al., 
2011). Therefore, confirming that FDCs are essential for the GC response and maintenance 
of the GC structure.  
The expression of adhesion molecules ICAM1 and VCAM1 have been shown as unessential 
to maintain naïve follicular B cells within the follicle. Disrupting the interaction of these 
molecules with their cognate receptors, αLβ2 and α4β1, respectively, using blocking 
antibodies does not affect the localisation of B cells within the follicles (Lo et al., 2003). Thus, 
it is not this mechanism that makes FDCs essential for the organisation of the GC structure. 
However, mice deficient in stromal CD21/CD35 have reduced T-dependent antibody 
responses, particularly with low doses of antigen (Roozendaal et al., 2007). And as 
discussed above, expression of human CD21 in CD21-/- mice restores humoral immune 
function, increasing IgG1 titres in hCD21+ mice, and was shown to interact with mCD19 on 
the mouse B cells to form the CD19/CD21 complex (Marchbank et al., 2000). This suggests 
that CD21 is an important receptor expressed by FDCs responsible for humoral immune 
responses, although there is no evidence that expression of this receptor has a role in GC 
organisation. 
CXCL13 has been shown to be expressed in FDC-enriched cell preparations (Tjin et al., 
2005), cultured FDC cell lines (Toellner et al., 1995) and FDCs present within inflammation-
induced ectopic lymphoid follicles (Shi et al., 2001). CXCL13 is the chemokine, expressed by 
FDCs, responsible for the migration of B cells to the light zone of the GC and therefore it can 
be presumed that depletion of FDCs from the GC results in disorganisation of the 
microarchitecture due to the loss of CXCL13 expression. CXCL13 signals to B cells through 
the receptor CXCR5 on their cell surface and, among other responses, causes an increase 
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in LT production (Aguzzi et al., 2010). It is known that a direct result of LT on FDCs is 
upregulation of CXCL13 production (Aguzzi et al., 2014); therefore, a feedback loop is 
created between the two cells. CXCL13 has been detected in concentrations as high as 1 
ng/mg of total spleen and lymph node tissue, indicating that local concentrations are likely to 
be highly chemotactically active (Luther et al., 2002). S1PR2, a receptor for chemokine 
sphingosine 1 phosphate (S1P), is upregulated on GC B cells due to the mandatory 
expression of the receptor for entering the GC (Green et al., 2012). S1P has been shown to 
inhibit the attracting effect of CXCL13 on GC B cells and FDCs produce low amounts of this 
molecule compared to other fibroblasts in surrounding tissues. This suggests the S1PR2 
signalling on GC B cells is necessary to actively exclude them from SIP+ areas outside the 
GC; allowing access to CXCL13 producing GC FDCs (Green et al., 2012). Other signalling 
molecules including oxysterol 7a25-dihydroxycholestrol which binds to the GPCR EBI2 
(GPR183) and S-Geranylgeranyl-L-glutathione (GGG) that binds to P2RY8 GPCR guide the 
localisation of B cell in the follicle (Pereira et al., 2009, Lu et al., 2019). Interestingly the 
enzyme gamma-glutamyltransferase-5 (GGT5) is highly expressed by FDCs generating a 
gradient of GGG that costrains B cells to the follicle (Lu et al., 2019).  
 Toll-like receptor expression  
FDCs express Toll like receptors (TLRs), which are known to trigger and shape the adaptive 
immune response to pathogens and stress. FDCs express TLR4 which responds to 
lipopolysaccharide (LPS) from Gram-negative bacteria. Expression of TLR4 is upregulated 
during GC responses, suggesting that FDCs can influence the adaptive immune responses 
through detection of innate immunity ligands (Shikh et al., 2007). Deletion of TLR4 
expression in the stromal compartment results in reduction of GC size and affinity maturation 
is diminished (Garin et al., 2010). In addition to this observation, deletion of downstream 
signalling molecule myeloid differentiation primary response protein 88 (Myd88), abolishing 
TLR4 signalling, or by depleting vitamin A, results in smaller GCs, fewer FDCs and a 
reduced level of IgA antibodies, showing class switch recombination is recurring less 
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frequently and the GC response is reduced. The effects of LPS on FDC activation were 
shown to be TNFR1 independent (Milicevic et al., 2011). Bone marrow chimeric mice that 
lack TLR4 expression on stromal cells, were shown to have lower levels of SHM and high-
affinity antibody production than wt. mice, further suggesting the expression and signalling 
pathways of TLR4 in FDCs is crucial for robust antibody responses (Garin et al., 2010). 
Although there is likely a complex interplay between TLR4 expressing innate immune cells 
that produce inflammatory cytokines and chemokines and the stromal fibroblast populations.  
Additionally, stimulation of FDC expressing TLR2 and TLR4 induced increased expression of 
TGFβ and BAFF, leading to IgA class switching in B cells (Suzuki et al., 2010). This study 
also suggested that TLR signalling may regulate FDC function due to the increase of 
chemokine and adhesion molecule expression upon stimulation with TLR ligands. Mice 
immunised with nanoparticles containing antigen and ligand for TLR4 and TLR7 caused 
sustained GCs that persisted for more than 1.5 years (Kasturi et al., 2011). The presence of 
these ligands enhanced B cell affinity maturation, suggesting that, as FDC expression of 
TLRs is crucial for GC B cell SHM, therefore TLR ligands may cause increased B cell 
responses by directly affecting FDC function.  
Interestingly, FDC activation by TLR ligands may have the capacity to promote autoreactive 
B cell responses (Das et al., 2016). Exposure of FDCs to self-antigen lead to the expression 
of INFα and TLR7 activation. FDCs were shown to have the ability to cycle and present self-
antigen after internalisation through CD21 and further activate TLR7. The IFNα expressed 
by these cells was shown to promote autoreactive B cell survival, therefore this mechanism 
of FDC activation could enhance autoimmune reactions.  
Prevention of autoimmunity and induction of apoptosis in GC B 
cells 
Random gene rearrangements and point mutations as part of the mutagenesis process in 
the GC reaction by B cells can result in these cells becoming self-reactive. FDCs prevent 
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autoimmunity by regulating the clearance of apoptotic GC B cells, of which there are large 
numbers as a result of the evolutionary selection process, as the vast majority of B cells 
within the GC do not achieve high antigen affinity. FDCs control GC B cell survival and show 
highly specialised macrophages, TBMs, which cells to phagocytose, thereby ensuring that 
apoptotic bodies are properly disposed of (Kranich et al., 2008). The protein responsible for 
induction of engulfment of apoptotic germinal centre B cells by TBMs is the secreted 
phosphatidylserine-binding protein milk fat globule epidermal growth factor 8 (Mfge8). 
Splenic Mfge8, in a study using bone marrow chimera transfer between wild-type and Mfge8-
/- mice, was shown to be derived from FDCs. TBMs acquire Mfge8 if they are situated in the 
proximity of Mfge8-expressing FDCs or in the lymph nodes that drain exogenous Mfge8. 
Mfge8-/- mice are seen to have impaired engulfment of GC B cell corpses by TBMs and 
suffer from autoimmunity, confirming that expression of this protein by FDCs is essential to 
facilitate the removal of apoptotic and self-reactive B cells which could lead to disease.  
A mouse model, in which the animals were engineered to conditionally express a 
membrane-bound self-antigen on FDCs, was used to show that self-antigen displayed on 
FDCs can mediate the elimination of self-reactive B cells at the transitional stage within 
SLOs (Yau et al., 2013). This study suggests that long term retention of self-antigen on 
FDCs may be an important function of these cells even under circumstances where the 
exposure to self-antigen is transient. Results from other studies complement these 
observations. It was shown that FDCs had the ability to retain autoantigen-containing 
immune complexes in a study that observed self-reactive IgG-expressing memory B cells 
and plasma cells generation was a by-product of random V gene diversification in the 
germinal centre (Scheid et al., 2011). Additionally, studies in human and mice have shown 
that complement deficiencies are associated with lupus-like symptoms; these symptoms 
were attributed to defects in immune complex removal as well as direct effect on B cell 
selection, therefore allowing the survival of autoreactive B cells (Carroll et al., 2000). Finally, 
studies show that loss of FcγRIIB, an important negative regulator of B cell activation, results 
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in loss of B cell tolerance (Tiller et al., 2010). Conclusions as to whether FcγRIIB-mediated 
retention of self-antigens by FDCs contributes to the maintenance of B cell tolerance have 
not been determined (Sharp et al., 2012).  
Although FDCs play a role in preventing autoimmunity by promoting ingestion of dying B 
cells, presentation of autoimmune complexes by FDCs can also contribute to autoimmune 
disorders when appropriate regulation of these interactions fail to occur. This presentation 
can also sometimes lead to subsequent FDC-mediated recruitment of self-reactive follicular 
helper T cells which in turn lead to the selection of autoreactive B cells. Diseases in which 
FDCs have been implicated in diseases such as Rheumatoid Arthritis (RA) and SLE 
(Vinusea et al., 2009). Using an RA mouse model, it was shown that mice develop high 
levels of anti-glycosylphosphatidylinositol (GPI) autoantibodies targeting GPI-anchored 
surface proteins. Drugs, such as decoy receptors for TNF and LT, ameliorate RA in mice 
and humans by interfering with FDC integrity. Natural IgM is present in the serum in the 
absence of an antigenic stimulus and has been shown to have low levels of self-reactivity 
(Coutinho et al., 1995). In RA, natural IgM binds to nuclear protein released from dying cells, 
resulting in immune complex (IC) deposition on FDCs and presentation to and selection of 
autoreactive GC B cells (Fu et al., 2011). There are also increased levels of IgM antibodies 
in obesity associated inflammation (Arai et al., 2013). The study revealed that IgM loaded 
with antigen formed a large immune complex, containing various elements, including 
apoptosis inhibitor of macrophage (AIM); it was shown that these complexes were 
responsible for the increased autoantibody production in mice fed a high-fat diet. As AIM 
was contained within the immune complexes, renal excretion of this protein was prevented, 
increasing blood AIM levels. While associated with AIM, IgM binding to the Fcα/µ receptor 
on FDCs was inhibited, preventing internalisation of IgM molecules through this receptor. 
Increased IgM levels in the blood supported IgM-dependent autoantigen presentation to B 
cells, which in turn stimulated IgG autoantibody production. In contrast, within AIM-/- mice, 
these responses were abrogated (Arai et al., 2013). These data suggest a model in which 
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increased IgM and AIM within these mice leads to the generation of isotype-switched 
pathogenic autoantibodies. 
Expression of other factors affecting the GC response  
FDCs have also been shown to provide a variety of factors with putative roles in the GC 
reaction. Human tonsil FDCs have been shown to express ligands for Notch, DII1 and Jg1, 
and in vitro experiments that block Notch signalling using gamma-secretase in FDC cell lines 
resulted in reduced GC B cell survival, therefore the expression of these proteins are thought 
to function to protect GC B cells from apoptosis (Yoon et al., 2009). Further supporting this 
observation is the cooperation between Notch and BAFF produced by FDCs known to 
support GC B cell growth; this was shown through blockage of both molecules 
simultaneously resulting in further decrease in B cell survival compared to blockage of the 
protein’s individually (Yoon et al., 2009). Additionally, Wnt5a expression by FDCs in culture 
has been shown to increase GC B cell survival by inducing Wnt/Ca2+-dependent activation of 
NFAT, NFκB, and BCL6 (Kim et al., 2012).  
Using an in-silico subtraction approach, the transcriptome of murine FDCs was analysed, 
identified transcripts for well-established FDC markers, such as CXCL13, Mfge8 and 
MadCAM1, as well as molecules such as, Serpina1, Cochlin, Perostin, the prion protein and 
Enpp2, which has not previously been associated with FDCs (Wilke et al., 2010). The 
function of many of these proteins on the GC reaction have not been investigated in detail, 
however a recent study on the extracellular matrix protein, cochlin, revealed a role in 
modulating innate immune responses (Py et al., 2013). This protein was shown the be 
specifically expressed by FDCs and selectively localised in the extracellular network of 
conduits in the spleen and lymph nodes. Upon inflammation, cochlin is cleaved and released 
into the blood stream where it acts on the production of cytokines, recruitment of innate 
immune effectors, and bacterial clearance. Choch-/- mice had defects in cytokine production, 
recruitment of immune effector cells and bacterial clearance, leading to reduced survival in 
models of lung infection with Pseudomonas aeruginosa and Staphylococcus aureus. As the 
47 
 
deficient mouse model show no defects in germinal centre formation, immunoglobulin 
responses or antibody affinity maturation, this protein is not thought to be involved in the 
FDC function of activation of B cells. These data suggest FDCs use this protein affect the 
innate immune response, but studies into the importance of this protein in these cells have 
not been undertaken at present.  
An additional important role for FDCs is the provision of survival signals and cytokines to 
enhance the GC reaction. FDCs are a source of BAFF (Suzuki et al., 2010), a B cell survival 
factor required for B cell homeostasis, and therefore may impact the survival of GC B cells 
through this mechanism. Studied undertaken in mice deficient in BAFF or its receptor initially 
develop GC responses, but these are not sustained (Vora et al., 2003). Additionally, high-
affinity antibody responses within these mice were attenuated, but analysis of the V region 
gene indicated that somatic hypermutation is still able to occur. Together these data provide 
evidence that BAFF is required for the maintenance, but not the initiation, of the GC reaction. 
Targeting of BAFF by Belimumab (GSK) has shown clinical success in the treatment of SLE.   
FDCs are also a source of the pro-inflammatory cytokine IL6; mice deficient in this cytokine 
have a reduction in the size of their GCs (Kopf et al., 1998). These mice also exhibit 
defective upregulation of C3, this reduction in complement-mediated signalling is thought to 
be associated with the altered GC phenotype. Another study confirmed that IL6 produced by 
immune complex-active FDCs promotes GC reactions, IgG responses and somatic 
hypermutation (Wu et al., 2009). They showed that activating FDCs with immune complexes 
increases the production of IL6 and that antibodies against IL6, inhibited specific antibody 
production in vitro. 
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7.3 B cells 
Mature B cells can be divided into two lineages named B1 and B2 (Browning et al., 2006). 
B1 cells are long-lived, emerging early in development, are self-renewing and produce 
polyreactive IgM’s that are considered essential for defence against encapsulated bacteria, 
also known as natural antibodies. In contrast, B2 cells, found within the B cell follicle, have 
the capacity to generate hypermutated class switched antibodies. B2 cells are routed into a 
mature follicular B cell or marginal zone B cell program. Follicular B cells traffic through 
SLOs and are involved in the adaptive humoral response. Through the GC reaction B cells 
undergo rapid proliferation and can differentiate into either plasmablasts that differentiate 
into plasma cells or memory B cells. Plasma cells derived from this mechanism express a 
unique signature of chemokine receptors and decrease expression of receptors for CXCL13, 
CCL21 and CCL19, allowing their migration from the GC to the medullary zone and then to 
the bone marrow, where they typically reside for 6-12 months in mice (Kunkel et al., 2003). 
Marginal zone B cells reside in the marginal zone of organs allowing them to sample the 
blood stream for pathogens.  
B cell activation requires interactions between antigen-primed B cells and follicular helper T 
cells via a CD40 ligand (CD40L) and secretion of the cytokine IL4 (Purwada et al., 2015). 
CD40 signal alone can induce activated B cells to differentiate down the memory pathway 
but not into germinal centre cells; for this additional cytokine signalling is required (Rickert et 
al., 2005). IL21 has been shown to upregulate BCL6 in B cells, which is a crucial factor for 
germinal centre formation and maintenance. FDC presentation of antigen by CD21 is known 
to be important for B cell activation as IgG titres are declined in CD21 deficient mice (Carroll 
et al., 2012).  
Activation of B cells is controlled by a number of regulatory molecules, including the surface 
immunoglobulin receptor complex. This complex is formed of a surface IgM molecule (BCR), 
CD19, CD21, CD81 and CD228 (Leu-13). CD19 and CD21 non-covalently associate in this 
multimolecular signal transduction complex to enhance B cell activation by lowering the 
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threshold for this mechanism to occur (Matsumoto et al., 1991). CD19 is a 95 kDa Ig 
superfamily glycoprotein expressed from the early stages of B cell development until plasma 
cell differentiation; its expression is restricted to B cells and FDCs (Tedder et al., 1994). 
Studies using CD19 monoclonal antibodies in vitro first suggested a role for this receptor in 
activation of B cells, as blockage of signalling resulted in a decreased activation of these 
cells (Bradbury et al., 1992). As CD21 is expressed much later in development than CD19 
and CD81, it is thought that signalling via this complex is developmentally regulated (Tedder 
et al., 1994). As CD21 has the ability to bind C3dg, binding of immune-complexes by this 
complex results in delivery of co-stimulatory signals to B cells, lowering the activation 
threshold. This will be discussed in further detail throughout the thesis.  
7.3.2 B cell function 
The main and most well-known function of B cells is their role in humoral immunity. In 
addition to this essential role, B cells also mediate many other functions important for 
immune homeostasis. B cells are required of the initiation of T cell immune responses. This 
was first discovered using administration of anti-IgM antiserum to deplete mice of B cells at 
birth (Ron et al., 1981). Animals were subsequently primed in vivo by antigen and in vitro 
analysis of their draining lymph node revealed that their T cell proliferative responses were 
severely impaired. Most recent studies in which B cells were depleted using CD20 depleting 
antibodies in normal adult mice, confirmed these early studies revealing that B cells are 
essential for optimal CD4 T cell activation during immune responses to low-dose foreign 
antigens (Bouaziz et al., 2007). Within these mice, plasma cells still remain, as this cell 
subset is CD20-. Additionally, in vivo dendritic cell ablation revealed both B cells and 
dendritic cells are needed for optimal antigen-specific CD4 T cell priming.  
B cell deficient mice have many abnormalities within the immune system, including a 
decrease in T cell number and diversity, defects within the spleen DC and T cell 
compartments and the absence of FDC networks (LeBien et al., 2008). These observations 
reveal a critical role in the development of the immune system but also show B cells are 
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important for its maintenance. B cells have been shown to release immunomodulatory 
cytokines which have been shown to influence antigen-presenting cell function, regulate 
wound healing and influence tumour immunity (LeBien et al., 2008). A subset of TNF-1 and 
IL10 expressing B cells have been described and are termed regulatory B cells (Mizoguchi 
et al., 2006). These cells were shown to regulate T cell-mediated inflammatory responses. In 
IBD, regulatory B cells have been shown to suppress inflammation by directly dampening 
proinflammatory responses such as IL1 and TNFα production by macrophages (Mizoguchi 
et al., 2000). 
 
7.4 Autoimmune disease 
In healthy individuals, the immune system is a complex set of mechanisms with the role of 
protecting hosts from infectious pathogens; however, this system can become dysregulated. 
Deficiencies in immune components can eliminate the system’s ability to respond to 
pathogenic threat. Alternatively, the failure of the immune system to distinguish self from 
nonself antigen, leading to a breach in tolerance, ultimately leads to the manifestation of 
autoimmune disease.  
Autoimmunity and its mechanisms that lead to clinical disease were first recognised around 
50 years after the work by Macfarlane Burnett and his hypothesis of the “forbidden clone” 
that won the Nobel Prize in 1960. This hypothesis initially proposed that autoimmunity 
develops due to activation of clones of cells that can react against the body by a viral 
infection or some metabolic change. These clones were thought to attack the tissues of the 
body resulting in the presentation of disease. Since then, studies have confirmed this 
hypothesis and contemporary theories now suggest that the development of an autoimmune 
disease requires a genetic predisposition and environmental factors that trigger the 
pathways leading to tissue destruction (Wang et al., 2015). It is now thought that 3-5% of the 
51 
 
population are affected by autoimmune disease, with autoimmune thyroid disease and type I 
diabetes being the most common reported conditions (Jacobson et al., 1997).  
Autoreactive cells prevail when immune tolerance is lost. Central tolerance in the thymus 
and bone marrow plays a key role in shaping immune system homeostasis. In healthy 
individuals, lymphocytes with potential self-reactivity are negatively selected and deleted in 
the thymic medulla. Upon exciting the thymus, mature T cells are selected again, in a 
process named peripheral tolerance; during this process most self-reactive T cells are 
deleted or rendered anergic. Immature B cells are usually deleted by a process named 
clonal deletion or clonal anergy if they express surface IgM that recognises self-surface 
proteins. Mature B cells also undergo peripheral tolerance, but autoreactive B cells are 
known to escape deletion by the process of receptor editing.  
It is possible for cells with self-reactive properties to be missed by this tolerance system as 
many cells are made on a daily basis. However, in otherwise healthy individuals this does 
not necessarily lead to disease. Autoantibodies are often observed in healthy individuals, 
such as antinuclear antibodies and rheumatoid factor and these are thought to help 
detection and degradation of self-antigens (Panda et al., 2015). When immune tolerance is 
broken, and autoantibodies and self-reactive lymphocytes become involved in inflammation, 
autoimmunity develops.  
7.4.2 Autoreactive B cells 
B cells can contribute to autoimmune diseases in a number of ways. These include; 
secretion of autoantibodies, presentation of autoantigen, secretion of inflammatory 
cytokines, modulation of antigen processing and presentation and generation of ectopic 
GCs.  
Autoantibodies are detected in many autoimmune diseases and in some diseases these 
antibodies themselves can have a pathogenic effect. Somatic hypermutation is one 
mechanism in which autoreactive antibodies can be produced. Autoantibodies are found in 
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patients with Rheumatoid Arthritis (RA); these antibodies typically target rheumatoid factor, 
type II collagen (CII) and citrullinated proteins and are found in the synovial fluid and serum 
of ~70% of patients with early RA (Cook et al., 1994). Rheumatoid factors (RhF) are 
autoantibodies specific for the Fc portion of IgG, 30% of healthy individuals have detectable 
levels of these antibodies within their serum, however, because they are low affinity and low 
titre, these antibodies do not cause any significant pathology (Kyburz et al., 1999). In 
disease, it is thought that RhFs form complexes with antigen to promote release of 
inflammatory factors, leading to increased disease pathology (Sakaguchi et al., 2003). CII-
specific autoantibodies were shown to have a pathogenic role in a study using an animal 
model termed collagen-induced arthritis (Holmdahl et al., 1986). Native collagens consist of 
three polypeptide chains linked in triple helices, type II collagen is composed of three α1-
type II chains (Trentham et al., 1978). Mice were immunised with CII antigen and developed 
CII-specific antibodies which lead to the triggering of arthritic symptoms; interestingly some 
antibodies against auto-antigens were shown to be more pathogenic than others. Passive 
transfer of these antibodies (Stuart et al., 1982), antibodies from RA patients (Wooley et al., 
1984) or monoclonal antibodies specific to CII (Nandakumar et al., 2003) also caused 
healthy mice to develop arthritic symptoms to varying levels dependent on CII-specificity, 
isotype and Fc receptor dependency, further supporting their pathogenic role in disease. 
High doses of mAb are needed to provoke arthritic responses, concentrations as high as 9 
mg of mAb were needed to induce moderate arthritis in mice (Nandakumar et al., 2003); as 
anti-CII epitopes are likely located in a repetitive structure on the surface of cartilage, it is 
possible that multimeric complexes form on joint surfaces, favouring arthritogenicity and also 
explaining why high doses of antibody are needed to elicit this response. Antigens of type I 
and III collagen however are not arthritogenic, even at high doses (Trentham et al., 1978). 
Indeed, CII-specific antibodies are thought to mediate immune complex formation in the joint 
resulting in complement activation and recruitment of inflammatory cells. Once cells are 
recruited to the joint and have been activated, proinflammatory cytokines will be produced, 
further activating the immune response. These cytokines will recruit synovial macrophages 
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and infiltrating mononuclear cells, leading to the eventual release of tissue-degrading 
enzymes that cause cartilage damage and worsen disease (Firestein et al., 2003). Passive 
transfer of anti-DNA antibodies into healthy mice induced features of SLE, showing that 
these autoantibodies also contribute to the pathogenesis of this disease (Tsao et al., 1992). 
Within diseases such as systemic lupus erythematosus, rheumatoid arthritis and Sjogren’s 
syndrome, the deposition of immune complexes composed of autoantigens bound by 
autoantibodies is a prominent feature that contributes to disease pathology (Hampe 2012). 
These complexes trigger inflammation through activation of complement and Fc-receptor-
dependent effector functions, such as antibody-dependent-cell-mediated cytotoxicity (Martin 
et al., 2004). Experimental models have shown that activation of complement by these 
immune complexes and have also been observed in the kidneys of patients with SLE and 
lupus nephritis (Quigg et al., 2004).  
Autoreactive B cells can act to stimulate or inhibit receptor functions through the action of 
autoantibody production. This was illustrated in a study focusing on autoantibodies targeting 
the thyroid stimulating hormone (TSH) receptor (Ando et al., 2005). TSH receptor 
autoantibodies are found in Graves’ disease and have been shown to stimulate the receptor 
function. This leads to the release of thyroid hormones and development of hyperthyroidism. 
In contrast, other autoantibodies against the TSH receptor found in autoimmune 
hypothyroidism block the binding of TSH to the receptor, thereby inhibiting the receptors 
function (Michalek et al., 2009).  
Autoantibodies also facilitate the uptake of self-antigen by antigen presenting cells (APCs). 
Monocytes and dendritic cells have been shown to use the Fc receptors expressed on the 
cell surface to take up antigen complexed with autoantibodies (Takai et al., 2005). Normal T 
cell tolerance is broken by presentation of these autoantigens to T cells by the APCs. This 
mechanism was confirmed in studies using autoantibodies to thyroid peroxidase antigens, in 
which these antibodies enhanced the uptake of antigens by APCs and consequently, 
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activated thyroid peroxidase-specific T cells (Nielsen et al., 2001). This response can be 
blocked by using blocking antibodies against FcγRs (Nielsen et al., 2009).  
In contrast to these functions, autoantibodies have also been reported to have protective 
functions and natural autoantibodies are often found in healthy individuals (Shoenfeld et al., 
2005). These antibodies are usually polyreactive and react with both self and non-self-
antigens. The natural autoantibodies present in mice are secreted by the B1 subset of B 
cells and are often of the IgM isotype (Baumgarth et al., 2005). One role for the nonspecific 
and low-affinity binding action of these natural autoantibodies may be to prevent 
autoreactive clones from reacting vigorously with self-antigens; it is thought that binding of 
natural autoantibody may mask the epitopes of pathogenic autoantibodies (Shonefeld et al., 
2005).  Higher levels of IgM are associated with apoptotic cell clearance and lower disease 
activity in patients with SLE (Gronwall et al., 2012). Pathogenic IgG autoantibodies are 
symmetrically glycosylated, whereas it was found that 10-20% of the total IgG molecules in 
sera are asymmetrically glycosylated (Mathov et al., 1995). The asymmetric glycosylation of 
these autoantibodies fail to trigger immune effector mechanisms or form insoluble 
complexes with antigens; therefore, these molecules are self-specific but have no 
deleterious effect in normal individuals and act as autoprotective antibodies. Competition for 
self-antigen between these antibodies and the pathogenic symmetrically glycosylated 
autoantibodies resulted in protection from severe immune responses in rats, confirming their 
protective role (Margni et al., 1998). Rheumatoid factor (RhF) autoantibodies are found in 
many autoimmune diseases. There is controversy over whether the presence of RhF 
antibodies exerts protection or induces disease. The presence of these autoantibodies in 
SLE patients was directly related with disease prevalence (Turner-Stokes et al., 1989), 
however many other studies have demonstrated a protective role against the development of 
lupus nephritis for example (Shonefeld et al., 2005). In another study RhF antibodies were 
shown to have the ability to block attachment of C3b, which is capable of reacting with 
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glomeruli receptors, indicating that these antibodies may have a role in inhibiting binding of 
immune complexes (Bolton et al., 1982).  
B cells also act as antigen-presenting cells in autoimmune diseases such as rheumatoid 
arthritis (O’Neill et al., 2005) and type 1 diabetes (Wong et al., 2004). Using nonobese 
diabetic (NOD) mice engineered to express a transgene encoding a mutant heavy chain 
immunoglobulin allowing presentation on the cell surface but prevents secretion of 
antibodies, the importance of antigen presentation in type 1 diabetes, in the absence of 
antibody production, thought to be unimportant in this disease, was investigated (Wong et 
al., 2004). Compared with transgene-negative B cell deficient mice, there was increased 
insulitis and incidence of diabetes in transgenic mice; implicating an antigen presenting 
function of B cells in disease development; however, disease level is not restored to that of 
wildtype NOD mice. Due to presentation of antigen through antigen-specific BCRs, rather 
than internalisation of antigen in other APCs, B cells are able to present antigen present at 
low concentrations; this mechanism is 1,000-10,000-fold more efficient than pinocytosis and 
is thought to be the mechanism allowing autoantigens to be presented (Lanzavechia et al., 
1987).  
The production of proinflammatory cytokines by activated B cells, such as IL6, IFNγ and IL4, 
further increase the inflammatory response by modulating the migration of dendritic cells, 
activating macrophages and providing feedback stimulatory signals for further B cell 
activation (Hampe 2012).  
Additionally, autoreactive B cells are able to aid in the do novo generation of ectopic GCs 
within inflamed tissues (Martin et al., 2006). These structures have been described in 
numerous autoimmune diseases such as RA, SLE and Graves’ disease. It is thought that 
ectopic GCs are not a unique disease-specific occurrence but a consequence of chronic 
inflammation. Inflammation is maintained within these structures due to residing plasma cells 
secreting autoantibodies (Manzo et al., 2005).  
56 
 
Autoreactive B cells may occur due to loss of tolerance which could be faulted by genetic 
mutations at tolerance checkpoints. The Sle1 locus located on the telomeric chromosome 1 
has been linked to SLE in several mouse models and human patients (Wakeland et al., 
2001). Functional analyses carried out in B6.Sle1 congenic mice carrying Sle1 on a non-
autoimmune B6 background, revealed this locus induces a loss of tolerance to nuclear 
antigens in B cells and activation of CD4+ T cells (Mohan et al., 1999). Further studies using 
a mouse model carrying the lupus susceptibility locus, it was shown that faulty negative 
selection at the immature B cell stage leads to spontaneous development of severe lupus 
nephritis in these animals through the action of anti-histone autoreactive T cells (Chen et al., 
2005). Over-expression of CD19 in mice was shown to lead to increased levels of serum 
antibodies, resulting in increased B cell activation (Engel et al., 1995). As surface CD19 
lowers the threshold for B cell activation, these results show that increased B cell signalling 
by overexpression of signalling molecules is another factor that can lead to autoimmunity. 
Interestingly, loss of CD19 reversed the phenotypes observed when the receptor is 
overexpressed (Zhou et al., 1994). Additionally, mouse studies highlighted that, lack of 
FcγRIIB expression on B cells leads to autoimmunity (Boross et al., 2011), which was also 
reflected in humans when the finding that patients with lupus express lower levels of this 
receptor due to a polymorphism in their FcγRIIB promoter (Blank et al., 2005).  
B cell activation factor (BAFF) overexpression in transgenic mice was shown to cause an 
expansion of peripheral B cells (Manca et al., 1991). These animals had increased 
autoantibody levels and developed a lupus-like disease. In addition to this observation, 
increased levels of BAFF have been observed in the serum of patients with RA (Rochas et 
al., 2009), SLE (Pers et al., 2005) and Sjorgren’s syndrome (Youinou et al., 2012). By 
measuring the levels of circulating BAFF and sCD23, an indication of B cell activation, it was 
shown that there was no correlation between BAFF concentration and B cell activation in 
patients with SLE or RA; however high levels of BAFF were associated with the presence of 
autoantibodies, ds-DNA antibodies in SLE and rheumatoid factors in RA (Pers et al., 2005). 
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An Ig/HEL-double transgenic mouse model further demonstrated the importance of BAFF in 
autoreactive B cell survival and function (Lesley et al., 2004). These autoreactive cells were 
shown to have an increased dependence on BAFF for survival; the increased BAFF 
concentration received by these cells lead to increased levels of NFκB, p52 and prosurvival 
kinase Pim2. The greater dependence of these autoantigen binding B cells on BAFF cause 
them to be poor competitors relative to non-autoantigen binding B cells. When placed in a 
diverse B cell compartment, these cells undergo apoptosis as BAFF receptor engagement 
and signalling is reduced. In elevated BAFF levels all autoantigen-engaged cells to be 
rescued from rapid competitive elimination; therefore, individuals that produce high BAFF 
levels may be more susceptible to the survival of autoantigen binding B cells (Lesley et al., 
2004). Furthermore, as deficiencies in apoptosis have been shown to lead to the 
development of lupus-like diseases, BAFF might also play an anti-apoptotic role in B cell 
tolerance loss (Pers et al., 2005).  
 
7.5 Complement and its role in autoimmune disease 
The complement system is composed of a network of over 30 tightly regulated proteins, 
either present as soluble proteins in the blood or membrane-associated proteins, that play 
an important role in host defence and inflammation. Activation of the complement pathway 
leads to opsonisation of pathogens, resulting in a number of mechanisms resulting in an 
immune response, the most common of these being removal of opsonised pathogens by 
phagocytes, attracted by the formation of anaphylatoxins C3a and C5a, and cell lysis (Sarma 
et al., 2012). Inappropriate activation of this pathway, as well as complement deficiencies, 
lead to many autoimmune diseases such as SLE and asthma. The complement system was 
first thought to be involved only in the innate immune response, but more recently increasing 
evidence has shown an important role for these proteins in adaptive immunity, specifically 
helping the elimination of pathogens by T and B cells and in maintaining immunologic 
memory preventing pathogenic re-invasion (Dunkelberger et al., 2010). 
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7.5.2 The complement pathway  
Complement activation occurs through three individual pathways, which converge at C3, the 
most abundant complement protein found in the blood (Sarma et al., 2012). These pathways 
are named; the alternative, classical and lectin pathways, and all result in the formation of 
the membrane attack complex. The alternative pathway is triggered by carbohydrates, lipids 
and proteins found on non-self surfaces and the lectin pathway is activated by mannose 
binding lectin or Ficolin binding to their ligands on the surfaces of yeast, bacteria, parasites 
and viruses (Qu et al., 2009). The classical pathway is initiated by immune complex binding 
to pathogens or non-self-antigens. Immune complexes are formed from IgG or IgM 
molecules binding to said antigen. It is this pathway that is the focus of this thesis.  
The classical pathway begins with the C1 complex, formed of C1q, C1r and C1s, which 
binds to the Fc portion of the IgG or IgM molecule on the immune complex. Binding is 
specifically through C1q to the exposed Fc portion of the antibody, which subsequently 
activates C1s and C1r. C1s is a protease than cleaves C4 and C2 to form the C3 convertase 
of the classical pathway, C4bC2a. Each pathway has its own complex that is able to cleave 
C3 to release C3a and C3b. C3b acts as an opsin, thereby helping to amplify complement 
activation by amplifying its own cleavage, in addition to aiding with phagocytosis in the 
continuation of the pathway. Other C3b molecules complex with C3 convertases to form a 
C5 convertase. This complex is composed of C3bBbC3b and C4bC2aC3b. C5 convertases 
cleave C5 into C5a and C5b. When C5b binds to C6 and C7, the membrane attack complex 
is initiated. C8 and multiple C9 molecules bind the C5bC6C7 complex to enable the MAC 
complex to insert itself into cell membranes and form a pore, allowing cell lysis to occur as 
the final result (Sarma et al., 2012) (Figure 7.6).  
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7.5.3 The function of C3 and C3 derivatives  
C3 contains an internal thioester bond that undergoes spontaneous hydrolysis, increasing its 
susceptibility to cleavage to form C3b (Platt et al., 2017). The C3b derivative of C3 has an 
exposed carbonyl group which can form bonds with neighbouring nucleophiles; depending 
on the surfaces bound by C3b determines whether it will form a catalytic complex and 
continue the complement cascade, or whether cleavage occurs to form a catalytically 
inactive fragment C3d. C3b binds to the surface of antigen and interacts with CD35 and is 
converted to iC3b by fluid phase factor I and H. Further editing by factor I, using CD35 as a 
cofactor, results in cleavage to form C3dg (Topanta et al., 2006). C3d is the final derivative 
of this pathway, cleaved from C3dg. C3d does not further activate complement but results in 
C3d/g-tagged antigen that has the capacity to bind to CD21 expression on FDCs and B cells 
(Carroll et al., 2012), although C3dg binds with a higher affinity.  
C3d and C3dg opsonised immune complexes, composed of antigen and IgM or IgG 
molecules, allow recognition of the antigen by FDCs and B cells through the interaction of 
C3dg and CD21. Binding of these derivatives of C3 to CD21 enhances antibody responses 
by reducing the threshold for B cell activation, due to simultaneous ligation of CD21 and 
surface Ig by opsonised immune complexes (Dempsey et al., 1996) and allows retention and 
internalisation of antigens by FDCs (Heesters et al., 2013). However, C3d has also been 
shown to enhance antibody titres in the absence of CD21, indicating that this protein can 
also enhance the immune response through CD21-independent mechanisms. In a study 
where CD21 knockout mice were immunised with streptavidin conjugated to C3dg or HIV-1 
Env gp120-C3dg proteins, mice were shown to have increased titres of antigen specific 
antibodies compared to mice immunised with antigen alone (Haas et al., 2004). A couple of 
mechanisms for CD21-independent responses have been proposed including; a prolonged 
half-life of the antigen by opsonisation with C3dg or there could be a secondary receptor for 
C3dg that elicits this response. Indeed, C3dg has been reported to bind to many other 
proteins found in physiology (Karen et al., 2004).  
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C3dg opsonised antigen-complexes were shown to enhance recognition and specific 
antibody synthesis by antigen-specific B cells, even though the complexes can be taken up 
by both antigen-specific and non-specific B cells (Thornton et al., 1996). Primary protein 
keyhole limpet hemocyanin (KLH) was opsonised with C3dg to form immune complexes. 
These complexes were able to bind to the CD21 expressed on KLH-non-specific B cells, 
leading to antigen processing and presentation on MHCII molecules to KLH-specific helper T 
cells. It is these cells that then go fourth and activate the KLH-specific B cells. The 
opsonised immune-complexes were also shown to induce expression of CD80 co-
stimulatory molecule on B cells by simultaneous CD21 ligation with C3dg and FcγRII 
stimulation by IgG. Ligation to either of these receptors resulted in the activation of a 
secondary co-stimulatory molecule, LFA-1 (CD11a, CD18).  
It was hypothesised that C3dg could be used as a natural adjuvant to enhance the 
secondary humoral immune response. One study investigated the adjuvant effect of C3dg by 
immunising mice with an antigen of the influenza virus conjugated to three tandem copies of 
C3d (Ross et al., 2000). Antigen complexed with C3d induced a similar antibody titre to that 
in mice immunised with antigen alone. However, antibody avidity maturation was enhanced 
in those mice immunised with C3dg-immune complexes, which correlated with a more rapid 
appearance of protective immunity and complete protection from live virus challenge. These 
mice also had antibodies able to protect them from heterologous virus challenge, whereas 
mice immunised with antigen only, did not. In another study, self-antigen collagen type II was 
opsonised with C3d and injected into a mouse model for collagen-induced arthritis (Del 
Nagro et al., 2005). Mice were also inoculated with complete Freund’s adjuvant (CFA), which 
is needed in many several animal models because it causes local inflammation and 
enhances antigen uptake. Mice that received opsonised antigen developed rheumatoid 
arthritis even in the absence of CFA, whereas mice that received CII alone did not develop 
RA, unless they heterologously received CFA. These results showed that C3d bypasses the 
need for a broad immunostimulatory effect elicited by a classical adjuvant.  
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As well as its possible role in disease, C3d may also have the potential to enhance immune 
responses by acting as an adjuvant in vaccines. DNA vaccines have been designed using 
C3d as the adjuvant leading to increased antibody titres against HIV-1 Env gp120 (Bower et 
al., 2006). Also fusion of hepatitis B antigen to C3d enhanced the antigen-specific antibody 
response in mice (Wang et al., 2004). Another study showed that free C3d inside tumour 
cells, or associated with irradiated tumour cells, accelerates anti-tumour T cell responses, 
allowing the prevention, and in some cases the reversal, of tumour growth (Platt et al., 
2017). These effects on tumour immunity were shown to be B cell-independent; instead C3d 
was seen to increase tumour infiltrating CD8+ T cells, by depleting Tregs and by preventing 
the expression of programmed cell death protein 1. These results suggest a potential role for 
free C3d in immune surveillance.  
 
7.5.4 The role of complement in autoimmune disease 
Although the complement system is important in the elimination of pathogens and mounting 
enhanced immune responses, dysregulation of this system has been shown to be involved 
in the pathogenesis of several autoimmune diseases such as SLE, Sjogren’s Syndrome, 
systemic sclerosis and rheumatoid arthritis (RA) (Chen et al., 2010). As the mechanisms of 
this system as delicately balanced, when dysregulation occurs, the complement system has 
the ability to cause damage, mediating tissue inflammation (Ballanti et al., 2013). 
Additionally, complement deficiencies have been associated with an increased risk in 
autoimmune disease development.  
Most heterozygotic complement-deficiencies are clinically normal; however homozygotic 
complement-deficient individuals develop clinical diseases (Ballanti et al., 2013). As 
complement deficiencies are usually caused by null alleles, from which functional protein is 
not produced, most heterozygotes produce half the normal plasma level of specific 
complement protein (Pettigrew et al., 2009). Exceptions to this observation are X-linked 
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recessive properdin deficiency, deficiency of C1 inhibitor which is autosomal dominant and 
mannose-binding lectin and factor I deficiencies which are autosomal co-dominant 
(Winkelstein et al., 2003). Deficiencies in complement components lead to presentation of; 
recurrent bacterial infections, HAE, rheumatic disorders, leukocyte adhesion deficiency, and 
haemolytic uremic syndrome (Pettigrew et al., 2009). Specifically, complement deficiencies 
within the mannose-binding lectin pathway lead to increased bacterial infections and more 
frequent Neisseria infections occurs as a result of deficiencies within the alternative pathway. 
Deficiencies in components of the classical pathway have been shown to lead to increased 
susceptibility to encapsulated bacterial infections and are implicated in SLE (Pettigrew et al., 
2009). 30% of patients with SLE are deficient in C2 and nearly 80% of patients are deficient 
in either C3 or C4 (Etzioni et al., 2003). C3 deficiency in these patients presents as recurrent 
pyogenic infections and membranoproliferative glomerulonephritis rashes (Walport et al., 
2001).  
Interestingly, C3 or factor B deficiency within the collagen-induced arthritis (CIA) mouse 
model resulted in protection against disease development upon immunisation with CII 
(Hietala et al., 2002). These mice displayed a decrease in their CII-specific IgG antibody 
response compared to wild-type mice; suggesting that C3 and factor B have a role in the 
development of disease phenotype. Repeat administration of antigen triggered arthritis in all 
mice, including those with complement deficiencies. Interestingly, arthritic score within these 
mice was lower than that in wild-type. This study implicates both the classical and alternative 
pathway in the development of CIA. Within humans, plasma levels of C3 within patients with 
active RA is significantly higher than in controls (Di Muzio et al., 2011); increased C3 levels 
represented a negative prognostic factor for anti-TNF therapy. It is of note that synthesis of 
C3 has also been shown to occur in chronically inflamed tissues, such as the rheumatoid 
joint. Cells responsible for the production of this protein include, lining cells, fibroblasts, 
mononuclear phagocytes and endothelial cells (Whaley et al., 1992). Additionally, evidence 
that complement system activation occurs in the synovial fluid is abundant. Decreased levels 
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of complement components within the synovial fluid of patients are observed, but increased 
levels of cleavage products, C3a, C3c, C5a etc., are found within these compartments 
suggesting high levels of complement activation (Jose et al., 1990). Mechanisms leading to 
increased activation of the complement pathway in RA patients could include, an increased 
level of circulating immune-complexes, including rheumatoid factors which have the ability to 
activate the classical complement pathway (Zubler et al., 1976). Increased levels of anti-
cyclic citrullinated peptide/protein antibodies are also found in RA patients; these may 
activate complement via both the classical and the alternative pathways (Trouw et al., 2009). 
The report discussed above in which C3d conjugated CII was injected into a mouse model 
for collagen-induced arthritis (Del Nagro et al., 2005), was the first to demonstrate that C3d 
can induce pathogenic autoantibodies and suggest that this molecule could be involved in 
the development of other B cell-dependent autoimmune diseases.  
Patients with systemic sclerosis (SSc) also have been shown to have lower C3 levels and 
this protein is now used as a candidate parameter for inclusion in the American College of 
Rheumatology classical criteria for SSc (Arthritis Rheum, 1980). Sjogren’s syndrome (SS) is 
an autoimmune disorder of the exocrine glands and is associated with lymphocytic infiltrates 
of the affected glands. Low levels of C3 has also been observed in patients with SS, 
however it is the decreased C4 levels, and thus C3dg levels, that show the closest statistical 
association with mortality and lymphoproliferation (Ioannidis et al., 2002).  
Additionally, proteins which are usually sequestered within cells, such as phospholipids and 
mitochondrial proteins, are recognised by the complement system and are able to activate 
the cascade if they become exposed by directly binding C1q or natural antibodies (Nauta et 
al., 2004). This activation leads to increased inflammation and recruitment of cells that 
further contribute to the inflammatory phenotype.  
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7.6 Summary, thesis hypotheses and overall aims 
Secondary lymphoid organs are essential for development of high specificity antibody 
responses. These responses primarily occur due to the germinal centre reaction, in which 
FDCs and B cells are the cells responsible for antigen presentation and subsequent high 
affinity antibody production, respectively. Interactions between these two cells types are 
essential for humoral immunity, but most published studies are carried out within mice due to 
the lack of a robust isolation protocol for human FDCs. FDCs and B cells within the germinal 
centre interact by the CD21 receptor which allows transfer of antigen from B cells to FDCs 
where it is retained and presented allowing recognition by antigen-specific B cells and 
subsequent antibody production. CD21 deficient mice do not develop GCs and have 
impaired antigen-specific immune responses (Carroll et al., 2012), therefore highlighting the 
essential function of this receptor in the development and function of the GC reaction. Due to 
these observations this receptor is the focus of this thesis. Little is known however about the 
exact mechanism of C3dg-opsonised antigen transfer between CD21 expressed on human 
B cells and FDCs. 
Therefore this work aims to investigate the hypothesis that: antigen transfer is due to (1) 
receptor number on the cell surface or (2) CD21 isoform expression on the different cell 
populations.  
CD21 and the complement pathway, including C3 and its derivatives, have been implicated 
in autoimmune diseases such as Rheumatoid Arthritis. The third results chapter in this thesis 
investigates the hypothesis that: a soluble form of the CD21 receptor inhibits C3dg antigen 
complex binding to B cells, consequently dampening C3dg-mediated immune responses, 
therefore acting as a break on the immune response, which does not occur in autoimmune 
disease.  
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The overall aims of this work are to:  
1) Isolate and characterise human FDCs from human tonsil. Assess CD21 absolute 
receptor number on FDCs (tonsil derived), T and B cells (tonsil and blood derived).  
2) Assess C3dg binding capacity of CD21 on FDCs (tonsil derived) and B cells (tonsil 
and blood derived), investigating potential differential C3dg binding between CD21S 
and CD21L isoforms. 
3) Further understand the function and role of sCD21 in healthy volunteers and disease 
patients. 
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8. Materials and Methods 
 
All human biological samples were sourced ethically and their research use was in accord 
with the terms of the informed consents under an IRB/EC approved protocol. Fresh healthy 
volunteer blood was derived from GSK BDU (Stevenage) under the Hertfordshire Ethics 
Committee (Ethics approval code: 07-H0311-103). Tonsil tissue was sourced from surgical 
discard at Lister Hosptial under the Cambs and Herts REC (Ethics approval code: 
06/Q0204/25). Tonsils collected at the University of York were collected at York Teaching 
NHS Trust, ethically approved and informed consent was obtained from all participants. 
These tonsils were collected under NRES REC 12/NE/0360 approved study (IRAS: 114771) 
to Prof. Mark Coles and Prof. Charles Lacey.  
Hepatic lymph nodes were collected during multi-organ donation procedures, after approval 
by the Medical Ethical committee of the Erasmus MC (MEC-2014-060) to Prof. Tom Cupedo 
by Prof. Wojciech G. Polak. 
Human serum samples were used from the BEACON cohort at the University of 
Birmingham. The ethics for this study was from the West Midlands Black Country (Ethics 
approval code: 12/WM/0258).  
All animal studies were ethically reviewed and carried out in accordance with Animals 
(Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of 
Animals. Animals were kept under specific pathogen free facility at the University of York. All 
procedural work was done under a home office licence to Mark Coles.  
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8.1 Immunofluorescent Staining of Frozen Tissue 
 
Snap frozen tissue was sectioned using a CryoStat (Leica) into 20 µm slices and stored on 
polylysine slides at -20°C until further use. For staining, sections were incubated at room 
temperature for 30 min and each section drawn around using a wax ImmEdge pen (Vector 
Laboratories). Samples were fixed in 4% paraformaldehyde for 10 min at room temperature 
before rehydration with PBS for a total of 15 min with changes of PBS wash every 5 min. 
Sections were incubated in a blocking buffer of PBS, 0.1% Tween-20 (Sigma-Aldrich), 0.1% 
Trition X-100 (sigma-Aldrich) and 5% serum (the serum of the host the secondary antibody 
was raised in) at room temperature (RT, 24°C) for 1 hour, this step significantly reduces non-
specific antibody staining. Block was removed and, without any washing steps, primary 
antibody mix, made in blocking buffer, added (concentrations can be found within Table 1). 
Sections were incubated for 1 hour at RT. Slides were washed as above and secondary 
antibody added (as required), incubating for 30 min at RT. Slides were washed and a drop of 
Prolong gold (Invitrogen) was added to each section. To mount, a No 1.5 glass coverslip 
(Fisher) was added on top of the slide and incubated overnight at 4°C. Slides were sealed 
using nail varnish the next day. Stained slides were stored at 4°C prior to image analysis. 
 
8.1.2 Confocal Microscopy 
 
Immunofluorescent stained sections were imaged using the Zeiss LSM 880 confocal 
microscope. Samples were excited with 405, 488, 561 and 633 nm lasers and images 
acquired using either the 20X lens or 63X oil objective. Using the Zen acquisition analysis 
functions, tile scans and Z stacks were performed to image large tissue sections at high-
resolution.  
For comparability across experiments, laser power, pinhole and detector voltage gain & 
digital offset were kept constand. Each fluorophore was imaged on separate tracks to 
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minimise spillover and single colour controls were performed to ensure accuracy. Images 
were taken at 1024 x 1024 pixels and line averaging of 4.  
For imaging chemokines (Figures 9.3.2, 9.3.3 and 9.3.4), the Airyscan module was used to 
increase spatial resolution beyond the diffraction limit of light. On a standard confocal 
microscope out of focus emission light is excluded through use of a pinhole at the focal 
plane. Image resolution is increased by decreasing the pinhole, but with the caveat of losing 
light energy. Airyscan deals with this issue using a hexagonal array of 32 detectors. Each 
detector acts as a small pinhole with positional information, this facilitates increased signal to 
noise ratio and spatial resolution in comparison to a standard confocal microscope (Huff, 
2015). 
Images were processed using ImageJ (Fiji), where z stack was merged at maximum 
intensity. 
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Antibody Clone Manufacturer Conjugated Concentration used 
Anti-human 
CD19 
HIB19 Biolegend Alexa 488 1 in 200 
Anti-human 
CD35 
Ber-MAC-
DRC 
Santa Cruz Unconjugated 1 in 200 
Anti-human 
CD21 
Bu32 Biolegend Alexa 647 1 in 200 
Anti-human 
CD21 
R4/23 Origene Unconjugated 1 in 200 
Anti-human 
CD21 
Bu32 Biolegend Unconjugated 1 in 200 
Anti-human 
CXCL13 
53610 R&D Biosystems Unconjugated 1 in 300 
Anti-human CD3 HIT3a Biolegend Alexa 488 1 in 200 
Anti-mouse CD3 17A2 Biolegend Alexa 488 1 in 200 
Anti-mouse 
CD21/CD35 
7E9 Biolegend Alexa 647 1 in 200 
Anti-mouse CD19 6D5 Biolegend Alexa 488 1 in 200 
Secondary antibodies 
Goat anti-Mouse 
IgG (H+L) Cross-
Adsorbed 
IgG Thermofisher 
Scientific  
Alexa 488 1 in 2000 
Goat anti-mouse 
IgG  Cross-
Adsorbed 
IgG Thermofisher 
Scientific 
Alexa 647 1 in 2000 
 
Table 1: Antibodies used for immunohistochemistry 
 
 
72 
 
8.2 Human Tonsil Tissue Digestion and FDC isolation 
 
Tonsils were obtained from routine tonsillectomies from Lister Hospital, Stevenage and York 
Teaching Hospital, York (Andrew Coatsworth, Charles Lacey, Becky Wiggans). Using a 
protocol adapted from Karin Tatre (University of Rennes), the tonsils were briefly dipped in 
70% ethanol and rinsed with PBS before being cut into small pieces (approximately 2 mm x 
2 mm x 2 mm) using scissors and the tissue transferred to a 50 ml Falcon tube. Pre-warmed 
digestion buffer (Leibovitz’s L15 Medium supplemented with L-Glutamine + 200 µg/ml + 800 
µg/ml Dispase II + 100 µg/ml Dnase I) was added to cover the tissue to the 25 ml mark. The 
suspension was pipetted carefully up into a sterile 25 ml strippette and expelled fast against 
the side of the tube to help disperse the tissue; this was repeated a total of four times. The 
tube was incubated at 37°C in a water bath for 20 min, repeating the dispersion step half-
way through the incubation. The supernatant was aspirated using a sterile Pasteur pipette 
and transferred to a 70 µm cell strainer placed onto a 50 ml Falcon tube. The cell 
suspension was made up to 35 ml with digestion buffer and centrifuged for 5 min at 200 xg, 
RT. Supernatant was removed, and the pellet resuspended in 25 ml of culture medium 
(RPMI1640 supplemented with 10% HI FCS, Glutamine and Penicillin/Streptomycin). Cells 
were counted using a Nucelocounter and cells pelleted as above. Cells were then either 
used for flow cytometry analysis, undergoing selective extraction through CD45 depletion 
and sorting for FDCs or frozen for future use.  
For freezing, the cell pellet was gently resuspended in 1 ml of ice-cold HI-FBS per cryovial 
and transferred to vials. 150 µl of 100% DMSO was then added per vial and mixed gently by 
pipetting. The vials were transferred to a cooled Mr Frosty filled with 99.9% isopropanol and 
placed at -80°C for 72 hours; vials were then stored at -140°C for long term storage.  
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8.3 Fluorescence-activated Cell Sorting (FACS) from Tonsil Derived Human 
FDCs, T and B cells 
 
Human tonsil digests were stained as described in section 8.8 with antibodies for 
identification of FDCs or T and B cells. Cells were sorted using a MoFlow (Beckman Coulter) 
or Aria (BD Biosciences). Cells were sorted through a 70 µm nozzle and separated by two-
way separation. Cells were identified using FSC/SSC, doublets excluded using SSC-H vs 
SSC-W, and live cells selected. For the FDC panel, FDCs and FRCs were collected using 
lineage-gp38+CD35+ (FDCs) and lineage-gp38+CD35- (FRCs) gating respectively (Figure 
9.3.9). Lineage markers include CD34, CD11b, CD31 and CD45. For sorting T and B cells, 
cells were collected using CD3+CD19- (T cells) and CD3-CD19+ (B cells) gating (Figure 
9.3.10). Cells were collected into eppendorfs or FACS tube containing a small volume of 
FACS buffer (PBS with 0.1% BSA, Sigma, and 2mM EDTA, Invitrogen). Sorted cells were 
pelleted by centrifugation for 5 min at 450 xg and subsequently processed as desired.  
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Antibody Clone Manufacturer Conjugated Concentration used 
FDC sorting 
Anti-human 
CD21 
Bu32 Biolegend PE 5 µl per 100 µl sample 
Anti-human 
CD35 
Ber-MAC-DRC Santa Cruz Unconjugated 5 µl per 100 µl sample 
Anti-human 
CD34 
581 Biolegend FITC 5 µl per 100 µl sample 
Anti-human 
CD31 
WM59 Biolegend FITC 5 µl per 100 µl sample 
Anti-human 
CD11b 
ICRF44 Biolegend FITC 5 µl per 100 µl sample 
Anti-human gp38 NZ-1.3 eBioscience PerCP eFluor710 5 µl per 100 µl sample 
T and B cell sorting 
Anti-human 
CD19 
HIB19 Biolegend PerCP Cy5.5 5 µl per 100 µl sample 
Anti-human CD3 APC/Cy7 Biolegend Alexa488 5 µl per 100 µl sample 
Isotype antibodies 
PE IgG1 MOPC-21 Biolegend PE 5 µl 
PerCP IgG1 MOPC-21 Biolegend PerCP 5 µl 
APC/Cy7 IgG2a MOPC-173 Biolegend APC/Cy7 5 µl 
Alexa488 IgG2b MOPC-154 Biolegend Alexa488 5 µl 
FITC IgG1 MOPC-21 Biolegend FITC  5 µl 
 
Table 2: Antibodies used for cell sorting 
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8.4 qPCR of Human Tonsil Tissue Derived Cell Populations 
 
 8.4.1 RNA Isolation 
 
RNA from isolated cells was extracted using the miRNAeasy Mini Kit (Qiagen). Cells were 
pelleted by centrifugation at 300xg for 5 min and resuspended in 350 µl QIAzol Lysis reagent 
and placed at room temperature for 5 min (NB: homogenate could be frozen at -80°C at this 
step). 140 µl chloroform was added to the homogenate and the tube shook vigorously for 15 
seconds. The tube was rested at room temperature for 2 minutes before centrifugation at 
4°C at 12000xg for 15 minutes. The aqueous phase was transferred to a new collection tube 
and 1.5 volumes of 100% ethanol added and thoroughly mixed by pipetting. 700 µl of the 
sample was immediately transferred to a Rneasy Mini spin column in a 2 ml collection tube 
and spun above 8000xg for 15 seconds at room temperature. The flow-through was 
discarded and step repeated with any remaining sample. 500 µl of Buffer RPE was added to 
the column and centrifuged for 2 minutes above 8000xg, discarding the flow-through. This 
step was repeated as above. The Rneasy Mini spin column was transferred to a new 2 ml 
collection tube and centrifuged at full-speed for 1 minute to dry the membrane. The column 
was then transferred to a 1.5 ml collection tube and 30-50 µl of RNase-free water added 
directly to the spin column membrane. The tube was centrifuged for 1 minute above 8000xg 
to elute the RNA.  
 8.4.2 Quantitative Real Time PCR  
 
8.4.2.1 Complementary DNA (cDNA) synthesis 
RNA samples were diluted to a known concentration in nuclease free water to a final volume 
of 10 µl in a 0.2 ml thin walled microcentrifuge tube. Using the high capacity cDNA reverse 
transcription kit (Applied Biosciences), a master mix was prepared containing (per 10 µl): 4.2 
µl nuclease free water, 2 µl 10X Reverse Transcription buffer, 0.8 µl 25X dNTPs, 2 µl 10X 
RT random primers and 1 µl Multiscribe® Reverse Transcriptase. Per sample 10 µl of 
76 
 
master mix was added to the 10 µl RNA sample and transferred to a thermocycler PCR 
machine (SensoQuest) for reverse transcription. PCR conditions were as follows: 25°C 10 
minutes, 37°C 2 hours, 85°C 5 minutes and then maintained at 4°C. cDNA was stored at -
20°C or diluted to a known concentration using nuclease free water for further use.  
  8.4.2.2 qRT-PCR reaction  
Two methods were used for qPCR, either Power SYBR® Green PCR Master mix or TaqMan 
Fast Universal PCR Master mix, no Amperase UNG (Applied Biosciences), depending on 
the genes to be analysed.  
Primers were designed to amplify the DNA region additional exon within the long isoform of 
CD21 (Table 3), as commercial primers were not available.  
For primers compatible with SYBR® Green, a master mix containing: 10 µl of Power SYBR® 
Green with 0.6 µl of primer mix, containing 10 µM forward and reverse primer, and 5.4 µl 
nuclease free water was added to a 96-well MicroAmp Optical reaction plate (Applied 
Biosciences), along with 4 µl of target cDNA. Alternatively, for TaqMan probes, a master mix 
containing: 10 µl TaqMan Fast Universal PCR Master mix, 5 µl nuclease free water and 1 µl 
of appropriate gene expression assay probe was added to plates with 4 µl target cDNA. 
Samples were added to the plate in duplicate and control wells containing 4 µl nuclease free 
water in replacement for target cDNA were included on each plate. Reactions were carried 
out using an Applied Biosystems 7300 Real-Time PCR System using the following 
programs. For TaqMan probes the program consisted of 50°C for 2 minutes, 95°C for 10 
minutes and 40 cycles of 95°C for 15 seconds before 1 minute at 60°C. For reactions 
containing SYBR® green primers the program performed was as follows: 95°C for 10 
minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. At the end of 
each program, the temperature was increased from 50°C to 95°C during which the 
fluorescence is analysed to produce a melt curve to assess the specificity of amplicon 
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production. Upon separation of double stranded DNA fluorescence is reduced; primers 
producing a single peak are considered specific. 
 
Gene Forward Primer Sequence Reverse Primer Sequence 
CD21L  CTACACTTGTGACCCTGGCT CTGGCATGTTTCTTCACACC 
GAPDH CAACTACATGGTTTACATGTTCCAA TGGAAGATGGTGATGGGATT 
   
Gene (Taqman probes) Assay ID Company 
CD21 Hs00153398_m1 Thermofisher Scientific 
CD19 Hs01047413_g1 Thermofisher Scientific 
CXCL13 Hs00757930_m1 Thermofisher Scientific 
CD3 Hs00174158_m1 Thermofisher Scientific 
CD35 Hs00559348_m1 Thermofisher Scientific  
CCL21 Hs00171076_m1 Thermofisher Scientific  
GAPDH Hs02786624_g1 Thermofisher Scientific  
 
Table 3: Primer and probe information 
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8.4.2.3 qRT-PCR analysis  
An automatic threshold (fluorescence normalised to reference dye) of 0.2Rn was set in the 
linear phase of the curve so that threshold cycles (Ct) could be determined for target genes 
and endogenous control genes. Ct is defined as the cycle number at which the fluorescence 
from the reporters passed the threshold. The mean Ct of the target gene from duplicate 
samples was calculated and normalised to the mean Ct for the endogenous control wells, 
this number is ΔCt. From this, the ΔΔCt was calculated by subtracting the ΔCt of the sample 
from the ΔCt of a calibrating sample (e.g. an untreated control). Finally, 2
-ΔΔCt calculated to 
measure relative expression in each sample. Data was plotted using Prism 7 (GraphPad).  
8.5 PCR 
  
Reactions were carried out using GoTaq® Green Master Mix (Promega). Each reaction 
contained a Master mix of: 12.5 µl GoTaq® Green 2X Master Mix, 1 µl primer mix, 
containing 10 µM of forward and reverse primer. This was added to 5 µl of cDNA template 
and the reaction made to a final volume of 25 µl using Nuclease-free water. The reaction 
was undertaken using a thermocycler PCR machine (SensoQuest) starting with 95°C for 2 
minutes and then cycling through 95°C for 1 minute, 65°C for 1 minute, 72°C for 1minute/kb 
of target product, for 35 cycles. The final extension was carried out at 72°C for 5 minutes 
and the reaction held at 4°C indefinitely.  
Gene Forward primer Reverse primer 
CD21 (long vs 
short primers) 
CAGATTCGTTGCAAAGCTGA AATCACTGGTGGAGGGTGAC 
pQXCIN cloning 
primers 
CTTAATTAACGGATCATGGGC
GCCGCGGGCCTG 
GAGAGGGGCGGAATTTCAGCTGGCT
GGGTTGTATGG 
 
Table 4: Primers for PCR. All produced by IDT technologies 
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 8.5.1 Agarose gel electrophoresis 
 
Typically, a 0.8% agarose gel was prepared by dissolving agarose (Sigma) into 1X Tris-
acetate-EDTA (TAE) buffer (Thermofisher) by heating using a microwave. The solution was 
allowed to cool to around 60°C before addition of ethidium bromide (10 µl per 100 ml) and 
subsequently poured into a gel cast. The gel was allowed to set and then placed in a gel 
tank filled with 1X TAE buffer.  
PCR samples were prepared by the addition of 6X DNA Gel loading dye (Thermofisher) and 
25-50 µl of the sample loaded into the wells. 10 µl of ladder GeneRuler 1Kb Plus 
(Thermofisher) was also loaded to each well. Gels were typically run at 100V for 30 minutes 
before visualisation with a UV light box (Thermofisher). Exposure time was dependent on 
intensity of band products.  
 8.5.2 DNA extraction from agarose gel 
 
For extraction of PCR products, the QIAquick gel extraction kit (Qiagen) was utilised. Firstly, 
using a UV light box, the DNA band of interest was excised from the agarose gel with a 
scalpel and the gel slice weighed. Next the gel slice was added to a 1.5 ml eppendorf tube 
and 3 volumes of Buffer QG added to 1 volume of gel (i.e. 100 mg ~ 100 µl); for gel slices 
above 400 mg, extraction proceeded in two eppendorfs/columns. The tubes were incubated 
at 50°C for 10 minutes with mixing by vortex every 2-3 minutes during the incubation. 1 gel 
volume of isopropanol (Sigma-Aldrich) was added to the sample, the sample mixed by 
pipetting and loaded into a QIAquick spin column. The column was centrifuged at 17900xg 
for 1 minute to bind DNA and the flow-through discarded.  A maximum of 800 µl was loaded 
to each column, for samples larger than this, this step was repeated with the remaining 
volume. 500 µl of Buffer QG was added to the column and centrifugation repeated as above. 
To wash the column, 750 µl of Buffer PE was added to the column and the tubes left to 
stand at room temperature for 2-5 minutes before centrifugation for 1 minute at 17900xg. 
The flow-through was discarded and the column centrifuged for a further 1 minute to remove 
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residual liquid. The column was placed in a clean 1.5 ml microcentrifuge tube and 50 µl of 
Buffer EB added to the centre of the column and incubated at room temperature for 1 minute 
before centrifugation for 1 minute to elute DNA. DNA concentration was determined using a 
nanodrop (Thermofisher) and used for downstream applications.  
 
8.6 PBMC Isolation from Peripheral Blood 
 
Accuspin tubes (Sigma-Aldrich) were prepared by the addition of 15 ml Ficoll (GE 
Healthcare Life Sciences) and spun at 1000 xg for 1 min. PBS was added to the blood 
sample to a total volume of 50 ml and split between two Ficoll Accuspin tubes. Tubes were 
centrifuged at 1000 xg for 10 min at RT without the brake. Using a Pastuer pipette, PBMCs 
at the interface were transferred to a fresh 50 ml polypropylene centrifuge tube. The 
contents of each tube were made to 50 ml with culture medium (RPMI1640 supplemented 
with 10% HI FCS, Glutamine and Penicillin/Streptomycin) and centrifuged at 250 xg at RT 
for 10 min to wash. Supernatant was removed, and pelleted cells gently re-suspended in 10 
ml culture medium. 100 µl of cell suspension was added to 400 µl PBS and cell counting 
performed using a NuceloCounter. Subsequently, cells were resuspended in appropriate 
buffer, concentration depending on experimental need.  
8.7 Thawing and Preparation of Tonsil cells for Flow Cytometry 
 
Vials of frozen cells were thawed in a water bath with gentle agitation until only a small ice 
pellet remained and transferred into 20 ml of pre-warmed culture medium (RPMI1640 
supplemented with 10% FI FCS, Glutamine and Penicillin/Streptomycin). Cell suspension 
was centrifuged at 200 xg for 5 min at RT and resuspended in isolation buffer (PBS with 
0.1% BSA, Sigma, and 2mM EDTA, Invitrogen). 100 µl of cell suspension was added to 900 
µl PBS for counting using a Nucleocounter and the centrifugation step repeated. Cells were 
resuspended in at 20x106 cells/ml in isolation buffer based on the previous cell count. For 
analysis of T and B cells, cells were transferred into a V-bottom 96 well plate for antibody 
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staining. For analysis of FDCs, CD45 depletion was performed using CD45 depletion beads 
(Thermofisher – Dynabeads). Using isolation buffer, 12% volume of beads that there are 
cells, were washed and subsequently added to the cell suspension. Cells were incubated at 
4°C with gentle agitation for 20 min. Then the tube was placed in a magnet for 2 min and 
supernatant transferred to a clean tube; this step was repeated. Cells were counted as 
above and pelleted by centrifugation at 200 xg for 5 min. Cell pellet was resuspended to a 
concentration of 20x106 cells/ml and transferred to a V-bottom 96 well plate for antibody 
staining.  
 
8.8 Surface Marker Antibody Staining for Flow Cytometry 
 
Flow cytometry staining was performed in a V-bottom 96 well plate. Cells were typically 
plated at a density of 2x105 cells/well for T and B cell staining and 2x106 cells/well for FDCs 
as there are fewer FDCs within the samples. Plates were spun at 400 xg for 3 min at 4°C to 
pellet cells and resuspended in 50 µl of antibody mix (concentrations found in Table 2). The 
plate was incubated for 20 min at 4°C. For live/dead discrimination, 5 µl per well of DAPI 
(1in90 pre-diluted stock) was added, the plate mixed briefly on a plate rotator and incubated 
for 10 min at 4°C in the dark. The cells were washed three times with 150 µl FACS buffer 
(PBS with 0.1% BSA, Sigma, and 2mM EDTA, Invitrogen) by spinning at 400 xg for 3 min 
and resuspending in a further 150 µl FACS buffer. After the final wash cells were 
resuspended in 200 µl FACS buffer. 
The samples were run using a Canto II or X-20 (BD Biosciences) flow cytometer. After 
running CS&T, voltages were set using single stained cells so that positive populations 
appeared around log104 where possible and ensuring all stains were brightest in their own 
channel with limited bleed into other channels. Compensation was carried out using 
Ultracomp beads (Thermofisher Scientific); 3 µl of antibody was added to 1 drop of beads 
and incubated for 10 min in the dark. 300 µl of PBS was added and the beads read on the 
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Canto. Compensation was applied prior to sample acquisition. Cells were identified by 
FSC/SSC, doublets were excluded, and live cells selected. Cells were further gated 
according to the staining panels used (Table 5). Data was analysed using the FlowJo 
(Treestar) software package.  
 
Experiment Gating strategy  Figure 
Human tonsil derived FDC 
sorting  
FDCs: lineage
-
gp38
+
CD35
+
 
FRCs: lineage
-
gp38
+
CD35
-
 
Figure 9.3.9 
Human tonsil derived T and 
B cell sorting  
B cells: CD19
+
CD3
-
 
T cells: CD19
-
CD3
+ 
Figure 9.3.10 
Identification of CD21
+
 FDCs  FDCs: lineage
-
gp38
+
CD21
+
 Figure 9.3.11 
Identification of CD21
+ 
T and 
B cells 
B cells: CD19
+
CD3
-
CD20
+
CD21
+
 
T cells: CD19
-
CD3
+
CD21
+
 
Figure 9.3.12 
FE8 blockage of C3dg 
binding on FDCs 
FDCs: lineage
-
gp38
+
CD21
+
C3dg
+ 
Figure 10.3.2 
FE8 blocking of C3dg 
binding on T and B cells 
B cells: CD19
+
CD3
-
CD20
+
CD21
+
C3dg
+
 
T cells: CD19
-
CD3
+
CD21
+
C3dg
+
 
Figure 10.3.3 
sCD21 blockage of C3dg 
binding on peripheral blood 
derived B cells 
B cells: CD20
+
C3dg
+
 Figure 11.3.17 
Activation of peripheral 
blood derived B cells using 
C3dg/anti-IgM complexes 
B cells: CD20
+
pERK
+
 Figure 11.3.24 
 
Table 5: Identification markers used for each cell type 
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Antibody Clone Manufacturer Conjugated Concentration  
Anti-human 
CD21 
Bu32 Biolegend PE 5 µl per 100 µl 
sample 
Anti-human 
CD35 
E11 eBioscience APC 5 µl per 100 µl 
sample 
Anti-human 
CD34 
581 Biolegend FITC 5 µl per 100 µl 
sample 
Anti-human 
CD31 
WM59 Biolegend FITC 5 µl per 100 µl 
sample 
Anti-human 
CD11b 
ICRF44 Biolegend FITC 5 µl per 100 µl 
sample 
Anti-human gp38 NZ-1.3 eBioscience PerCP eFluor710 5 µl per 100 µl 
sample 
Anti-human 
CD19 
HIB19 Biolegend PerCP Cy5.5 5 µl per 100 µl 
sample 
Anti-human CD3 HIT3a Biolegend APC/Cy7 5 µl per 100 µl 
sample 
Anti-human 
CD20 
2H7 Biolegend Alexa488 5 µl per 100 µl 
sample 
Anti-human 
CD21 
7D6 Novus Biologicals Unconjugated 5 µl per 100 µl 
sample 
Anti-human 
CD21 
R4/23 Origene Unconjugated 5 µl per 100 µl 
sample 
Anti-human IgM MHM-88 Biolegend FITC 5 µl per 100 µl 
sample 
Anti-human 
pERK 
4B11B69 Biolegend Alexa 488 5 µl per 100 µl 
sample 
 
Table 6: Antibodies used for flow cytometry 
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Antibody Clone Manufacturer Conjugate Volume used 
PE IgG1 MOPC-21 Biolegend PE 5 µl 
PerCP IgG1 MOPC-21 Biolegend PerCP 5 µl 
APC/Cy7 IgG2a MOPC-173 Biolegend APC/Cy7 5 µl 
Alexa488 IgG2b MOPC-154 Biolegend Alexa488 5 µl 
FITC IgG1 MOPC-21 Biolegend FITC  5 µl 
 
Table 7: Isotype antibodies used for flow cytometry 
8.9 Receptor Quantification on FDCs, T and B cells 
 
Tonsil derived FDCs and peripheral blood and tonsil derived T and B cells were stained with 
their respective antibody staining panels as previously described using a range of Bu32 
(CD21 clone) concentrations, starting at 10 µg/ml and serially diluted 3-fold, to identify a 
saturating antibody concentration appropriate for use in receptor numeration.  
Quantibrite-PE beads (BD Biosciences) were used to calculate the absolute CD21 receptor 
number on the cell membrane of FDCs (tonsil derived), T and B cells (blood and tonsil 
derived). Following antibody staining with 1 µg/ml Bu32-PE, the determined saturating 
concentration, and respective antibody panels as described, cells were resuspended in 200 
µl FACS buffer and run on the cytometer using the appropriate voltage settings.  
CD21 positive cells were identified in each cell type. Cells were identified using FSC/SSC, 
doublets excluded, and live cells selected. FDCs were identified as lineage-gp38+CD21+ 
(Figure 9.3.11), B cells were identified as CD19+CD20+CD21+ (Figure 9.3.12) and T cells 
identified as CD3+CD21+ (Figure 9.3.12). All gates were drawn using FMO and isotype 
controls.  
After collection of sample data, a single vial of Quantibrite beads were resuspended in 300 
µl PBS and beads were run using the same settings as respective sample data; PE voltage 
varies from cell type. Beads contain four populations, each with a known average number of 
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Figure 8. 1: Absolute receptor number using Quantibrite-PE beads 
PE molecules (Figure 8.1A). Geometric mean of these populations was plotted against the 
number of PE molecules to create a standard curve (Figure 8.1B) from which the number of 
PE molecules on each cell type could be interpolated using the PE geometric mean of each 
sample. Two standard curves were drawn for the different voltages used for FDCs and T/B 
cells and number of CD21 molecules were interpolated from respective curves. The number 
of PE molecules was then divided by 2.1, due to this being the number of PE molecules 
present on each CD21-PE antibody (Biolegend, confirmed by company using lot numbers), 
therefore normalising the data between each labelling protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) The geometric mean of each of the PE-bead populations was calculated using FlowJo. (B) Log 
geometric mean is plotted against the known number of PE molecules on respective bead 
populations 
86 
 
8.10 Making C3dg-Strep(APC) Complexes 
 
In separate 1.5 ml microcentrifuge tubes, the stock solutions of Streptavidin-APC (Prozyme) 
and biotinylated C3dg (provided by GSK) were diluted to form 20X concentrations, 400 
µg/ml and 462.4 µg/ml respectively. 400 µl of 20X Streptavidin-APC was added to 400 µl 
20X C3dg to generate 800 µl of 10X concentrated C3dg:Streptavidin-APC complexes. 200 µl 
of PBS was added to the remaining streptavidin to generate a 10X stock of a “No C3dg” 
control, i.e. streptavidin alone. The microcentrifuge tube was incubated at RT in the dark for 
30 min to promote complex formation, then stored on ice in the dark until required.  
 
8.11 Blocking C3dg binding to CD21 using FE8 on tonsil derived FDCs and 
blood and tonsil derived B cells 
 
Cells were prepared from fresh blood and frozen tonsil digests as previously described 
(sections 8.6 and 8.2 respectively) and stained for extracellular flow cytometry analysis as 
above (section 8.8). To determine an appropriate C3dg-Strep(APC) concentration, cells 
were stained with a range of concentrations starting at 10 µg/ml and 3-fold serial dilutions 
made.  
Cells were then stained with Bu32 and C3dg, Bu32 and FE8 or FE8 (CD21 clone) and C3dg 
(1 µg/ml) and incubated for 20 min in the dark at 4°C. Appropriate antibody staining panels 
were subsequently added and staining protocol continued as above (Section 8.8). 
Costaining confirmed whether the nature of the antibodies were competitive for the ligand 
binding site of CD21.  
For the final assay FE8 was used to block C3dg binding to CD21 on FDCs and B cells. 
Samples were prepared and before staining for flow cytometry, were preincubated with a 
range of FE8 concentrations starting at 2 µg/ml then 3-fold serially diluted. Isotype antibody 
was also used to stain control samples using the same range of concentrations. Samples 
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were incubated for 20 min at 4°C and subsequently stained following the extracellular 
staining protocol previously described with the addition of 1 µg/ml C3dg to each well.  
Samples were read using the Canto II and voltages set according to single stained controls. 
Analysis was undertaken by gating on CD21+ cells and assessing C3dg-APC geometric 
mean of this population. Data values were normalised by performing the following 
calculation:  
FE8 geometric mean/isotype geometric mean x100 
This value was plotted against FE8 concentration to obtain a binding response curve.  
 
8.12 Making retroviral vectors to express CD21 isoforms in Human Epithelial 
Kidney cells (HEKs) 
 
 8.12.1 In-Fusion® Cloning 
 
  8.12.1.2 Primer design 
 
Primers were designed using In-Fusion® online cloning tools Primer Design. The vector 
sequence, in this case pQXCIN (Figure 8.4), and the insert sequence, CD21 and CD21L, is 
analysed by the program. Restriction enzymes are chosen depending on where the gene is 
wished to be inserted and the program designs primers that will add 15 bp extensions onto 
the insert sequence, allowing for insertion of the gene of interest into the vector.  
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Figure 8. 2: In-Fusion primer design programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
  8.12.1.3 Vector linearisation 
 
Vector pQXCIN was linearized with EcoRI-HF (New England Biolabs) and BamHI-HF (New 
England Biolabs). On ice, vector was diluted to 0.3 µg/µl and 3 µl, i.e. 1 µg, of plasmid DNA 
added to each reaction (3 reactions were set up in total, a total of 3 µg plasmid DNA was 
linearised). 10 units of each enzyme (1 µl in this case) was added to the reaction with 5 µl 
10X CutSmart buffer (New England Biolabs) and the final reaction volume made up to 50 µl 
with nuclease free water. Reactions were run at 37°C for 15 minutes in a thermocycler 
(SensoQuest) and then loaded onto an 0.8% agarose gel for electrophoresis separation of 
products following the protocol above (Section 8.5.1). Linearised plasmid was extracted from 
the gel following the protocol described above (Section 8.5.2).  
The plasmid and insert sequences are entered into the online programme and the restriction 
enzymes to cut the DNA selected. Primers are designed automatically by the programme (2). This 
was done for pQCXIN with CD21S and CD21L cDNA.  
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  8.12.1.4 PCR amplification of the target gene 
 
In-Fusion® PCR Premix (Clontech) was used to amplify the CD21 (SinoBiological) and 
CD21L (cDNA provided by GSK) insert from carrier vectors (Figure 8.3). 12.5 µl of PCR 
premix was added to 0.5 µl of the forward and backwards primers, designed for In-Fusion® 
cloning. 150 ng (1.5 µl in this case) of cDNA was added to each reaction and the nuclease-
free water added to a final volume of 25 µl. The reactions were run using a thermocycler 
(SensoQuest) using the following conditions: 98°C for 10 seconds, 55°C for 10 seconds, 
72°C for 15.5 seconds; this cycle was repeated 35 times. Samples were loaded onto a 0.8% 
agarose gel and products separated using electrophoresis following the protocol described 
in section 8.5.1. Insert was extracted from the gel following protocol detailed in section 8.5.2.  
  8.12.1.5 In-Fusion® cloning reaction   
 
The ratio of vector:insert to be used in the cloning reaction was calculated by analysis of 
plasmid and vector DNA sequences by the online Clontech ratio calculator 
(https://www.takarabio.com/learning-centers/cloning/in-fusion-cloning-tools). In this case 200 
ng of vector was used and 189.2 ng of each insert used. 4 µl of the In-Fusion® enzyme was 
added to DNA mix and nuclease free water added to a final volume of 20 µl. Reactions were 
placed in a thermocycler (SensoQuest) and heated at 50°C for 15 minutes and subsequently 
placed on ice.  
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Figure 8. 3: InFusion cloning method (adapted from takarabio.com) 
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  8.12.1.6 Transformation of cloning reaction into competent E.coli  
 
Reactions were transformed into Stellar Competent bacteria (Clontech) by the addition of 
2.5ul of the In-Fusion® cloning reaction to 50 µl bacteria on ice. A vector only control was 
also performed for each transformation. Cells are rested on ice for 30 minutes before heat-
shock at 42°C for 40 minutes. Cells are placed back on ice for 1-2 minutes before the 
addition of 450 µl SOC (Clontech), prewarmed to 37°C, and incubated at 37°C for 1 hour 
with gentle, continuous mixing.  
Cells were spread on LB/ampicillin plates, made with sterile LB broth (Sigma-Aldrich) and 
Bacto agar (Sigma-Aldrich) and the addition of 50 µg/ml ampicillin (Sigma-Aldrich). Plates 
were incubated overnight at 37°C and colonies picked the next day.  
  8.12.1.6 Miniprep of bacterial colonies  
 
Bacterial colonies were picked and placed in 4 ml of LB media containing 50 µg/ml ampicillin 
and allowed to grow at 37°C for 4 hours with constant mixing. Cells were pelleted by 
centrifugation at 6000 rpm for 5 minutes. Cells were then mini-prepped using the QIAprep 
spin miniprep kit (Qiagen). Pelleted bacteria was resuspended in 250 µl of Buffer P1 and 
transferred to a microcentrifuge tube. 250 µl of Buffer P2 was added to the tube and mixed 
thoroughly by inverting the tube 4-6 times. Immediately afterwards, 350 µl Buffer N3 was 
added and thoroughly mixed by inversion. The tubes were centrifuged for 10 minutes at 
13000 rpm in a table-top microcentrifuge (Eppendorf). The supernatants of samples were 
applied to a QIAprep spin column and centrifuged for 40 seconds. This flow-through was 
discarded. The column was washed by the addition of 500 µl Buffer PB and centrifugation as 
above. The column was then washed with 750 µl Buffer PE and centrifugation repeated. The 
columns were spun for an additional 1 minute to remove any residual wash buffer before 
addition of 50 µl of Buffer EB. The column was left to stand at room temperature for 1 minute 
before centrifugation for 1 minute at 13000 rpm to elute DNA.  
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Eluted DNA was quantified using a nanodrop and then digested with EcoRI-HF and BamHI-
HF using the protocol described in section 8.12.1.3 and subsequently run on an agarose gel 
(as described in section 8.5.1) to check isolated DNA was the vector pQXCIN containing the 
insert, CD21 or CD21L. 
  8.12.1.7 Maxiprep of bacterial colonies  
 
Colonies were picked from LB-agar plates and placed into 100 ml LB plus 50 µg/ml 
ampicillin and grown overnight at 37°C whilst shaking. Glycerol stocks were made of the 
cultures by taking 500 µl of the cell solution and adding 500 µl of 50% glycerol in PBS. 
Stocks were stored at -80°C.  
For Maxipreps, 35 ml of bacteria was pipetted into a 50 ml Falcon tube and spun at 3200xg 
for 30 minutes to pellet cells. Supernatant was removed and 4 ml of cold P1 buffer was 
added to each falcon and pellet resuspended. 4 ml of P2 buffer was added to the tube and 
inverted to mix before the addition of 4 ml P3 and mixing again. The lysate was poured into 
the barrel of a QIA filter cartridge and incubated at room temperature for 10 minutes. During 
this time, 4 ml of QBT buffer was added to Qiagen-tips and allowed to flow-through to 
equilibrate the column. The cap of the QIA filter cartridge outlet nozzle was removed, and 
the plunger inserted. The lysate was filtered into the equilibrated Qiagen-tip and allowed to 
flow through. The column was washed twice with 10 ml of Buffer QC and then DNA eluted 
with 5 ml of Buffer QF, prewarmed to 55°C into a fresh 15 ml falcon tube. DNA was 
precipitated by adding 3.5 ml of room temperature isopropanol to the eluted DNA and 
centrifugation at 3200 xg for 45 minutes. The supernatant was discarded, and the pellet 
washed with 2 ml of 70% ethanol (Sigma-Aldrich) by centrifugation at 3200xg for 20 min at 
4°C. The supernatant was discarded, and the pellet allowed to dry for 5 minutes. Samples 
were resuspended in 250 µl nuclease-free water and quantified with a nanodrop 
(Thermofisher) before being stored at -20°C.  
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8.13 Cell culture of Human Epithelial Kidney cells (HEKs) 
 
 8.13.1 Cell culture  
 
HEK cells were sourced from ATTC and cultured in Dulbecco’s modified eagle medium 
(DMEM; Sigma-Aldrich) supplemented with 2mM L-glutamine, 15% FCS and 1% pen-strep. 
Complete media is termed as D15%. 
 8.13.2 Cell subculture  
 
Upon reaching confluency (~80-90%), media was removed, and cells washed twice in 
Dulbecco’s-PBS (D-PBS; no CaCl2, no MgCl2; PAA) and 2ml or 5ml 1X Trypsin-EDTA added 
to a T75 flask or T175, respectively. Cells were incubated at 37°C for up to a maximum of 7 
minutes with constant monitoring for rounding and detachment. Once cells were detached, 
flasks were tapped to remove cells and 5ml warm D15% added to terminate trypsin activity 
and cells collected. The cells were centrifuged for 5 min at 300xg and resuspended in 5ml 
D15% for cell counts using a ViCell cell counter. Depending on experimental requirements, 
cells were seeded in 12 and 6 well plates (VWR). Table 8 was used for calculating number 
of cells to be seeded in different culture plates. For routine passage, cells were split 1:3. At 
least 1 vial of cells was frozen from each passage.  
Dish Surface Area 
cm
2
 
Seeding 
density 
(~25%) (x10
6
) 
Seeding 
density 
(~60%) (x10
6
) 
Confluency 
(x10
6
) 
Growth 
media 
T75 75 0.375 0.9 1.5-20 10ml 
T25 25 0.125 0.3 0.5-0.7 4ml 
T160 162 0.8125 1.95 3.5-4.0 17ml 
6-well 9 0.05 0.12 0.2 3ml 
12-well 4 0.02 0.048 0.08 1ml 
24-well 2 0.01 0.024 0.04 0.5ml 
Table 8: Determining the approximate cell number for seeding at particular densities  
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 8.13.3 Cryopreservation 
 
Cells were resuspended at 1x106 cells/ml in D15% culture media after detaching and 
quantifying cells. 500 µl of freezing media (0.5x106) were transferred to cryovials (Corning) 
with the addition of 500 µl of freezing media (FCS, 20% dimethyl sulfoxide; DMSO; Sigma-
Aldrich), added drop-wise. Vials were immediately transferred to a Mr Frosty (Nalgene) and 
stored at -80°C. For long-term storage vials were deposited in liquid nitrogen.  
For revival of frozen cells, vials were removed from liquid nitrogen storage and transferred to 
a 37°C water bath until only a small portion of the cell mix remained frozen. Cells were 
added to 3 ml of pre-warmed media and pelleted by centrifugation at 300xg for 5 min. The 
pellet was resuspended in 10 ml of warm media and transferred to a T75 flask. The next day 
media was replaced with fresh warm media so as to discard dead cells.  
8.14 Transfection of Human Epithelial Kidney cells (HEKs)  
 
Cells were seeded into a 6-well plate (Section 8.13.1) so that they were 50-80% confluent on 
the day of transduction. The next day, transduction was carried out using lipofectamine LTX 
(Thermofisher). For each well, 35 µl lipofectamine was diluted in 500 µl Opti-MEM 
(Thermofisher). A total of 15 µg DNA for interest was diluted into 500 µl Opti-MEM and 
PLUS reagent (Thermofisher) added at a 1:1 volume as total DNA added. Each tube was 
incubated separately for 5 minutes at room temperature before addition of the DNA to the 
lipofectamine reagent. This solution was incubated at room temperature for 25 minutes. 
Meanwhile, the HEK cells were prepared by aspirating media and subsequently washed 
twice with PBS. After the second wash, 9 ml of Opti-MEM was added to the cells and the 
transfection reagent/DNA mix added dropwise. Plates were incubated for 24 hours at 37°C 
before removing Opti-MEM and replacing media with D15%. Cells were harvest 48-60 hours 
later, when 70-90% confluency was reached.  
To harvest cells, media was removed from the cells and frozen at -80°C as CD21/CD21L 
containing supernatant. Cells were lifted by the addition of 1 ml 1X Trypsin-EDTA and 
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incubated for up to 5 minutes at 37°C. 1 ml D15% was added to stop the reaction and cells 
collected from wells and pelleted by centrifugation at 350xg for 5 minutes. Cells were 
resuspended in media and counted using a ViCell cell counter and resuspended at an 
appropriate density for subsequent use.  
8.15 C3dg binding/blocking experiments 
 
HEK293T cells were transfected with CD21S or CD21L and harvest as described in Section 
8.13.1. Cells were resuspended in flow buffer at a final cell density of 0.5x106 cell/ml and 
100 µl of cells were added to each well in a 96 well plate.  
C3dg-strepavidin-APC complexes were prepared to a final concentration of 1 µg/ml and 10 
µg/ml as in Section 8.10. During the incubation of the complex, FE8 (provided by GSK) and 
isotype (Biolegend) antibodies were titrated starting at a final assay concentration of 6 µg/ml, 
3-fold dilutions were made to gain the full dilution series. After the complex incubation 
period, a serial dilution of C3dg-strepavidin was made with a starting concentration of 10 
µg/ml, making 3-fold dilutions to complete the series.  
Plates containing cells were spun at 400 xg for 3 minutes to pellet cells and were 
resuspended in 50 µl of FE8/isotype antibody titration or flow buffer. Cells were incubated for 
20 minutes at room temperature before the addition of C3dg-strepavidin, 1 µg/ml for those 
samples preincubated with antibody titration, or titration series for those samples 
resuspended in flow buffer. CD21-PE (Bu32, Biolegend) was also added to samples to a 
final concentration of 1 µg/ml. The plate was mixed briefly by a plate rotator before 
incubation for 20 minutes at 4ºC. DAPI stain (Biolegend) was added to each well, the plate 
mixed briefly and incubated for a further 10 minutes at room temperature. Samples were 
washed three times with 150 µl flow buffer (PBS, Dibco, plus 0.2 mM EDTA, Invitrogen, and 
2% BSA, Sigma) by spinning the plate at 400 xg for 5 min, removing the contents of the well 
and resuspending the pellet in flow buffer.  
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Samples were read using the BD Canto II. After running CS&T, voltages were adjusted 
using single stained cells, making sure all stains were brightest in their own channel. 
Compensation was set up using Ultracomp beads (BD Biosciences) and then data collected.  
In addition to binding data, CD21 absolute receptor number expression in each transfection 
was calculated using Quantibrite-PE beads (BD Biosciences) following the protocol detailed 
in Section 8.9.  
 
8.16 Western blot for CD21 protein 
 
HEK293T cells transfected with CD21S and CD21L DNA as described above (Section 8.14) 
were lysed using RIPA buffer (Sigma) plus protease inhibitor cocktail (Sigma). Cell lysate 
was left on ice for 30 minutes and then centrifuged at 13,000 xg for 2 minutes to pellet 
insoluble proteins. 4X LDS + DTT was added to each sample and then boiled at 90ºC for 10 
minutes before repeating the centrifugation step above. Cells were placed on ice until 
loading onto gels.   
20 µl of each sample and 4 µl ladder (LiCor) was loaded onto an 8% Bris-Tris SDS gel 
(Invitrogen). The gel was run in 1X MOPS buffer (Thermofisher Scientific) at 180V for 45 
minutes. The gel was removed from the cassette and transferred to nitrocellulose using the 
iBlot transfer (Invitogen), run time was 7 minutes using the standard manufacturers protocol. 
The blot was blocked for 60 minutes at room temperature in Odessey blocking buffer (LiCor) 
before the addition of primary antibody made to a concentration of 1 in 1000 in Odessey 
blocking buffer and incubated at room temperature for 60 minutes on a rocker. The blot was 
washed briefly with PBS + 0.05% Tween three times and then washed for 3 minutes three 
times. Secondary antibody, rabbit anti-mouse IgG-HRP (Invitrogen) was made to a 
concentration of 1 in 5000 in PBS + 0.05% Tween and incubated at room temperature for 60 
minutes on a rocker. The blot was washed as above before addition of ECL and imaged 
using an imaging box (Biorad). Blots were each exposed for around 40 seconds before 
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further downstream processing, i.e. greyscale and intensity adjustments, to gain the best 
visualisation of the bands present. 
 
8.17 Validation of a human CD21 ELISA and measuring soluble CD21 levels 
in healthy volunteer and Rheumatoid Arthritis patient serum  
 
A commercial CD21 ELISA (abcam) was first validated for use with serum samples (details 
within results section 11.3.1) and subsequently used to measure sCD21 levels within healthy 
volunteer and Rheumatoid Arthritis patient serum.  
All reagents were made to the manufacturer’s instructions, the volumes prepared determined 
by the number of wells required for each assay (see table). A 1X standard diluent buffer was 
made by diluting the 10X stock in distilled water. Standards were made within 1in4 diluted 
serum, due to matrix interference; therefore human serum was diluted with 1X standard 
diluent. Recombinant CD21 (R&D systems) was added to the first standard at a final 
concentration of 600 µg/ml and serially diluted 2-fold into the remaining 6 standards. For the 
blank standard 1in4 diluted serum alone was used. 1X Biotinylated anti-CD21 and 1X 
Streptavidin-HRP solution was made by dilution in their respective diluent buffers according 
to the number of wells used in the assay (see table 9). All serum samples were diluted 1in4 
in a separate 96-well plate before addition to the ELISA plate.  
100 µl of all samples and standards were loaded into the appropriate wells and 50 µl of 1X 
Biotinylated anti-CD21 added to all wells before incubation at RT for 1 hour. The plate was 
washed three times using PBS + 0.05% Tween using an automatic plate washer. 100 µl of 
1X Streptavidin-HRP solution was added to each well and the plate incubated at RT for 30 
min. The wash step was repeated as described above. 100 µl of Chromogen TMB substrate 
solution was added to each well and incubated in the dark for 12 min at RT. 100 µl of Stop 
Reagent was added to each well and absorbance read immediately on a spectrophotometer 
using 450 nm.  
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For data analysis, the absorbance of the blank measurements (1in4 diluted serum alone) 
was subtracted from each of the samples. A standard curve was drawn using the 
background corrected absorbance values and the known CD21 concentrations; curves were 
drawn using a log-4 parameter fit. sCD21 concentration of samples was interpolated from 
this curve and interpolated value multiplied by 4 to account for the dilution made.  
Each time the assay was performed quality control samples were run on the plate, samples 
were made from 1in4 diluted human serum in 1X standard diluent, spiked with a known 
concentration of rc-CD21. These samples were made by spiking recombinant CD21 into 
neat serum 4-fold the desired concentration and subsequently diluting serum 1in4 in 1X 
standard diluent buffer. The final CD21 concentration within these samples was 20 ng/ml, 50 
ng/ml and 100 ng/ml. Samples were loaded onto the plate and analysed as above.  
Humanised mouse serum was also analysed for sCD21 content, using the protocol as 
detailed above.  
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Number of well strips used Volume of reagent Volume of Diluent  
Biotinylated anti-CD21 
Number of well strips used Volume of Biotinylated anti-
CD21 (µl) 
Volume of Biotinylated 
Antibody Diluent (µl) 
2 40 1060 
3 60 1590 
4 80 2120 
6 120 3180 
12 240 6360 
Strepavidin-HRP 
Number of well strips used Volume of Strepavidin-HRP 
(µl) 
Volume of HRP-Diluent (ml) 
2 30 2 
3 45 3 
4 60 4 
6 75 5 
12 150 10 
 
Table 9: Volume of CD21 ELISA reagents used 
 
8.18 Using soluble CD21 to block binding of C3dg to peripheral B cells  
 
Soluble CD21 was titrated with a starting concentration of 5000nM and serially diluting 2-
fold. Two soluble CD21 reagents were used, recombinant CD21 (R&D Systems), the full-
length protein, and a protein construct consisting of only SCR’s 1 and 2 (GSK), the ligand 
binding site of CD21. 0.2 µg/ml C3dg-StrepAPC complexes, made as above, were added to 
soluble CD21 and incubated at RT for 20 minutes.  Using this concentration of C3dg creates 
a molar ratio of 10,000 sCD21:1 C3dg at the top titration point.  
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Meanwhile, PMBCs were isolated from blood donated at the BDU, GSK (Stevenage), using 
the method described above (Section 8.6) and plated into V-bottom 96-well plates at a cell 
density of 1x105 cells/well. Cells were pelleted by centrifugation at 450 xg for 3 minutes and 
resuspended in the sCD21/C3dg titration. The cells were then stained for extracellular flow 
cytometry analysis following the protocol described in Section 8.8.  
B cells were identified as CD19+ and C3dg binding assessed (Figure 11.4.18). Percentage of 
C3dg binding was assessed by recording C3dg-strepAPC MFI and normalising this value to 
the MFI of samples containing 0 nM sCD21. A binding response curve was created by 
plotting these values against log sCD21 concentration.  
8.19 Culture of B cell lines (Raji and Ramos) 
 
 8.19.1 Cell culture of B cell lines  
 
Cell lines, Raji (ATCC number CCL-86) and Ramos (ATCC number CRL-1596) were 
cultured in RPMI medium 1640 (GIBCO) supplemented with 2mM L-glutamine, 10% FCS 
and 1% pen-strep (provided by Sodexo, GSK).  
 8.19.2 Thawing B cell lines 
 
Raji and Ramos cells were thawed after removal from liquid nitrogen in a 37ºC water bath 
and suspended in 10 ml growth media. Cells were spun at 300 xg for 4 minutes and media 
discarded. Cells were resuspended at a density of 0.5x106 cells/ml.  
 8.19.3 Subculture of B cell lines 
 
Every 2 to 3 days, medium was changed, and cultures spilt to a density of 0.5x106 cells/ml 
by transferring cells into centrifuge tubes and spinning for 4 minutes at 300 xg. The 
supernatant was aspirated, and 10 ml of culture media added. Cells were counted using a 
ViCell cell counter and the spin repeated. Finally, cells were resuspended to the required 
density and transferred to a new culture vessel.  
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8.20 Activation of peripheral B cells with C3dg-anti-IgM complexes 
 
The day before performing activation assays, cell lines were fed as described in Section 
8.19.3 and replated at a density of 0.5x106 cells/ml.  
In advance of cell preparation, proteins for stimulation cocktails were prepared at 30x final 
assay concentration. Anti-human IgM (FC5MU), F(AB’)2 Fragment (Sigma) was prepared by 
dilution in PBS to 300 µg/ml and serially diluted to gain an anti-IgM titration. Biotinylated 
C3dg (provided by GSK) was prepared to a concentration of 9 µg/ml and neutravidin 
(Sigma) was diluted to a concentration of 30 µg/ml. Stimulation reagents were mixed to a 
ratio of 1:1:1 so the cocktail was at a 10X final concentration and left at room temperature for 
30 minutes and then placed on ice 5 minutes prior to cell stimulation.  
Cell lines were removed from flasks and pelleted by centrifugation at 350 xg for 5 minutes. 
Cells were resuspended in RPMI and counted using a ViCell cell counter. The spin was 
repeated, and cells resuspended in complete RPMI at a density of 0.5x106 cells/ml before 
allowing the cells to rest for an hour.  
Meanwhile Phospho fix/lyse solution (BD Biosciences) was diluted to create a 1X solution 
and prewarmed to 37ºC in a water bath and Perm-buffer III (BD Biosciences) was chilled on 
ice.  
Next, 180 µl of rested cells were added to 20 µl of chilled stimulation cocktail and transferred 
to a 37ºC humidified CO2 incubator for 10 minutes. After the stimulation period, the cells 
were fixed immediately by adding 1-fold volume of 1X Phospho fix/lyse buffer. The 
incubation period was repeated as above. Plates were then centrifuged at 600 xg for 5 
minutes and the supernatant aspirated, leaving no greater than 50 µl of residual volume. 
Pellets were vortexed to disrupt the cells and permeabilised by the addition of 200 µl of pre-
chilled Perm buffer III (BD Biosciences), resuspended thoroughly by pipetting up and down, 
and then transferring into a 2 ml deep well plate containing 200 µl of pre-chilled Perm buffer 
I, making the total volume 400 µl. The plate was then stored at -20ºC for 30 minutes. After 
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the incubation period, the plate was centrifuged at 600 xg for 5 minutes and supernatant 
removed. The cells were resuspended in 200 µl of flow buffer (PBS, Dibco, plus 0.2 mM 
EDTA, Invitrogen, and 2% BSA, Sigma) and transferred to a V-bottom plate. The 
centrifugation step was repeated three times to wash the cells. After the final wash, cells 
were resuspended in 50 µl of antibody mix. Antibody mix contained flow buffer, anti-CD20-
PE (Biolegend) and anti-pERK-APC (Invitrogen). Cells stained with single antibodies were 
prepared for compensation. Samples were mixed and incubated at 4ºC for 30 minutes in the 
dark. Cells were washed 3 times in 150 µl flow buffer.  
Samples were read using a Canto flow cytometer (BD Biosciences). Voltages were adjusted 
based on negative and positive cells and compensation calculated with single stained 
compensation beads (Invitrogen) applied using the compensation wizard. Approximately 
10,000 events were collected for each sample. Events were imported into FlowJo (version 
10) and CD20 events were plotted as a scatter plot against side scatter to reveal CD20 
positive events (Figure 11.3.23). CD20 positive events were gated and pERK+/- events were 
plotted as histograms within this gate. Percent positive phospho-protein content was 
calculated using gating on unstimulated and isotype control stained cell samples.  
8.21 Blocking B cell line activation with FE8 and sCD21 
 
The day before performing activation assays, cell lines were fed as described in Section 
8.19.3 and replated at a density of 0.5x106 cells/ml.  
Ahead of cell preparation, stimulation complexes were prepared at 4x final assay 
concentration. Anti-human IgM (FC5MU), F(AB’)2 Fragment (Sigma), biotinylated C3dg 
(provided by GSK) and neutravidin (Sigma) were prepared to a concentration of 12 µg/ml, 40 
µg/ml and 12 µg/ml respectively and incubated together for 30 minutes at room temperature 
and then placed on ice. Final concentrations of reagents in the complex were as follows: 1 
µg/ml neutravidin, 0.3 µg/ml C3dg and 0.3 µg/ml anti-IgM. 
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A titration of FE8 antibody (provided by GSK) was made starting at 72 µg/ml (4x final assay 
concentration,18 µg/ml) and subsequent 3-fold log serial dilutions made in PBS. The same 
titration series was made with an isotype control antibody (Biolegend). Recombinant CD21 
(R&D systems) was titrated, starting at 500 µg/ml (4x final assay concentration, 125 µg/ml) 
and serially diluted using 3-fold log titrations into PBS. To control for protein addition into the 
assay, the equivalent dilution series was made using recombinant IL7R (R&D systems). 
Cell lines were removed from flasks and pelleted by centrifugation at 350 xg for 5 minutes. 
Cells were resuspended in RPMI and counted using a ViCell cell counter. The spin was 
repeated, and cells resuspended in complete RPMI at a density of 2x106 cells/ml before 
allowing the cells to rest for an hour.  
Before the addition of any stimulation reagents to plates, 50 µl of RPMI was added to each 
well. For the FE8 assay, 50 µl of the FE8 or isotype antibody titration was added to 
appropriate cells along with 50 µl of rested cells. For the rc-CD21 assay, 50 µl of rc-CD21 or 
rc-IL7R was added to 50 µl of 4x stimulation complex. Both assays were incubated at room 
temperature for 20 minutes. After this preincubation period, 50 µl of cells was added to the 
rc-CD21 assay wells and 50 µl of stimulation complex added to the FE8 assay wells. The 
total assay volume was 200 µl.  
The samples were transferred to a 37ºC humidified CO2 incubator for 10 minutes. After the 
stimulation period, the cells were fixed immediately by adding 100 µl of Phospho fix/lyse 
buffer (BD Biosciences), prewarmed to 37ºC. Cells were incubated at 37ºC for 10 minutes 
before centrifugation at 600 xg for 5 minutes. Supernatant was removed, leaving no greater 
than 50 µl of residual volume. Pellets were vortexed to disrupt the cells. Cells were 
permeabilised by the addition of 200 µl of pre-chilled Perm buffer III (BD Biosciences), 
resuspended thoroughly by pipetting up and down, and then transferred into a 2 ml deep 
well plate containing 200 µl pre-chilled Perm buffer III, making the total volume 400 µl. Plates 
were stored at -20ºC for at least 30 minutes. After this time, plates were centrifuged at 600 
xg for 5 minutes and the supernatant removed. Cells were resuspended in 200 µl flow buffer 
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(PBS, Dibco, plus 0.2 mM EDTA, Invitrogen, and 2% BSA, Sigma) before transfer to a V-
bottom plate. The plate was centrifuged at 600 xg for 5 minutes and the wash step was 
repeated three times. After the final wash, the cells were resuspended in 50 µl of antibody 
mix. Antibody mix contained flow buffer, anti-CD20-PE (Biolegend) and anti-pERK-APC 
(Invitrogen). Cells stained with single antibodies were prepared for compensation. Samples 
were mixed and incubated at 4ºC for 30 minutes in the dark. Cells were washed 3 times in 
150 µl flow buffer as above. 
Samples were read on a BD Canto flow cytometer. Voltages were adjusted based on 
negative and positive cells before collecting samples. For each sample around 10,000 
events in the CD20+ gate were collected. Events were imported into FlowJo (version 10) 
and CD20 events were plotted as scatter plots against side scatter to reveal CD20 positive 
events. CD20 positive events were gated and pERK+/- events were plotted as histograms 
within this gate. pERK+ gate was set using isotype control antibody stained and 
unstimulated cell samples.  
8.22 Statisical analysis 
 
Statistical analysis was done using GraphPad Prism. When comparing two data-sets a two 
way T-test was used, using multiple comparisons if the data-set was to be compared to more 
than one other factor. Data was plotted on graphs with bars illustrating the mean values and 
error bars representing the standard deviation of the mean (SD) (GraphPad).  
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9. Results chapter 1: Identification and characterisation of 
human Follicular Dendritic Cells 
 
9.1 Introduction 
 
9.1.2 Human FDCs and their identification 
 
FDCs are shown to express complement receptors CD21 and CD35 (Imai et al., 1996) in 
both primary and secondary follicles within the light zone of the germinal centre. FDCs are 
also critical for germinal centre formation; mice deficient in CD21/CD35 (no FDCs) have 
unorganised germinal centres and are unable to retain antigen. Ablation of FDCs in mice 
lead to rapid loss of the primary follicles structure leading to unorganised bands of cells and 
T cell-zones (Wang et al., 2010), highlighting the importance of these cells’ role in the 
microarchitectal organisation of secondary lymphoid organs (Wang et al., 2011). Expression 
of CXCL13 by FDCs contributes highly towards this organisation (Cyster et al., 2000). This 
chemokine is essential for the attraction of CXCR5+ B cells from the dark zone to the light 
zone of the germinal centre. CXCL13 expression has been previously detected in FDC-
enriched cell preparations (Tjin et al., 2005), during the culture of FDC cell lines (Murakami 
et al., 2007), and FDCs within inflammation-induced ectopic lymphoid follicles (Shi et al., 
2001). Expression of this chemokine is dependent on LTα1β2 and directly induces 
expression of this molecule by naïve B cells, therefore a positive feedback loop to augment 
CXCL13 production (Ansel et al., 2000).  
FDCs express low affinity antibody receptors, CD23 for IgE (Maeda et al., 1992) and FcγRIIb 
for IgG (Qin et al., 2000). It has been suggested that although these receptors are not as 
important as complement receptors for immune complex trapping, they do enhance long-
term retention of these complexes by the FDC. In addition to this observation, FDCs lacking 
FcγRIIB are unable to convert poorly immunogenic immune complexes into an immunogenic 
form for presentation to B cells (Qin et al., 2000). The direct interaction of the immune 
complex with FcγRIIB on FDCs causes upregulation of the receptor, as well as ICAM-1 and 
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VCAM-1, suggesting this engagement is important in initiating pathways leading to FDC 
activation (El Shikh et al., 2006). Interactions between FDCs and B cells are facilitated by 
the expression of integrin ligands VCAM-1 and ICAM-1 on FDCs (Koopman et al., 1991). 
This close interaction allows B cells to encounter the opsonised antigen presented by FDCs 
on CD21, a receptor common between both cell types (Bradbury et al., 1992). 
Human FDCs have been shown to express CD14, CD10 and CD21, but not CD45 (Munoz-
Fernandez et al., 2006) using flow cytometry. These results, along with the 
immunohistochemical observation of smooth muscle-actin expression in the cytoplasm of the 
cell, suggested that FDCs were related to bone marrow stromal cell progenitors and 
myofibroblasts and were not derived from haematopoietic origin. Other markers which 
identify FDCs include CD40 and BAFF known to promote B cell responses. BAFF is needed 
for maintaining B cell homeostasis and FDCs have been identified as a major source of this 
factor (Gorelik et al., 2003). This evidence came from the observation that FDC cell lines and 
freshly isolated FDCs from human tonsils, express BAFF mRNA (Zhang et al., 2005) as well 
as immunohistochemical analysis showing BAFF staining within the germinal centre (Hase 
et al., 2004). CD40 signalling of B cells promotes germinal centre formation, immunoglobulin 
isotype switching, somatic hypermutation and long-lived plasma and memory B cells 
(Danese et al., 2004), therefore this pathway is essential to germinal centre reaction as 
absence of CD40 stimulation eradicates the germinal centre response (Paus et al., 2006).  
Several monoclonal antibodies are available that are reported to bind to specific FDC 
antigens. The antigen FDC-M1 is also abundant on tingible body macrophages in germinal 
centres but its molecular identity remains undetermined. However, the FDC-M2 antigen has 
been identified as complement component C4 in immune complexes, this observation is 
consistent with the knowledge that deposition of immune complexes and complement 
components are observed on FDCs within the germinal centres (Imai et al., 1996). Other 
antibody clones specifically against CD21 expressed on FDCs have been reported, but this 
will be discussed later in the thesis.  
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FDCs can be isolated from irradiated mice using collagenase and DNaseI (Sukumar et al., 
2005). However, isolation of human FDCs is more challenging and, despite it being achieved 
in the past (Schriever et al., 1989), there is no standardised protocol. Due to this, the vast 
majority of published in vivo studies are carried out within murine models and were 
discussed within the main introduction to this thesis. In mice, both CR1 and CR2 (CD35 and 
CD21 respectively) are transcribed from the same gene and then alternatively spliced from 
this mRNA, while in human these proteins are derived from two distinct but closely related 
genes on chromosome 1 (Boackle et al., 2003). Alternative splicing of a single exon 
generates two isoforms in human (Fujisaku et al., 1989) which do not exist within mice. 
Expression of CD21 is exclusive to murine B cells and FDCs, whereas in human expression 
extends to a broader distribution of cell types. Mouse CR2 is 67% homologous to the human 
equivalent and binds with similar affinities to human and mouse C3d (Fang et al., 1998). 
Despite this similarity, interspecies differences lead to little translatability of murine studies to 
human biology.  
 
9.1.3 Human FDC cell lines 
 
Many FDC-like cell lines have been reported within the literature, however their use to collect 
reliable information about the human FDC characteristics and function is questioned due to 
phenotypical and functional discrepancies between these lines and primary cells.  
An early study showed how long-term culture of primary FDCs could be achieved and that 
the resultant cell line expressed FDC markers CD14, CD40, ICAM-1 and VCAM-1 (E. Clark 
et al., 1992). These cells where shown to bind human B cells but not T cells and augment B 
cell proliferation together with anti-µ sera and/or CD40 mAb, both characteristics important 
to FDC function. A small population of cells were shown to express CD35 early after culture, 
but expression decreased over time and CD21 expression was neither detected nor could be 
induced by culture using cytokines. Expression of CD21 is essential for FDC functionality; 
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therefore the ability of the cultured cells to act in the same way as primary FDCs is 
questionable. These cells, now termed the FDC-1 cell line, were used in a further study 
detailing the cells ability to activate B cell maturation. As few as 50 to 100 FDC-1 cells were 
shown to increase B cell IgM production by 10 to 100-fold (E. Clark et al., 1995). This 
augmentation of FDC-dependent IgM production was shown to depend on either IL6 or IL7 
and was inhibited with IL4. For this stimulation to occur, cells did not require contact with B 
cells, another discrepancy between primary FDCs and this FDC-like cell line. Primary FDCs 
activate B cells through interactions between C3dg-opsonised antigen and CD21 receptors 
expressed by both cells, hence it is necessary for cell-cell contact to occur. Supernatants 
from cultured FDC-1 cells could also stimulate B cells to produce IgM, suggesting cells were 
generating a soluble molecule with the ability to activate B cells, rendering the need for cell-
cell contact unnecessary. Additionally, human foreskin fibroblasts were also shown to induce 
production of IgM by B cells, suggesting the mechanism of activation used in this study was 
not FDC-dependent.  
There are reports of another cell line derived from EBV transformed FDC-enriched cell 
populations (Lindhout et al., 1994). This study obtained cell lines (FLCs) consisting of slowly 
duplicating, large cells with a fibroblast-like morphology. These cells could be distinguished 
from other human fibroblast cell lines by displaying a phenotype including expression of 
ICAM-1, CD40 and CD75, however expression of CD21 was not reported. These FDC-like 
cells were also shown to bind nonautologous B cells and preserve them from apoptosis, 
another important function of FDCs.  
A study comparing these two cell lines showed that primary cultured FDCs did not enhance 
the CD40-dependent proliferation of germinal centre B cells however; FLCs augmented it 
(Tsunoda et al., 1996). Characteristic to human FDCs, both cells were shown to produce a 
significant amount of cytokine-dependent IL6; however, out of the 72 long term cultures of 
FLCs, only 2 divided. As FDCs have been shown to readily de-differentiate in culture, this 
raises the question to whether these cells are still ruminant of primary human FDCs in vivo.  
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Another FDC-like cell line, HK cells, was also shown to have the ability to stimulate germinal 
centre B cell proliferation resulting in memory B cells (H. Kim et al., 1995). Similar to studies 
using the other reported FDC cell lines discussed above, this proliferation was also 
dependent on the presence of anti-µ or anti-CD40. Cell-cell interaction between the HK cell 
line and germinal centre B cell was also shown to rescue the cells from apoptosis, a 
characteristic of primary FDCs in vivo. Although long term culture did not affect the ability of 
the cells to bind B lineage cells, characteristic phenotypes of FDCs were not detectable by 
FACs, suggesting again the cells had de-differentiated.  
Considering the phenotypes and functional abilities of the cell lines discussed, it is clear that 
work towards further understanding the function of FDCs must be undertaken on primary 
human FDCs, highlighting the importance of developing a robust isolation protocol for these 
cells to enable this work.  
 
9.1.4 CD21 expression on Germinal Centre cell types 
 
It is known that both FDCs and B cells express CD21; a receptor essential for the function 
and interaction between both cell types. An impaired humoral immune response is found in 
Cr2-/- mice (Fang et al., 1998) verifying the essential nature of this receptor for the germinal 
centre reaction and strong antigen-specific IgG responses. These effects are presumably 
due to impaired antigen trapping by FDCs which could affect B cell maturation into plasma or 
memory B cells and the absence of complement receptors resulting in the lack of B cell 
activation. In addition, it was reported that antibody responses from B cells were dramatically 
enhanced by the addition of FDCs to cultures (Qin et al., 1998) and therefore FDCs were 
providing an important costimulatory signal to B cells, shown to be CD21. A ligand blocking 
antibody against CD21 dramatically reduced these responses, demonstrating a role for the 
receptor within this system (Qin et al., 1998).  
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The essential function of CD21 on FDCs is antigen retention, in the absence of this receptor 
FDCs are unable to present antigen and the size of germinal centres appear reduced 
(Fischer et al., 1998). To preserve antigen for long time periods, FDCs trap the CD21 bound 
antigen in recycling endosomal compartments, protecting the antigen from degradation 
(Heesters et al., 2013). Delivery of said antigens to secondary lymphoid organs occurs in 
multiple ways dependent on size of antigen and opsonisation with complement. Lymph-
borne antigen smaller than 70 kDa can flow directly to FDCs via the conduit network, 
alternatively larger complexes are captured by SCS macrophages and transported across 
the SCS to FDCs (Gretz et al., 2000). If the antigen is opsonised with C3-derived 
complement fragments, naïve B cells can capture these molecules using CD21 expressed 
on their surface and shuttle it to FDCs where unidirectional transfer of the antigen-complex 
between the CD21 molecules occurs (Heesters et al., 2013).  
CD21 on B cells is non-covalently complexed with CD19, CD81 (TAPA-1), and Leu-13 
(Matsumoto et al., 1991).  Engagement of this receptor synergistically enhances signalling 
through the B cell antigen receptor (BCR) and lowers the threshold for B cell activation 
(Cherukuri et al., 2017). Co-ligation of the CD21/CD19 complex to the BCR occurs through 
binding of C3dg-tagged antigen that serves as a bridge between CD21 and the BCR (Fearon 
et al., 1995) causing Ca2+ flux and drives cells into cell cycle (Carter et al., 1988). This 
crosslinking also enhances BCR-mediated antigen processing. In addition, studies were 
undertaken in murine B cells that showed CD21 and CD19 uncoupling significantly 
diminishes survival of germinal centre B cells and antibody titres (Barrington et al., 2009).  
Interestingly, FDCs also express low levels of CD19 (Barrington et al., 2009); however the 
role of this receptor in this cell type is unclear. Transfer of immune complexes between 
murine naïve B cells and FDCs, and antigen retention on FDCs, was shown to be CD19-
independent (Barrington et al., 2009). As CD21 is expressed in molar excess to CD19 on 
FDCs, it is thought that the majority of CD21 is not contained within the CD19/CD21 
complex, unlike in murine B cells where CD19 was shown to be expressed in molar excess 
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to CD21 at all stages of development (Fearon et al., 2000). Coligation of CD19/CD21 in B 
cells lowers the threshold for cell activation (Carter et al., 1992), however it is unlikely that 
CD19 on FDCs has a role in activation as the CD19/CD21 complex is unlikely to form due to 
low levels of CD19 expression, although this has not been studied within the current 
literature. Single cell RNA sequencing revealed that murine FDCs express high levels of 
CD81 (Rodda et al., 2018), the tetraspanin protein involved in the anchoring of the 
CD19/CD21 complex in B cells. Tetraspanins are known to regulate trafficking of their 
partner proteins (Charrin et al., 2014). Specifically, CD81 has been shown to traffic CD19 
along the secretory pathway at the post-ER compartment and is essential for normal CD19 
expression in murine B cells (Shoham et al., 2003). CD81 or CD19 deficient mice express 
normal levels of CD21 (Tsitsikov et al., 1997) suggesting this receptor is not regulated by 
CD81 in the same way as CD19. However, as this has not been studied within humans, and 
CD19 expression is much lower on FDCs than B cells, a role for CD81 in internalisation of 
CD21 into recycling endosomal compartments within human FDCs cannot be completely 
discarded.  
Published data has shown that a small subset of peripheral T cells (Fischer et al., 1991) and 
early CD4++ and CD8++ human thymocytes (Tsoukas et al., 1988) express CD21. Knowledge 
of the physiological role of CD21 on T cells is limited but it has been reported that HIV-1 can 
mediate infection of T cells via CD21 independently of CD4 (Boyer et al., 1991). It has been 
hypothesised that CD21-C3dg interactions may be a mechanism of enhancing T cell 
adhesion as CD21+ T cells have been shown to have increased cell-cell interactions (Levy et 
al., 1992), however further evidence for this does not currently exist.   
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9.2 Summary and aims:  
 
The focus of this chapter is the identification, isolation and characterisation of FDCs from 
human tonsil compared to tonsil lymphocytes and stromal fibroblasts. Isolation of these cell 
types allows the potential for downstream functional assays to be undertaken focusing on 
the role of the CD21 receptor. As both FDCs and B cells express this receptor and its role is 
essential for the germinal centre reaction it is important to further understand its different 
functions on both cell types.  
This chapter also addresses the first component of the overall hypothesis described in the 
introduction to this thesis. The literature describes C3dg opsonised antigen complex transfer 
between the CD21 receptor on B cells to CD21 on FDCs. We hypothesise this transfer could 
occur due to multiple factors, one of which is due to the number of CD21 receptors on the 
surface of FDCs compared to B cells. To address this idea, absolute quantification of surface 
receptor number on these cells will be analysed which has not previously been investigated. 
Expression of CD21 on both tonsil and blood derived human T and B cells will also be 
compared. In brief the aims of this chapter are:  
1. Characterise germinal centre cells within human secondary lymphoid organs (tonsil 
and lymph node) using immunohistochemistry and established cell surface receptors.  
2. Develop a protocol to isolate human FDCs from tonsil tissue. 
3. Identify and isolate human FDCs from tonsil tissue and confirm the identity of sorted 
cells using qPCR for well characterised markers of the cell populations.  
4. Determine absolute CD21 receptor number on the surface of FDCs, T and B cells in 
tonsil. 
5. Compare CD21 receptor expression in T and B cells from tonsil compared to 
circulating lymphocytes.  
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9.3 Results 
 
9.3.1 IHC characterisation of Secondary lymphoid organs 
 
It was important to first identify FDCs within human tonsil and lymph node tissue and confirm 
expression of key markers before isolation of these cells could occur; therefore, to visualise 
the cells within these micro-structures, immunohistochemistry of human tonsil and lymph 
node tissue was undertaken. 
Frozen human and lymph node tissue sections were stained confirming that germinal 
centres can be found within these tissues and FDCs (CD35+) and B cells (CD19+) that can 
be visualised within these microstructures (Figure 9.3.1). The cells are tightly packed 
suggesting the potential for a high incidence of interactions between the two cell types. 
CD35+ cells are in a tight structure forming the light zone of the germinal centre, confirming 
these tissues contain FDCs (Figure 9.3.1). CD19+ cells  are seen within this light zone but is 
also seen outside of this zone, the dark zone, confirming B cells can be identified within 
these organs.   
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To extend these observations, tonsil tissue was stained with antibodies against CD35 and 
CXCL13 (Figure 9.3.2). This analysis shows that CXCL13 is tightly associated with the 
CD35+ cells, previously identified as FDCs (Figure 9.3.3). CXCL13 is the ligand for CXCR5, 
a receptor expressed by B cells and this causes B cells to migrate to the light zone within the 
germinal centre (Tjin et al., 2005), which may explain the close association of the chemokine 
with FDCs. Within lymph node tissue, a large proportion of FDC networks were seen to be 
inactivated; smaller, less connected cells, with little CXCL13 signal (Figure 9.3.2), 
suggesting CXCL13 production is higher in activated FDCs. Increased CXCL13 expression 
in mature networks during an immune response occurs to attract more B cells to the dark 
zone and undergo high affinity antigen selection, therefore producing a larger immune 
response when required. As human tonsil tissue is obtained from tonsillectomy patients it is 
reasonable to suggest that their FDC networks are activated and undergoing an immune 
response, unlike the lymph node tissue derived from donor liver transplants used in this 
investigation and thus thought to be naïve. This may be the reason all networks imaged 
here, within tonsils, are activated.  
Costaining of tonsil and lymph node tissue with antibodies against CD21 and CD35, 
confirmed FDCs are CD21+CD35+ (Figure 9.3.5); suggesting both are suitable markers for 
FDC identification.  
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The left hand side shows an immature FDC network with relatively low expression of CD35 (green) 
and CXCL13 (red). The right hand side shows a mature FDC network with upregulated CD35 and 
CXCL13. Scale bar = 20um. This image is representive of 3 patients, 3 sections were stained from 
each patient and multiple images taken of germinal centres within each section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9.3. 2: CXCL13 expression in human lymph nodes 
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(A) CD35 (green) and CXCL13 (red) expression in human tonsils, scale bar = 20um. (B) Close up 
of CXCL13 and CD35 expression, scale bar = 5um. (C) Z=stack of CD35 and CXCL13 in human 
tonsils. These images are representive of 3 patients investigated. 3 sections were stained from 
each patient and multiple images were taken of germinal centres for each section.  
Figure 9.3. 3: 2D and 3D images of CXCL13 expression in human tonsil tissue 
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Figure 9.3. 4: IHC controls for CXCL13 expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scale bar = 10um 
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Figure 9.3. 5: Human FDCs in the tonsil and lymph node are CD21 and CD35 positive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Human tonsil tissue stained for CD21 (A488-green) and CD35 (A647-red), x63 magnification, 
scale bar = 50um. (i) CD21 (green) and CD35 (red) overlay. (ii) CD21 only. (iii) CD35 only. (B) 
A647 secondary only control shows no signal in the red channel, therefore staining is specific for 
CD35, scale bar = 20um. (i) CD21 (green channel) and A647 secondary (red channel). (ii) Red 
channel only. (C) CD35 isotype control antibodies show no non-specific staining, x63 
magnification, scale bar = 20um (i) green and red channel. (ii) red channel only. (D) A488 
secondary only control shows no signal in the green channel; antibody is specific for CD21, x63 
magnification, scale bar = 20um. (i) green channel only. (ii) green and red channel. (E) CD21 
isotype control antibodies show no non-specific staining, x63 magnification, scale bar = 20um. (i) 
green channel only. (ii) green and red channel. These images are representiative of 3 patients, 3 
sections were stained from each patient and each section was imaged multiple times.  
121 
 
Staining both tonsil and human lymph node tissue sections with antibodies against CD21 
identifies the stromal-like cells within the germinal centre known to be FDCs (Figure 9.3.5). 
Antibodies against CD19 confirm B cells are present within the section but staining does not 
overlap with the measured CD21 signal. It is known that CD21 is expressed by B cells, 
however it does not appear to be detectable using this method. Reasons for this discrepancy 
could be due to the bright signal seen on the stromal cells (assumed FDCs) for CD21 
staining. Similarly, FDCs are reported to express low levels of CD19 at the mRNA level 
(Barrington et al., 2009), however IHC staining performed within the current study suggests 
they are negative for this marker. This observation supports the hypothesis of bright versus 
dim cells and the ability to detect expression on both cells by IHC when both cell types are 
present in the tissues. Other explanations could include differences in receptor expression 
by the cell types; it is known that CD21 on B cells is in a co-complex with CD19 (Bradbury et 
al., 1992) which could be masking the epitope recognised by the antibody clone chosen. 
Additionally, as CD21 has two isoforms, named short and long, and it is reported FDCs 
express the long form, this could also be a reason for this discrepancy. Although the 
antibody clone Bu32 binds both isoforms, it is possible it may have a higher affinity for one 
isoform over the other.  
In summary this immunohistological imaging of human secondary lymphoid organs shows 
FDCs can be identified as CD35+CD21+CXCL13+ in contrast to CD19+ B cells. Both cell 
types are found to have tight interactions within the germinal centres of these tissues. 
Interestingly, where both cell types are reported to be CD21+, only FDCs are identifiable by 
this marker in an IHC setting, possibly due to differing expression levels by the two cell 
types.  
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9.3.2 Isolation of primary human FDCs from tonsil tissue 
 
FDC development and function has been extensively studied using murine models both in 
vivo and in vitro, however far less is understood about human FDCs. As no standardised 
protocol exists for their isolation, work was undertaken to develop a reproducible and robust 
isolation method for human FDCs from readily available tonsil tissue.  
There are few literature-based protocols for human FDC isolation but attempts to reproduce 
these methods were unsuccessful from human tonsils. Therefore, efforts began to develop a 
reliable FDC isolation protocol. Initially, many different collagenase enzymes were tested for 
their ability to digest tonsil tissue. Multiple liberase blends were used to digest tonsil tissue 
with varying results; liberase was chosen due to reports describing the enzyme as a 
collagenase with increased specificity, resulting in more efficient cleavage and digestion of 
tissue. Using this enzyme, stromal-like cells were isolated and could be cultured in vitro but 
flow cytometry analysis for FDC markers (CD21, ICAM-1 and CD35) revealed FDCs were 
not present within these cell cultures (data not shown). Engagement with collaborators in the 
Tarte lab (unpublished, University of Rennes) and the C3 DPU at GSK (Stevenage), lead to 
development of the resulting protocol. During method development, samples were taken at 
different time points during the tissue digestion steps for flow cytometry analysis to 
investigate the optimal time conditions for the extraction of FDCs from tissue. Incubation at 
37ºC for 20 minutes was determined as the optimal digestion time for extraction of FDCs 
from human tonsil tissue with the final cocktail of enzyme chosen. Additional incubation time 
also allowed the increased isolation of FRCs, but as FDCs were the cell of interest for this 
study, incubation time was kept to 20 minutes.  
The final protocol used for FDC isolation is detailed within Materials and Methods Section 
8.2. In brief, tonsil tissue was digested using a cocktail of DNase I, Collagenase IV and 
Dispase and subsequently CD45 depleted to remove CD45+ lymphoid cells. An antibody 
staining panel was developed to correctly identify FDCs within the tonsil digests (Figure 17). 
FITC was used as a “lineage” channel containing markers; CD45 (lymphoid cells), CD11b 
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(macrophage), CD31 (endothelial cells) and CD34 (progenitor cells). Markers within this 
channel exclude cells of hematopoietic lineage such as T and B cells. Germinal centre 
stromal cell populations, FDCs and FRCs, express gp38, therefore lineage-gp38+ cells 
contain these cell types. On average, when using this protocol, 300 FDCs were isolated from 
each sample per 2x106 cells. Finally, to separate the stromal cell types, CD21 or CD35 was 
used. FDCs are positive for both these receptors but they are not expressed on FRCs. 
Therefore, FDCs were identified as lineage-gp38+CD35/CD21+. Identification and isolation of 
this cell population allows downstream analysis of function and characterisation using mRNA 
and protein analysis tools.  
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Data presented above confirmed that FDCs within the germinal centre can be identified 
using CD35 or CD21 by immunohistochemistry (Figure 9.3.6). To further confirm the 
interchangeability of the two receptors as FDC markers using flow cytometry, FDCs derived 
from human tonsil tissue were costained with antibodies against CD21 and CD35. A single 
FDC population (lineage-gp38+CD35+CD21+) is seen, therefore the same population will be 
analysed whether cell identification uses CD35 or CD21 (Figure 9.3.8). For isolation by cell 
sorting, CD35 was used to identify FDCs, described as a lineage-gp38+CD35+ population. In 
later investigations focusing on CD21 biology, it is important to confirm cells of interest are 
CD21+, therefore CD21 was chosen to identify FDCs, described as a lineage-gp38+CD21+ 
population.  
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As B cells also express CD21 and are tightly associated with the stromal cells of the 
germinal centre within tonsil tissue; showed in this investigation by IHC (Figure 9.3.1). CD35 
was chosen as the FDC identification marker for cell sorting to ensure collection of FDCs 
only. When assessing CD21+ cells, it was confirmed that the FDC population identified were 
not an FRC/B cell doublet, which would also be lineage-gp38+CD21+ when assessed by flow 
cytometry. Although the FDC population is positive for CD19 (Figure 9.3.9A), which is highly 
expressed by B cells, staining with CD20 reveals the FDCs are CD20- therefore do not have 
B cells attached (Figure 9.3.9B). Low levels of CD19 surface expression by FDCs has been 
previously reported, the function of which is unknown (Barrington et al., 2009). Expansion of 
the lineage+ population shows the expected high CD20+ staining of the B cells contained in 
this gate (Figure 9.3.9C), confirming the antibody staining with CD20 was successful and 
FDCs are truly negative for this marker.  
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Figure 9.3. 9: FDCs isolated from human tonsil are CD19 positive and CD20 negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Lineage negative, gp38 positive cells are gated for CD21. CD21 positive cells are also CD19 
positive (B) but CD20 negative, therefore are not FRC/B cell doublets. (C) Lineage positive cells 
are both CD20 and CD21 positive; this gate contains B cells. Data collected by Laura Rapley 
(GSK). 
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Figure 9.3. 10: Sorting T and B cells from human tonsil tissue 
It was then possible to isolate FDCs (lineage-gp38+CD35+ gated cells) using cell sorting 
(Figure 9.3.7). FRC/MRCs (lineage-gp38+CD35- cells) were also collected to use as controls 
in further experiments. Tonsil samples that had not undergone a CD45 depletion were used 
to isolated T cells (CD3+) and B cells (CD19+) by cell sorting (Figure 9.3.10). Identification by 
flow cytometry of these cell types is important for downstream functional assays 
investigating antigen carriage on FDCs and B cells and isolation allows assessment of CD21 
mRNA and protein expression within the cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Cells are gated for PBMCs (B) and single cells. (C) Live cells are selected and (D) 
separated into T and B cells using CD3 and CD19 staining respectively.  
131 
 
To further characterise the sorted cell populations and confirm their identity, qPCR was 
performed for key cell markers (Figure 9.3.11), similar to those used previously in IHC and 
flow cytometry analysis of the cell populations. The isolated lineage-gp38+CD35+ cell 
population was shown to express CD35, CD21 and CXCL13 mRNA, consistent with the 
protein expression seen using IHC in this investigation, confirming this population are FDCs. 
B cells express CD21 and CD19, which is also confirmed here by qPCR at the mRNA level 
(Figure 9.3.11C and 9.3.11B). T cells were identified by expression of CD3 mRNA (Figure 
9.3.11F). The lineage-gp38+CD35- sorted population, are CCL21+ but negative for the other 
markers investigated here (Figure 9.3.11E), confirming they are the stromal cell FRC/MRCs. 
Interestingly, FDCs express much higher levels of CD21 at the gene level than B cells and T 
cells express low levels of CD21. These data support the previous observations seen by IHC 
where FDCs are bright for CD21 and mask the dimmer staining for CD21 on B cells.  
These data confirm that FDCs from human tonsil tissue can be identified and continue to 
express key cell markers after FACS sorting using the developed protocol.  
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Figure 9.3. 11: qPCR for known markers of germinal centre cell populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3, bars represent SD (A) CD35 expression; FDC population expresses high levels. (B) CD19 
expressed by B cells and low levels expressed in FDCs. (C) CD21 expressed highly in FDCs, B 
cells and low levels expressed in T cells. (D) CXCL13 expressed in FDCs. (E) CCL21 expressed in 
FRC population. (F) CD3 expressed highly by T cells.   
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9.3.3 Absolute CD21 receptor number on the surface of germinal centre cells 
 
As CD21 is a critical receptor within the germinal centre reaction expressed by these cells, 
the remainder of this work focuses on the role of CD21 within biology. Although it is well 
accepted that FDCs, T and B cells express CD21, absolute receptor number on these cell 
types has not previously been investigated. Consistent with published data, this investigation 
has shown that FDCs express CD21 by IHC and qPCR, however B cells are not CD21+ by 
IHC analysis but can be identified as CD21+ by flow cytometry and qPCR. These 
observations suggest a higher expression of CD21 receptor by FDCs, a phenomenon that 
could lead to transfer of C3dg-bound antigen between the two cells as hypothesised. This 
discrepancy was the driver for this work which aimed to quantify and compare the number of 
CD21 receptors expressed on the surface of human tonsil derived FDCs, B cells and T cells, 
as well as comparing peripheral and tonsil derived T and B cells.  
CD21 expression on T and B cells was assessed by flow cytometry. B cells were 
CD19+CD20+CD21+ cells (Figure 9.3.13); both CD19 and CD20 were used as markers in this 
analysis to demonstrate that either receptor can be used as a marker for B cells. FDCs have 
low level expression of CD19 (Figure 9.3.9A), therefore CD20 staining confirms these cells 
are B cells. T cells were identified using CD3; only a small population of these cells are 
CD21 positive (Figure 9.3.13A viii). This data was collected on a higher voltage than that for 
FDC data collection due to the brightness of CD21 signal on the cell surface (Figure 9.3.15). 
This was thought to be due to receptor number; this is further discussed in later experiments. 
For this investigation, FDCs were identified as lineage-gp38+CD21+ as described above 
(Figure 9.3.12). 
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Figure 9.3. 14: Bu32 binds to FDCs, T and B cells in a concentration dependent manner 
In order to accurately calculate the number of CD21 receptors on the cell surface, antibodies 
were used at saturating concentrations to ensure all receptors are bound and therefore 
counted.  Starting at 10 µg/ml, a serial dilution of CD21 antibody, clone Bu32, was 
undertaken on FDCs (tonsil derived), T and B cells (tonsil and blood derived). Bu32 binds to 
all cell types in a concentration dependent manner (Figure 9.3.14) and saturating 
concentrations are reached at 1 µg/ml for all cells of interest. Bu32 MFI on T cells is lower 
than the other cell types investigated; saturating concentrations of the antibody are still 
reached at 1 µg/ml (Figure 9.3.14A and B iii) perhaps influenced by the presence of B cells 
within the sample compared to if the population had been isolated previous to performing the 
saturation curve.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Tonsil derived FDCs, T and B cells, saturating concentrations of Bu32 are reached at 1ug/ml, 
n=3, bars represent SD. (i) Bu32 binds to FDCs in a concentration dependent manner. (ii) Bu32 
binds to tonsil derived B cells in a concentration dependent manner. (iii) Bu32 binds to the small 
population of CD21 positive, tonsil derived T cells in a concentration dependent manner. (B) Blood 
derived B and T cells, saturating concentrations of Bu32 are reached at 1ug/ml, n=3. (i) Bu32 binds 
to peripheral B cells in a concentration dependent manner. (ii) Bu32 binds to peripheral T cells in a 
concentration dependent manner.  
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Using the saturating concentration of Bu32-PE (1 µg/ml) , the MFI of CD21 on the different 
cell types was converted to absolute receptor number using Quantibrite-PE beads. 
Quantibrite beads are conjugated with a known quantity of PE molecules which can be 
plotted against the measured MFI of each bead set to create a standard curve (Figure 8.1). 
Using the CD21+ population of each cell type, the number of receptors on the cell surface is 
then interpolated from the standard curve using the MFI of each sample. Similar to IHC 
staining, CD21 staining on FDCs is brighter than that of B and T cells; therefore, FDC CD21 
quantitation data was collected using lower PE voltages than those used for T and B cell 
CD21 quantitation (Figure 9.3.15). Receptor number was interpolated from standard curves 
drawn from data collected on respective voltages (Figure 9.3.15). 100% of FDCs and 99.6% 
of B cell populations were CD21 positive.  FDCs express >30-fold higher CD21 on their cell 
surface than B cells (Figure 9.3.16), an average of 140000 on FDCs compared to 5500 on B 
cells. As FDCs are much larger than B cells, approx. 3000 µm3 compared with 300 µm3 
respectively, the increase may be due solely to cell size, but this is unknown as receptor 
density was not investigated.  B cells express higher numbers of CD21 than CD21+ T cells, 
of which ~20% of the T cell population express CD21. CD21+ T cells express an average of 
200 receptors per cell, significantly lower than the other cell populations investigated (FDCs 
and B cells), of which 99% of cells were CD21+.  
It is noted that B cells isolated from blood express higher numbers of receptors than those 
isolated from tonsil; this may be reflective of biology or alternatively may be due to how the 
samples were processed. PBMCs from blood were isolated by Ficoll, tonsil derived cells 
have been isolated from the tissue both mechanically and using enzymes, cells have also 
been through one freeze/thaw cycle, this tissue processing may cause the cells to lose some 
level of surface receptors.  
In summary, data shows FDCs express high numbers of CD21 receptors on their cell 
surface, >30-fold higher than B cells which also express many CD21 receptors. Both FDCs 
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Figure 9.3. 15: CD21 data is collected at different voltages for FDCs and T/B cells 
and B cells are 99% CD21+ whereas only 20% of T cells express CD21 on their cell surface 
at low numbers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orange – T cells, Blue – B cells, Red – FDCs, Green – isotype (T cell representative image). (A) (i) 
CD21 staining on FDCs is brighter than that of T and B cells therefore a lower PE voltage is used 
to collect this data. T cell CD21 positive cells are not visible above isotype staining (ii) Quantibrite 
beads standard curve derived from “low” PE voltage data. FDC receptor numeration was 
calculated from this curve. (B) (i) At higher PE voltages T cell and B cell data is spread to show B 
cells express higher levels but FDC data is off-scale. T cell CD21 positive cells are now visible 
above isotype staining. (ii) Quantibrite beads standard curve derived from “high” PE voltage data. 
T and B cell receptor numeration was calculated from this curve.  
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Figure 9.3. 16: Absolute receptor numeration of CD21 molecues on the cell surface 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Quantibrite beads were used to calculate the number of CD21 receptors on the cell surface of 
human tonsil derived FDCs, T and B cells and peripheral T and B cells. FDCs express 33-fold 
higher CD21 on their cell surface than B cells; B cells express more CD21 than T cells. Significant 
using a multiple comparisons ANOVA test. n=3, bars represent SD.  
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9.4  Discussion:  
 
The literature reports unidirectional transfer of C3dg-opsonised antigen complexes between 
CD21 on B cells and CD21 on the surface of FDCs. The mechanism for transfer is not fully 
understood, therefore this chapter explores the hypothesis that transfer occurs due to an 
increased number of CD21 receptors expressed on the surface of FDCs compared to B 
cells. In order to calculate the absolute receptor expression on these cells types, it was 
necessary to develop a robust method for human FDC isolation from tonsil tissue, as 
published methodologies proved unreliable and unsuccessful. Therefore the first aim of this 
chapter was to identify and isolate human FDCs from secondary lymphoid tissue to allow for 
downstream analysis of CD21 expression and function of this receptor in further work.  
Histological studies give context to cell specific expression of known surface markers in 3D 
space as well as cellular interactions within the germinal centre microarchitecture. These 
techniques allowed identification of FDCs and B cells within secondary lymphoid organs, 
confirming FDCs as CD35+CD21+CXCL13+ cells (Figure 9.3.1, 12 and 15) and B cells as 
CD19+ cells (Figure 9.3.1). In alignment with published data (Naiem et al., 1983), B cells are 
not CD21+ when identified using IHC (Figure 9.3.5) but qPCR and flow cytometry analysis 
(Figure 9.3.11 and 23 respectively) reveals CD21 expression by these cells, something that 
is well documented in the literature. This discrepancy was the first indication that CD21 
expression on FDCs may be greater than that on B cells; therefore it is thought that the high 
number of receptors bound by antibody on the FDCs in tissue sections causes a bright 
signal masking any signal from the CD21 on the B cells. This observation is not considered 
in the literature when assessing specificity of antibody clones by IHC. Both CD21 antibody 
clones R4/23 (Naiem et al., 1983) and 7D6 (Liu et al., 1997) were reported to bind only to 
FDCs within tissues, with weak reactivity to B cells outside of FDC zones. These results 
were interpreted as antibody specificity for FDCs rather than considering levels of epitope 
expression. Weak staining of B cells with the CD21 antibody clone Bu32 (the clone used 
within this study) is observed, consistent with the reports discussed above; but staining 
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within areas devoid of FDCs is likely to reveal strong CD21 signal on the surface of these 
cells, however this was not undertaken in this investigation. 
Human FDCs were successfully isolated from tonsil tissue and identified using lineage-
gp38+CD35+ gating by flow cytometry (Figure 9.3.7). The standardised method developed 
allowing reliable exclusion of FDCs from human tonsil tissue is detailed in Methods Section 
8.2. It was important to establish these methods and identification of this cell type to allow for 
further experiments using human FDCs to occur. qPCR analysis confirmed isolated 
populations were FDCs (CXCL13+CD21+CD35+CD19+), FRCs (CCL21+), B cells 
(CD19+CD21+) and T cells (CD3+) as widely reported in the literature (Figure 9.3.11).  
After successful isolation and characterisation of human FDCs and B cells was achieved, 
absolute numeration of CD21 receptors on the cell surface was undertaken with the hope 
that this information may help understanding of antigen transfer between CD21 of B cells 
and CD21 on FDCs. Absolute receptor numeration confirmed FDCs express CD21 at higher 
levels than B cells on their cell surface (Figure 9.3.16). FDCs express over 30-fold more 
receptors than B cells. B cells were shown to express ~8000 CD21 receptors per cell; cells 
typically bear 10,000 – 20,000 receptors for a particular ligand (Lodish et al., 2000), 
therefore the number of CD21 molecules on B cells is around average. In contrast, FDCs 
express ~150,000 CD21 receptors per cell. As FDCs are ~10 times larger than B cells 
(~3000 µm FDCs versus ~300 µm B cells), the number of CD21 receptors expressed by 
these cells are also thought the be around average levels due to their size. Bearing this in 
mind, although receptor density was not thoroughly investigated, as the size difference 
between FDCs and B cells is around 10-fold, it is reasonable to suggest receptor density on 
FDCs is ~3-fold higher than that on B cells. This increased density of CD21 receptors and 
the larger cell size in comparison to B cells may allow FDCs to bind a greater proportion of 
C3dg molecules present on the C3dg-immune complexes bound by B cells, thus rapidly 
sequestering the immune complexes by endocytosis into endosomal compartments would 
allow unidirectional transfer of complexes from B cells to FDCs. This concept was previously 
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suggested in the literature (Heesters et al., 2014), in which they proposed that is was the 
size of the FDC that allowed for unidirectional transfer of C3dg-antigen complexes, however 
this was not investigated further in this particular study. Previous studies visualising antigen 
transfer between B cells and FDCs using a mouse model also suggested that one 
mechanism of action for this transfer could be receptor number (Phan et al., 2007). Murine 
FDCs have also been shown to express higher levels of CD21/CD35 on their surface than B 
cells, although absolute quantification has not been reported. This study suggested that this 
increased receptor expression may be potentially important in the successful competition 
with migrating B cells for the capture and retention of noncognate immune complexes.  
Electron microscopy studies have been utilised to visualise the spacing of antigen 
complexes, and hence CD21, on the FDC membrane (Shikh et al., 2010). Antigen 
complexes were found to be periodically arranged on the FDC cell membrane, spaced 200 
to 500 Angstroms apart. This spacing is likely optimal for multimerised FDC-immune 
complexes to simultaneously engage multiple BCRs and induce B cell activation. These 
findings further support the hypothesis that greater CD21 receptors allow for antigen transfer 
to FDCs as the spacing observed here suggests that FDCs would are able to bind to multiple 
C3dg molecules on the immune complexes, creating greater contacts to the complex than 
the B cell, again resulting in successful competition within transfer.  
To conclude, immunohistochemical studies allowed visualisation and identification of FDCs 
and B cells within the germinal centre of secondary lymphoid organs, tonsil and lymph node; 
revealing CD21 staining occurs only on FDCs due to high expression of this receptor 
compared with B cells. Development of a robust FDC isolation protocol from tonsil tissue 
allowed for CD21 receptor numeration on human FDCs as well as tonsil and blood derived T 
and B cells. Receptor numeration revealed a small population of T cells expressing a low 
number of CD21 receptors, approximately 200 receptors per CD21+ cell. This experiment 
also confirmed that FDCs express >30-fold higher CD21 receptor numbers on their cell 
surface than B cells. When considering the relative size of FDCs and B cells, it is thought 
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that CD21 expression on FDCs is ~3-fold denser than that on B cells. Therefore this data 
suggests the increased cell size and CD21 receptor density may be a mechanism for 
unidirectional transfer of C3dg-antigen complexes from B cells to FDCs.  
A second hypothesis regarding another possible mechanism for antigen transfer is that 
transfer occurs due to differential CD21 isoform expression on B cells and FDCs. The FDC 
isolation method developed here will further allow investigation into this second hypothesis 
and reveal a greater insight into the mechanism for antigen transfer. Therefore the 
remainder of the thesis will focus on CD21 C3dg-binding functionality and the receptors role 
in health and disease, determined by the vast difference in receptor number expressed on 
the cell surface and the essential role CD21 has within the germinal centre reaction.  
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10. Results chapter 2: CD21 function and isoforms in biology 
10.1 Introduction 
CD21 is an essential receptor involved in the initial formation and function of the germinal 
centre reaction. It is expressed on both FDCs and B cells and is responsible for C3dg-
antigen complex binding and transfer of said complexes between B cells and FDCs.  
The CD21 protein is formed of sushi domains, also known as complement control protein 
(CCP) modules, or short consensus repeats (SCR). These domains exist in a variety of 
complement and adhesion proteins; the structure is based on a beta-sandwich arrangement, 
one face made of three β-strands (Campbell et al., 1991). The complete structure of the 
CD21 molecule, 15 SCRs, (Gilbert et al., 2006) and the structure of the first two SCRs 
complexed with C3d, the binding domain of the receptor and its ligand, have been solved by 
X-ray crystallography (van den Elsen et al., 2011). The structure for the first two SCRs was 
solved as an asymmetric unit containing four molecules: two CD21(SCR1-2) and two C3d 
molecules forming CD21(SCR1-2):C3d complexes. The interactions between the SCR 
domains and C3d are in the acidic pocket on the concave surface of C3d and most contacts 
are between C3d and SCR1.  
The structure of all 15 SCRs (CD21S) shows there are flexible linkers between the SCR 
domains suggesting the role of these structures is to enable reorientation of CD21 and 
effective C3dg binding independent of the surface topology of the antigen (Gilbert et al., 
2006). Conservation of the six longest linkers in CD21 across species including murine and 
ovine, suggests some immunological importance of this structure. These linkers are 
distributed throughout the length of the CD21 receptor and appear to act as conformational 
variable joints (Gilbert et al., 2006).  
During development of B cells, CD21 expression is tightly regulated; demonstrated using 
immunofluorescence analysis with the human CD21 monoclonal antibody clone HB5 
(Tedder et al., 1984). This study revealed that, within the foetal bone marrow and liver, preB 
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and immature B cells do not express CD21. However, there was a small population, 
approximately 25%, of B cells in the foetal spleen that were CD21+. In contrast, 50% of B 
cells within the adult bone marrow were shown to express CD21. Mature B cells in the blood 
from both new-borns and adults, and in the peripheral lymphoid tissue of adults, uniformly 
express CD21. In addition, activated B cells, which were responsive to T cell-derived 
differentiation factors were CD21+, whereas plasma cells did not express CD21. These 
findings suggest that loss of CD21 expression at the message and protein level has a key 
role in B cell development and maturity. 
In CD21 knockout mice germinal centre formation is still retained, although the size is 
reduced and lack of CR1 and CR2 on both B cells and FDCs reveals an essential function 
for these receptors in germinal centre phenotype and immune function (Y. Fang et al., 1998).  
Interestingly CD21 also has a role in many diseases. FDCs have been shown to be a 
reservoir for HIV infectious particles and blockade of C3d binding to CD21 prevented 
transmission of virus to CD4 T cells (Heesters et al., 2015). Viral complexes have been 
opsonised allowing binding to CD21 expressed on FDCs and B cells, blocking C3dg binding 
to the receptor prevents virus from entering the cell and being transmitted to other cell types. 
CD21 is also named the Epstein-Barr virus (EBV) receptor as the virus is able to initiate 
infection of B cells by binding SCRs 1 and 2 of the receptor, similar to C3dg (Fearon et al., 
1995). After binding, within minutes the virus undergoes passive endocytosis, de-
envelopment, and passage of the viral nucleocapsid to the cytoplasm and vectoral 
movement of the nucleocapsid to the nucleus (Nemerow et al., 1984).  
CD21 deficiency in humans has been associated with hypogammaglobulinemia (Thiel et al., 
2012). The first patient described with this deficiency suffered from recurrent upper 
respiratory tract infections in early childhood and gastrointestinal infections later in life. 
Within this study, the patient’s B cells were completely devoid of CD21 surface protein, no 
intracellular CD21 protein was detectable and there was no sCD21 present within the patient 
sera (Thiel et al., 2012), however expression of CD19 and CD35 was normal within these 
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Figure 10.1. 1: Genetic CD21 deficiency is associated with hypogammaglobulinemia 
cells. Analysis of the patient’s family found consistent decreased CD21 expression on B cells 
compared with healthy controls, suggesting the deficiency was genetic (Figure 10.1.1). 
Sequencing of the patient’s genomic DNA revealed a heterozygous mutation disrupting the 
highly conserved “GT” splicing donor site of exon 6, causing a frame shift of the entire exon 
and resulting in shorter CD21 mRNA, coding for a truncated CD21 protein. A second 
mutation was found within exon 13 introducing a premature stop codon and presumably 
causing nonsense-mediated mRNA decay. The patient’s father and sister are carriers of the 
exon 6 mutations and the mother carries the exon 13 mutation; neither mutation was found 
within 100 healthy control subjects. Because of this deficiency the patient’s B cells exhibited 
only one tenth of the immune complex binding observed with normal B cells (Figure 10.1.1) 
and complex binding could not be inhibited using CD21 blocking mAb FE8, unlike in healthy 
B cells (Theil et al., 2012). However, CD21 deficiency did not prevent EBV infection of the 
patients B cells, indicating although CD21 is a receptor for EBV binding, entry via CD21 is 
not absolute.  
Studies on a second patient with a compound heterozygous CD21 deficiency, also resulting 
in hypogammaglobulinemia, showed that CD21 deficient B cells had a normal BR mediated 
signalling upon stimulation in vitro, but slightly reduced SHM frequency and class switch 
recombination (Wentink et al., 2015).  
 
 
 
 
 
 
 
 Data from Thiel et al., 2012. (A) Family members have decreased CD21 expression and patient is 
completely devoid of CD21 expression and subjects have defective binding of C3d-containing immune 
complexes compared with healthy controls.  
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Figure 10.1. 2: CD21 is found in two isoforms 
 
10.1.2 CD21 isoforms in human biology 
 
Alternative splicing within the human CD21 gene generates two isoforms termed CD21 short 
(CD21S) and CD21 long (CD21L) (Fujisaku et al., 1989). The short form of CD21 contains 
15 SCRs and the long form differs by the insertion of one additional SCR; this SCR is known 
as SCR11 or SCR10a and is located in the middle of the protein (Figure 10.1.2). Although 
the crystal structure of CD21S has been published (Gilbert et al., 2006), to date, there is no 
known structure of CD21L. The published structure of the SCR1/2 binding site of CD21 and 
its ligand C3d suggests that the additional SCR within the long isoform of CD21 does not 
directly affect the binding of C3d to the receptor as only SCR1 and 2 interactions are 
involved. However, this does not rule out that this isoform may have a greater affinity for 
C3dg binding using an alternative mechanism. 
 
 
 
 
 
 
 
 
 
 
 
CD21 short (CD21S) is made of 15 SCRs, CD21 long (CD21L) has an additional SCR, named 
SCR10, in the middle of the protein. It is unknown what the function of this additional SCR has at 
present. 
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FDCs have been shown to specifically express CD21L whereas B cells express the short 
form (Liu et al., 1997). An early study used amplified CD21 cDNA derived from human B 
cells and FDCs, revealing a larger band product for the FDCs (Liu et al., 1997). The products 
were sequenced revealing a 177bp insertion encoding SCR10a in the FDC samples which 
was absent from the B cell derived shorter PCR product. The function of this additional SCR 
is as yet unknown. It is interesting that SCR10a would create another SCR within the folded 
region of the protein (Figure 10.1.2). The addition of this protein unit could alter the structure 
of CD21 completely, potentially making the protein more stable, but as there is no published 
CD21L structure, this is unknown. 
A study analysing the CD21 exon-intron junctions revealed the presence of three types of 
exons in the SCR region of CD21 (Fujisaku et al., 1989). The types of exon occur in the 
following order; four exons each of which encode two SCRs, five exons that together encode 
a single SCR, followed by six exons which encode SCRs which are split in identical 
positions, this position being after the second guanidine of a glycine codon three amino 
acids past the second cysteine. This exon order is repeated for each group of four SCRs 
within the CD21 receptor, indicating the CD21 gene likely evolved from duplication of a gene 
containing four SCRs. As CD21L has 16 SCRs it suggests the short form of CD21 changes 
the repetitive conformation of the 4 SCR units, potentially changing the functionality of the 
receptor.  
Interestingly, many antibody reagents have been utilised to demonstrate CD21L expression 
by FDCs. One of the first reported was a murine monoclonal antibody clone, R4/23, was 
shown to react strongly with FDCs using immunohistochemical techniques (Naiem et al., 
1983). Due to this observation, and only weak staining of B cells outside of zones containing 
FDCs, the antibody was reported to be CD21L and thus FDC specific. Another monoclonal 
antibody, 7D6, was also reported to specifically recognise human FDCs (Liu et al., 1997). 
Again, this was determined using staining patterns of human tonsil sections; 7D6 was shown 
to bind to FDCs but not B cells, therefore it was concluded from this study the antibody was 
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specific for CD21L. Within the same study, expression cloning was utilised allowing the 
production of a cDNA clone encoding the long human CD21 isoform, containing exon 10a. 
Transfection of mouse Ltk- cells with this cDNA further showed that the other FDC mAbs, 
DRC-1 and KiM4, also recognise CD21L (Liu et al., 1997). Weak cross reactivity with B cells 
was reported for all of these antibodies; raising the question as to whether it is isoform 
expression that’s responsible for these observations. In addition, it was noted that the B cell 
lymphoma line, Raji, among others, also expressed the 7D6 antigen (Liu et al., 1997).  
10.1.3 CD21 dependent antigen presentation  
 
Antigen transfer occurs between CD21 on B cells and CD21 on the surface of FDCs within 
germinal centres.  
Delivery of antigen to secondary lymphoid organs is dependent on size. Large antigen-
complexes are bound by subcapsular sinus macrophages, whereas small antigens (under 
70 kDa) are rapidly channelled into follicles via the conduit system. The latter pathway 
provides a directed flow of small antigen to the FDC resulting in transient antigen retention 
or, in the presence of antigen and complement, long term binding with CD21 receptors. 
FRCs secrete collagen-rich fibres that form this network in the paracortical region; imaging 
studies revealed trafficking of T and B cells within the peripheral lymph nodes through 
directed migration along these stromal “highways” (Bajenoff et al., 2006). A study on 
neonatal lymph nodes revealed an absence of B cell follicles, but these SLOs do have a 
developed T cell zone and a dense conduit network (Bajenoff et al., 2009). It was shown that 
as new T and B cells enter the developing lymph node, the conduit network density is 
maintained in the T cell zone, but not the B cell zone. B cell accumulation leads to 
remodelling of the follicular network, a process dependent on both FDC dendritic processes 
and the network of FRC fibres (Gonzalez et al., 2010). In adults, the residual follicular 
conduits are then able to transport low molecular weight soluble antigen to FDC regions, 
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allowing the capture of soluble antigens draining from subcutaneous sites by antigen-specific 
B cells even in the absence of Ag-specific antibodies.  
Studies investigating delivery of larger lymph-borne particulate antigens, such as vesicular 
stomatitis virus, demonstrated a mechanism for antigen transfer via uptake of antigen by 
macrophages lining the sub-capsular sinus (SCS) (Junt et al., 2007). Antigen is shuttled to 
the underlying surface where it is made available to cognate B cells. Experiments using 
large protein antigens were showed to bind SCS macrophages after sub-cutaneous injection 
into passively immunised mice; this study also revealed antigen capture was complement-
dependent (Phan et al., 2007). Formation of immune complexes activated the complement 
pathway resulting in C3-coated immune complexes that enhance uptake of antigen via CR3 
and FcRIIb receptors expressed on the surface of the macrophage (Phan et al., 2007). C3-
coated complexes are subsequently shuttled to B cell compartments and transferred to 
naïve B cells. It is possible that complexes are partially protected during the delivery phase; 
FcRIIb is known to recycle to the surface following internalisation and not go through a 
lysosomal compartment (Bergtold et al., 2005).  
CD21 expressed on B cells is essential for transport of lymph-borne C3-coated immune 
complexes into the B cell follicles and transfer to FDCs. Marginal zone B cells acquire 
antigen complexes from SCS macrophages through CD21 receptors on their cell surface. 
These B cells have been shown to have a unique surface phenotype; expressing high 
numbers of CD21 and CD35 and the non-classical MHC molecule, CD1d3 (Cinamon et al., 
2008). Uncoupling CD21/35 from CD19 in naïve B cells in mice still allowed for uptake of C3-
coated immune complexes and delivery to FDCs, indicating the CD21/35 receptor includes a 
cytoplasmic domain that allows CD21 signalling after C3-immune complex uptake 
independent of CD19 and triggers B cells migration to the FDC (Barrington et al., 2009). 
Alternatively, the CXCL13 chemokine gradient created by FDCs may be enough to cause B 
cell migration within follicles; therefore, direct signalling by C3-IC may not be essential 
(Cinamon et al., 2008). Thus, B cells enter the peripheral lymph node, they cycle to the sub-
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capsular sinus, attracted by chemokine gradients produced by marginal reticular cells, attain 
antigen from SCS macrophages before migrating to FDCs via an additional FDC-dependent 
chemokine gradient.  
Antigen-complexes now bound by CD21 on the surface of B cells are transferred to FDCs. 
Transfer of C3dg-antigen complexes is dependent on CD21 and FcRIIb receptors. FcRIIb is 
upregulated following FDC activation; although these receptors appear to enhance long-term 
retention of immune complexes, as FcRIIb is not constitutively expressed, the initial capture 
and retention of these complexes is largely due to CD21 (El Shikh et al., 2006). In mice, it 
was shown that FDCs acquire complement-coated immune complexes from noncognate B 
cells via CD21 and rapidly internalise the co-ligated receptor/ligand complex using an actin-
dependent pathway (Heesters et al., 2013). Immune-complexes were retained within a 
nondegradative cycling compartment and were displayed periodically on the cell surface 
where they were accessible to antigen-specific B cells. Endocytosis of antigen into these 
compartments, similar to that observed in macrophage antigen delivery, explains how they 
are protected from damage and how long-term retention is achieved by FDCs. This essential 
role of CD21 on FDCs concentrates antigen in the lymphoid tissues. It is not clear, however, 
whether antigen retention by FDCs is required for the initiation of the primary antibody 
response. Chimeric mice in with CD21 deficient FDCs are able to produce a normal IgM 
primary response; this suggests other sources of antigen may be sufficient to trigger early B 
cell activation (Ahearn et at., 1996) but presentation of antigen by FDCs is needed to 
produce a memory B cell response (Rossbacher et al., 2006). It is known that B cells acquire 
antigen and are most efficiently activated when it is attached to membrane; therefore, 
retention of antigen and C3dg on the FDC surface enhances antigen-specific B cell 
responses (Carrasco et al., 2004). Studies using multi-photon intravital microscopy support a 
role for FDCs as an essential source of antigen for B cells (Suzuki et al., 2009). Contact 
between FDCs and B cells were often brief but occasionally persisted for over 30 minutes. A 
prolonged display time of antigen ensures even rare B cells have the chance to encounter 
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antigen. These investigations also identify a role for CD21/CD35 in efficient uptake of 
medium affinity antigens in their murine model, demonstrating how CD21/CD35 deficient B 
cells acquired fewer antigens from FDCs. One potential model of transfer between 
receptors, is that unidirectional transfer occurs between CD21S and CD21L receptors, 
suggesting the complex is bound with low affinity to CD21S on B cells permitting efficient 
uptake of complexes to CD21L on FDCs. As these two isoforms differ in the expression of 
SCR10a, this sequence may modify the stability, membrane organisation or affinity for ligand 
of the CD21L isoform, allowing this unidirectional transfer of opsonised antigen-complexes to 
occur. 
10.1.4 The role of C3dg 
 
Another important role for CD21 is the binding of C3dg-opsonised antigen complexes 
allowing antigen-specific antibody responses to occur. The central component in 
complement activation is C3; when complement pathways are activated C3 is cleaved into 
two fragments: C3a and C3b (Merle et al., 2015). The C3b fragment is further cleaved by 
factor I into iC3b and subsequently to C3dg and C3c. C3a, the smallest fragment, has the 
shortest half-life, while C3dg, the larger fragment (37 kDa), has a plasma half-life of 4 hours 
(Teisner et al., 1983). CD21 binds to cleavage products C3dg and, with a lower affinity, iC3b, 
covalently attached to antigens. These proteins play a critical role in humoral immunity as 
blocking with antibodies, a soluble receptor or deletion of CD21 receptors leads to impaired 
humoral immunity to model protein antigens, bacteria and viruses.  
Studies using animals depleted of C3 demonstrated a correlation between the concentration 
of C3 present and the humoral immune response elicited; depletion of C3 caused a 
reduction in the antibody response (Pepys et al., 1972). In vivo C3 depletion has a greater 
effect on the antibody response to T cell-dependent antigen than the T cell-independent 
antigen response. Studies in humans genetically deficient in C3 did not reveal defects in 
antibody responses after routine immunisations, however these studies used high doses of 
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antigen in adjuvant therefore may not be directly testing C3-dependent pathways (Alper et 
al., 1972). Studies using limiting doses of T-dependent antigen, bacteriophage ФX 174, 
showed no switch from IgM to IgG antibody synthesis (Ochs et al., 1986). The same antigen 
was used to further highlight the role of C3 in humoral immunity using a C3-deficient dog 
model (O’Neil et al., 1988). The serum IgG levels of the dogs were within the normal range 
but significantly lower than compared with normal controls. Additionally, specific antibody 
production was defective upon primary response to antigen. After secondary immunisation 
with the T-dependent antigen, the total antibody titres were within normal ranges, but the 
animals made proportionately more IgM and less IgG antibody than that seen in control 
groups, indicating there was a defect in class switching in the C3 deficient model. These 
effects could not be rescued with an increase in the antigen dose. Memory B cell 
development was also impaired in mice depleted of C3 by treatment with cobra venom 
(Pryjma et al., 1975). 
C3dg is known to lower the threshold of B cells for activation. C3dg bound to a primary 
protein antigen complex with natural antibody was shown to enhance recognition and 
specific immunoglobulin synthesis by antigen-specific B cells (Thornton et al., 1996). 
Interestingly, antigen was taken up and processed via CD21 by both antigen-specific and 
non-specific B cells. The C3dg-immune complexes induced expression of the B cell 
costimulatory molecule CD80 upon ligation to CD21; this was followed by FcγRII stimulation 
via the IgG antibody on the complex. This suggests that non-specific B cells may have the 
capacity to function as antigen-presenting cells for antigen-specific T helper cells in the 
same way as macrophages, promoting expansion of this subset of cells (Thornton et al., 
1996). This study concluded that C3dg-mediated antigen recognition enhanced the immune 
response to antigen present at low levels, and hence is important when only a few antigen-
specific B cells with low affinity to antigen are available due to the threshold of activation 
being lowered when antigen is complexed with C3dg. Preculture of tonsil B cells with 0.01 to 
1 µg/ml polymeric C3dg caused a dose-dependent enhancement of proliferation, however 
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C3dg alone did not induce this effect; anti-IgM had to be present to cause activation of cells 
(Carter et al., 1989).   
EBV and C3dg were mapped to binding a common domain of the CD21 receptor; antibody 
clone OKB-7 blocked uptake of both ligands (Clifford et al., 1989). By analysis of CD21 
deletion mutants and chimeric mouse models, it was determined that the NH2-terminal two 
SCRs (SCR1 and 2) are necessary and sufficient to bind gp350/220 (EBV) and C3dg with 
equal affinities. Molina et al., suggested that the SCR1 sequence 10-LNGRIS-15 and the 
SCR2 sequence 84-GSRPYRHGDSVTFA-97 contribute to C3dg binding; rat mAbs 7G6 and 
4E3, which inhibit binding of mouse or human C3dg to mouse CD21 independently, have 
their epitopes corresponding to these sequences in the mouse CD21 protein (Molina et al., 
1995). An IgG1 mouse mAb, FE8, was shown to interfere with the binding of both C3dg and 
EBV to CD21 expressed on human B cells. This antibody was subsequently found to bind a 
conformational epitope in the recess between SCR1 and SCR2, the ligand binding site of 
CD21 (Wolfgang et al., 1998). FE8 blocked binding of soluble C3dg or particles carrying 
multiple copies of surface bound C3dg to CR2 or induced complete removal of these ligands 
from the receptor. Removal of ligands by this antibody suggests a lower affinity of C3dg for 
its receptor than FE8. This phenomenon has also been demonstrated in additional models 
where administration of mAb against CD21/CD35 inhibited the primary and secondary in 
vivo response in mice (Gustavsson et al.,1995). This study utilised an ELISPOT assay to 
determine the number of antigen-specific, IgG-producing B cells, an indication of T cell 
priming within this model system. Data revealed a 99% suppression of the primary antibody 
response when CD21/CD35 is blocked, however the secondary response is only partially 
inhibited (82-93%) or has been shown to be unaffected in other studies (Thyphronitis et al., 
1991). One explanation for this is that the initial primary reaction elicited is lower and, 
therefore, easier to supress than a secondary response; it is known that the complement 
system is required only in responses to suboptimal antigen doses, therefore works to 
enhance the primary immune response (Bottger et al., 1987).  
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Surface plasmon resonance has been utilised to study the interactions between CD21 and 
C3dg. Kd values for binding to SCR1-2 (ligand binding site) and SCR1-15 (full length 
protein) were determined as 22.4 nM and 27.1 nM, respectively (Ling et al., 1991). While the 
Kd values for each of the molecules are indistinguishable; the binding kinetics differed 
greatly. C3dg both associated and dissociated 10-fold slower from SCR1-15 than SCR1-2 
(Sarrias et al., 2001). This suggests that the structure of the protein affects its binding 
kinetics, hence the additional exon in CD21L may modulate antigen-complex binding and 
maintenance on the surface of FDCs, and perhaps indicating Koff rates are the determining 
factor in antigen stability.  
An additional function of C3d as a molecular adjuvant has been suggested, even in the 
absence of CD21. Studies carried out in a CD21/35-/- mouse model revealed immunisation 
with SA-C3dg tetramers produced primary and secondary antibody responses in these mice 
similar to wild-type mice (Karen et al., 2004). Thus, suggesting C3dg can function as a 
molecular adjuvant in the absence of CD21/35 expression. One mechanism in which C3dg 
could function as a molecular adjuvant could be through its known interactions with 
numerous serum proteins, cell surface receptors and membrane-associated regulatory 
proteins; said interaction could potentially result in enhanced humoral immune responses 
using CD21-independent mechanisms. Immunisation of CD21/35-/- mice with antigen only, 
no C3dg, resulted in impaired antibody responses, confirming the importance of CD21/35 
expression in responses to antigens administered in the absence of adjuvants.  
10.1.5 Tetramer biology  
 
Interestingly, when examining the effect of monomeric, aggregated and latex-bound C3dg 
for their actions on tonsil B cells, the aggregated and latex-bound form of C3dg caused B 
cell activation, whereas C3dg in a monomeric form inhibited this response (Bohnsack et al., 
1988). This phenomenon was also noted in additional studies in which use of polymeric 
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C3dg activated B cells; whereas incubation of cells with monomeric C3dg had no effect on 
the activation response (Carter et al., 1989).  
The application of tetrameric complexes has transformed understanding of antigen specific T 
cell responses by permitting visualisation of weak but specific ligand interactions of TCR and 
MHC (Altman et al., 1996). This study utilised tetramers of human lymphocyte antigen A2 
complexed to two different HIV-derived peptides or with a peptide derived from influenza A 
matrix protein bound to peptide-specific cytotoxic T cells in vitro and to T cells from the blood 
of HIV-infected individuals. Studies revealed the affinity to isolated, soluble monomeric 
MHC/peptide complexes for their specific TCR partners is weak and therefore use of these 
complexes had long hindered efforts to identify antigen-specific T cells by ligand binding 
methods using labelled, monomeric MHC/peptide complexes. Upon using tetrameric 
complexes, which engage more than one copy of the TCR on the surface of a T cell, thereby 
increasing the avidity of the interaction between receptor and ligand, allowed effective 
identification of antigen-specific T cells by flow cytometry, even those subsets present at low 
frequencies (Altman et al., 1996).  Subsequent studies using defined oligomers of soluble 
antigen-MHC molecules of natural ligands for the TCR also revealed that monomeric stimuli 
failed to activate T cells, even at concentrations 20,000-fold higher than the doses of 
tetramer used (Boniface et al., 1998). The occupancy of the TCR using higher 
concentrations of the monomeric complexes would be much higher than using a lower 
concentration of tetrameric complexes, but the failure of T cells to respond excluded 
occupancy as the reason for the greater potency of tetramer versus monomer and dimer 
activation. Therefore, it is thought that tetramers allow colocalisation of TCRs, resulting in 
increased stimulation of cells.  
These results are mirrored in studies using monomeric and tetrameric complexes of C3dg. 
Under physiological conditions, monomeric C3dg was unable to bind to recombinant CD21, 
whereas the HIV viral ligand, gp350/220, was saturable and univalent under the same 
conditions (Moore et al., 1989). These studies indicated the affinity of the C3dg monomer for 
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rCD21 under physiological conditions is approximately 104-fold less than that of the viral 
ligand. Applying what is known about the increased affinity of ligands with weak binding 
when they are found in a tetrameric complex, it is reasonable to suggest C3dg-tetramer 
complex binding to rCD21 may have been possible under physiological conditions. This 
concept was confirmed in a study using biotinylated C3dg create C3dg-immune complex 
tetramers with fluorochrome-conjugated streptavidin (Henson et al., 2001). Again, flow 
cytometry analysis showed monomeric C3dg was unable to bind CD21, whereas C3dg-
tetramer complexes caused tight ligand-receptor interactions. This multimeric C3dg complex 
caused phosphorylation of the mitogen-activated kinase, p38, in mature B lymphoma cells 
and enhanced the activation of primary B cells in combination with sub-stimulatory 
concentrations of anti-IgM monoclonal antibody.  
An investigation utilising diphtheria toxin (DT)-C3d fusion protein and C3dg-streptavidin (SA) 
tetrameric complexes to assess the role of CD21 during BCR-induced activation and in vivo 
immune responses, revealed monomeric DT-C3d inhibited immune responses (Youngkyun 
et al., 2005). Immunisation of mice with DT-C3d reduced DT-specific Ab responses 
independently of CD21 expression or signalling. This inhibition had previously been 
described in studies where anti-Ig-induced Ca2+ responses in human B cells were inhibited 
with monovalent C3dg (Tsokos et al., 1990). It was suggested that crosslinking of CD21 by 
multivalent ligands promotes the formation of domains of membrane Ig that have a 
conformation able to activate phospholipase C, resulting in increased Ca2+ responses. In 
contrast, immunisation with SA-C3dg tetramers dramatically enhanced antigen-specific 
responses, as well as enhancing BCR-induced Ca2+ responses (Youngkyun et al., 2005). As 
monomers should not be able to induce BCR crosslinking, it is thought that in order for B cell 
activation and antigen-specific antibody responses, multimeric C3dg-immune complexes 
must form in order to allow for this crosslinking effect to occur and allow downstream 
signalling resulting in increased humoral immune responses. Interestingly, stimulation with 
higher concentrations of SA-C3dg significantly inhibited BCR-induced Ca2+ responses. 
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Therefore, it was concluded that C3dg can enhance or inhibit antigen-specific humoral 
immune responses through both CD21-dependent and -independent mechanisms 
depending on the concentration and nature of antigen-C3dg complexes (Youngkyun et al., 
2005). The concept of CD21 as both a positive and negative regulator of B cell signalling 
also provides explanation for phenotypic observations in CD21 deficient mice. CD21-/- mice 
are generally hyporesponsive to antigen challenge (Takahashi et al., 1997) whereas 
defective CD21 ligand binding in lpr/lpr mice contributes to the development of autoimmunity 
(Boackle et al., 2001). The lpr/lpr mouse model contains a mutation within the CD21 gene 
encoding a single polymorphism that introduces a glycosylation site located within the C3dg 
binding domain of the receptor, interfering with its ability to form dimers. This mutation 
reduces ligand binding and receptor-mediated cell signalling. This mutation may lead to 
autoreactive B cells being able to escape mechanisms that would normally render them 
tolerant to autoantigen. Alternatively, this mutation may affect antigen presentation by the 
receptor, binding and internalisation of autoantigen by the mutated receptor may result in the 
presentation of unique peptides which are recognised by autoreactive cells. 
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10.2 Summary and Aims 
Within humans, the CD21 receptor exists in two isoforms, CD21S and CD21L. CD21S is 
reported to be expressed on B cells, whereas FDCs are said to express the long isoform, as 
determined using antibody staining patterns with specific CD21L antibody clones (Fujisaku 
et al., 1989). An essential role of CD21 elicited through the binding of C3dg-immune 
complexes, allowing presentation of antigen to B cells resulting in high affinity, antigen-
specific antibody responses. The literature describes unidirectional transfer of these C3dg 
opsonised antigen complexes between CD21 receptors on B cells to CD21 on FDCs.  
In the previous chapter, the hypothesis that receptor number on the cell surface was a 
contributor to the action of antigen transfer between cells was explored. Using tetrameric 
C3dg-immune complexes; a second hypothesis that CD21L expressed on FDCs has a 
higher affinity for C3dg binding allowing C3dg-opsonised antigen transfer from B cells to 
FDCs is assessed with this work (Figure 10.2.1).  
Therefore, the specific aims of this chapter are:  
1) To assess C3dg binding to CD21 on FDCs (tonsil derived) and B cells (tonsil and 
blood derived). 
2) Investigate the potential differential binding of C3dg to CD21S and CD21L 
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Figure 10.3. 1: Biotinylated C3dg is complexed to a streptavidin molecule to form "immune-
complexes" 
10.3 Results  
10.3.1 Assessing CD21 functionality through binding of C3dg-immune 
complexes on primary cells  
 
In order to assess C3dg binding, first an “immune-complex” was established. The complex 
composed of 100% monobiotinylated C3dg bound to a streptavidin molecule, fluorescently 
labelled with an APC molecule. Theoretically the complex takes the form of a tetramer, as 
depicted in Figure 10.3.1A. A tetrameric form of the complex was used to allow visualisation 
of receptor binding with a greater assay window. Use of monomeric C3dg complexes, in 
which only one C3dg molecule is conjugated to the streptavidin-APC molecule, were shown 
to bind to CD21+ cells, however signal obtained from this interaction is lower than that using 
tetrameric complexes, suggesting a lower affinity ligand-receptor interaction (Figure 
10.3.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
(A) Streptavidin is labelled with an APC molecule. C3dg is 100% mono-biotinylated. Tetrameric 
C3dg-StrepAPC complexes are formed from 4 biotinylated-C3dg molecules binding StrepAPC. 
Monomeric C3dg-StrepAPC complexes only have 1 C3dg molecule bound to the StrepAPC. (B) 
Tetramers bind to CD21+ cells with high affinity than monomeric complexes. 
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Binding of this “C3dg-immune complex” was assessed on primary FDCs (tonsil derived), B 
and T cells (blood and tonsil derived) using a titration of the complex, starting with a 
concentration of 10 µg/ml and serially diluting the reagent 3-fold. Binding was assessed on 
CD21+ cells; important as the aim of this investigation was to assess CD21 functionality 
using its ability to bind C3dg. CD21+ cells were gated as shown in Figure 10.3.3 for T and B 
cells and FDCs in Figure 10.3.2. Gates were set using CD21 isotype control samples and 
Streptavidin-APC alone (no biotinylated-C3dg) stained samples to ensure staining was 
specific for CD21 and C3dg respectively. C3dg was shown to bind to all cells in a 
concentration dependent manner (n=3 independent donors, Figure 10.3.4) however 
saturating concentrations of C3dg were not reached for any of the cell types investigated 
(Figure 10.3.4) as immune-complex concentrations higher than 1 µg/ml caused a high non-
specific background signal on CD21- cells. Saturating concentration of C3dg are not 
essential for the final assay as long as sufficient signal can be measured with the 
concentration of C3dg used; therefore 1 µg/ml C3dg was used for the subsequent assays. 
Binding of complexes to CD21+ T cells is in a concentration dependent manner; however 
MFI is lower than the other cell types investigated. This is due to only a small population of T 
cells expressing the CD21 receptor (Figure 9.3.16); hence no further investigation of CD21 
functionality on T cells was carried out during this work.  
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The CD21 antibody clone FE8 is known to block C3dg binding to the ligand binding site on 
the CD21 receptor. Before using this reagent in the final assay, all antibody clones and 
reagents were validated for their ability to co-stain or block binding of CD21+ cells. Firstly, to 
assess the blocking ability of FE8, both C3dg and FE8 were added to cells simultaneously. 
The resultant data showed that in the presence of FE8, C3dg is unable to bind CD21 (Figure 
10.3.5C). FE8 was also added prior to staining with C3dg-immune complexes; again, C3dg 
is unable to bind to CD21 in the presence of FE8 (Figure 10.3.5D). This data concludes that 
FE8 can be used as the blocking reagent within the final assay. It is important that CD21+ 
cells can still be identified within this assay; therefore an antibody clone that binds to CD21 
in the presence of C3dg and the blocking antibody FE8 was identified. The ability of the 
CD21 antibody clone Bu32 (used previously for receptor numeration in Chapter 1) to bind to 
the receptor in the presence of FE8 or C3dg was investigated. FDCs were shown to be 
double positive for Bu32 and FE8 or Bu32 and C3dg (Figure 10.3.5 A and B respectively) 
when reagents were added simultaneously; therefore, they can be used in the same assay 
in order to identify CD21 on cells (Bu32) while assessing biology of CD21 (FE8 or C3dg). It 
was concluded that Bu32 binds to an epitope away from the ligand binding site on CD21, 
while FE8 and C3dg compete for binding at this site (Figure 10.3.5E).  
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In the final assay to assess C3dg-immune complex binding to CD21, cells were 
preincubated with unlabelled FE8 (13 nM serially diluted 3-fold) before addition of a fixed 
concentration of C3dg-complex (1 µg/ml C3dg equivalent). FE8 blocked C3dg binding to 
CD21 on tonsil derived FDCs in a concentration dependent manner (IC50 0.4 nM, n=3; 
Figure 10.3.6A). FE8 also blocks C3dg binding to tonsil and blood derived B cells in a 
concentration dependent manner (IC50 0.07 and 0.06 respectively, n=3; Figure 10.3.6A). 
These data show that approximately 6-fold more FE8 is needed to block C3dg binding to 
FDCs than B cells. The literature suggests FDCs express the long form of CD21, whereas B 
cells express the short form. This raised the question as to whether the observed difference 
in blocking ability was due to the affinity of the receptor isoforms. However, as FDCs have 
over 30-fold higher CD21 receptors on their cell surface compared with B cells (Figure 
9.3.16) it would be expected that if the receptors expressed on the surface of the FDC had 
higher affinity, a fold-change in the amount of FE8 needed to block C3dg binding would be 
more comparable to this change in receptor expression rather than the 6-fold change 
observed. Therefore, it is reasonable to suggest that more FE8 is needed because of the 
increase in receptor number, and this data suggests that CD21 on FDCs does not have a 
higher affinity for C3dg than the receptor on B cells. Isotype control antibodies had no effect 
on C3dg binding at any of the concentrations tested (n=3, Figure 10.3.6B).  
The IC50 of B cells from blood and tonsil are comparable; however, there is a difference in 
the shape of the FE8 blocking response curves. Using the same high concentrations of FE8, 
C3dg binding can be blocked completely on blood derived B cells (0% C3dg binding), 
however in B cells (and FDCs) from tonsil, blocking at the highest concentration of FE8 used 
is incomplete. This may be influenced by the different cell isolation methods; tonsil cells had 
undergone a tissue digestion protocol (Methods section 8.2) whereas blood derived cells 
were isolated using a Ficoll gradient, a gentler method of isolation. Additionally, the source of 
the cells may be a reason for the differences observed.  
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In summary, this work shows that C3dg-immune complexes bind to CD21+ FDCs and B cells 
in a concentration dependent manner and that this binding can be blocked using the CD21 
blocking antibody clone, FE8, also in a concentration dependent manner. Blocking of C3dg 
requires an antibody concentration 6-fold higher for FDCs than that of B cells, suggesting 
CD21L, reported to be expressed on FDCs, does not have a higher affinity for C3dg than 
CD21S expressed on B cells due to the observation that FDCs express 33-fold higher CD21 
receptors on their cell surface (Figure 9.3.16). This concept was further investigated in the 
following experiments. 
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Figure 10.3. 6: FE8 blocks C3dg binding to FDCs and B cells in a concentration dependent manner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(n=3, bars represent SD). (A) FE8 titration, starting at 13.3 nM and serially diluted 3-fold. C3dg 
was added to all samples to a final concentration of 1 µg/ml. Blocking occurs on tonsil derived B 
cells at an IC50 of 0.07 nM and blood derived B cells at 0.06 nM. Blocking occurs on FDCs at 
an IC50 of 0.4 nM, a 6-fold greater concentration of FE8 than that on B cells. (B) No effect on 
C3dg binding is seen using IgG1 isotype antibody (unlabelled) on any cell type at any 
concentration tested.  
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10.3.2 Investigating the presence of the long isoform of CD21 in biology 
 
Expression of CD21S and CD21L at the mRNA level  
FDCs are reported to express the long isoform of CD21; detection of this isoform within 
these cells was confirmed using qPCR. Primers were designed to amplify “total” CD21 
message and CD21L specific message (Figure 10.3.7C) and assays undertaken using 
primary FDCs, FRCs, T and B cells isolated from human tonsil tissue (n=3 donors).  
Primers for total CD21 detected message in both FDCs and B cells relative to gene 
expression in the total tonsil (n=3 independent donors, Figure 10.3.7A). FRCs act as a 
negative control within the assay. These data agree with the protein expression data (Figure 
9.3.16), however FDCs express greater than 30-fold higher CD21 protein than B cells on 
their cell surface, whereas a 2-fold difference in CD21 mRNA is observed between FDCs 
and B cells. This difference could be due to the stability of mRNA compared with protein; 
protein is more stable and therefore degradation and high turnover of mRNA could be a 
reason for this discrepancy. Another interpretation of this data could be, cleavage of CD21 
protein on the surface of B cells to form soluble protein is thought to occur (M. Masilamani et 
al., 2003), therefore more mRNA relative to the levels of CD21 detected on the cell 
membrane could be made by these cells.  
Primers were designed around the 10a exon boundary to specifically detect CD21L mRNA 
expression (Figure 10.3.7C). These primers used a SYBR green based probed for detection 
of amplification whereas total CD21 was detected with TaqMan probes (commercially 
available). TaqMan probes are naturally more specific for their targets than SYBR green 
primers; products were run on an agarose gel after amplification by qPCR and one band, of 
the correct size, was observed using the primers designed for CD21L detection (data not 
shown – done by undergraduate project student), but as the resultant band was not 
sequenced, there is no way to confirm this band was CD21L. However, as expected, FDCs 
express high levels of CD21L mRNA relative to total tonsil and B cells do not appear to 
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express this CD21 isoform at the mRNA level (Figure 10.3.7B). Therefore, it is assumed that 
primers were specific for the long isoform of CD21 as this data reflects that previously 
reported in the literature. Raw Ct values (delta-delta Ct plotted in Figure 10.3.7, data not 
shown) were approximately equal for FDCs in both total CD21 and CD21L assays, 
suggesting all CD21 expressed by FDCs is the long isoform.  
This data shows that the CD21L isoform is expressed in FDCs but not B cells at the mRNA 
level, confirming what was previously described in the literature. CD21L protein was 
assessed in further detail in the following data.  
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(n=3, bars represent SD) SYBR green probes for CD21 and CD21L showed (A) FDCs and B cells 
express CD21 at the mRNA level relative to levels found in total tonsil. FRCs act as a negative 
control within this assay. CD21 probes will identify “total” CD21 mRNA, therefore both CD21S and 
CD21L isoforms will be detected. (B) FDCs express CD21L at the mRNA level relative to total 
tonsil. FRCs and B cells do not express CD21L at the mRNA level relative to total tonsil. CD21L 
SYBR green primers specifically identify CD21L isoform. (C) Primer design for CD21L SYBR 
green probes. Forward primer is located within exon 11/10a; the addition sequence added in the 
long isoform of the protein. The reverse primer spans the exon-exon boundary of exon 11/10a and 
exon 12. This design ensures products will only be produced is CD21L mRNA is present in the 
sample. 
Figure 10.3. 7: FDCs express CD21L at the mRNA level, B cells express CD21S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
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Immunohistochemistry staining of human tonsil tissue with CD21 
antibody clone R4/23 
In order to investigate CD21L at the protein level, isoform specific reagents are required. 
CD21L was first reported to be specifically expressed by FDCs using immunohistochemistry 
in a study utilising the CD21 antibody clone R4/23. This antibody was said to be specific for 
the long isoform of CD21 due to staining patterns of FDCs seen within human tonsil tissue 
whereas CD21 expression on B cells was absent (Naiem et al., 1983). This data was 
replicated in this study confirming that only the FDCs are identified when staining is carried 
out using R4/23 (Figure 10.3.8); however previous data revealed staining with the CD21 
antibody clone Bu32 also reveals the same staining pattern, i.e. only CD21 expression on 
FDCs are detected (Figure 9.3.5). It was previously concluded that this result occurred due 
to the high numbers of CD21 receptors expressed by FDCs in comparison to B cells, 
therefore detection on CD21 expressed on B cells theoretically should be seen in zones 
devoid of FDCs; this observation was reported in the study using R4/23. Weak binding of B 
cells in zones outside of the germinal centre, in which there were no FDCs present, was 
visualised using this antibody (Naiem et al., 1983). This was the first indication that R4/23 
may not be specific for the long form of CD21; therefore, further investigation was 
undertaken to confirm the isoform preference of the antibody.  
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Figure 10.3. 8: Immunohistochemistry of secondary lymphoid organs with CD21 antibody clone R4/23 
reveals the same staining pattern as Bu32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Human tonsil tissue stained with R4/23 (A647-red) and CD19 (A488-green), magnification x63, 
scale bar 20 µm. (ii) green channel alone – CD19 (iii) red channel alone – R4/23. (B) R4/23 
secondary alone control. No staining in (ii) confirms staining with this antibody is specific for R4/23. 
(C) R4/23 isotype control. No staining in (ii) confirms CD21 specific staining of the R4/23 antibody. 
176 
 
Figure 10.3. 9: Transfected HEK293T cells express CD21S and CD21L 
Using CD21S and CD21L transiently expressing HEK293T cells to 
assess R4/23 specificity 
CD21 short and long isoforms were cloned into the vector pQCXIN (Materials and Methods 
section 8.12) with the final aim to create transiently transfected cell lines specifically 
expressing CD21S or CD21L in order to further understand the specificity of CD21L antibody 
reagents. HEK293T cells (HEK) were the cell line of choice in these experiments. HEK cells 
were transfected with plasmids using lipofectamine (methods section 8.14) and harvest 36 
hours after transfection to assess CD21 expression. Supernatants were also collected and 
frozen at -80°C for future use.  
CD21 expression was assessed using the Bu32 antibody clone. Flow cytometry analysis 
revealed transfections were successful; on average 69.5% of transfected cells were CD21+ 
(n=4 independent transfections, Figure 38). Untransfected cells and cells stained with 
isotype antibody were all negative for CD21 (Figure 38).  
 
 
 
 
 
 
 
 
 
 Flow plot is representative of 4 individual transfections performed to obtaining the following data 
depicted in Figures 10.3.10, 10.3.12 and 10.3.13. 64.4% of cells transfected with pQXCIN-CD21L 
became CD21+ve. 75.1% of cells transfected with pQXCIN-CD21S became CD21+ve. 
Untransfected cells and cells stained with IgG1-PE isotype antibody are negative for CD21.  
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Expression of a single isoform within transfected cells was assessed using western blotting. 
There is a small size difference between CD21S and CD21L, 145 kDa versus 150 kDa 
respectively. This difference can be resolved on a western blot; assessment of protein lysate 
from untransfected HEKs and cells transfected with CD21S and CD21L using this method 
revealed no bands, a protein band at 145 kDa and a protein band at 150 kDa, respectively 
when blotted using the CD21 antibody clone Bu32 (Figure 10.3.10B). This observation 
confirmed HEK cells do not endogenously express CD21 and transfected cells are 
expressing CD21S or CD21L protein only. Additionally, PCR was performed using primers 
designed to result in a smaller band when CD21S is present and a larger band when CD21L 
is present (Figure 10.3.10C). Again, transfected HEK cells were shown to specifically 
express CD21L or CD21S only (Figure 10.3.10C). Raji cells and total tonsil acted as controls 
for this data, showing that Raji cells only express the short form of CD21, creating only the 
smaller of the two bands, and as total tonsil contains both CD21S and CD21L, presumably 
due to the presence of B cells and FDCs within the sample, both bands are present within 
this sample. It was previously reported that Raji cells express the long isoform of CD21, 
determined through binding of another CD21L antibody clone, 7D6, to surface expressed 
CD21 (Liu et al., 1997), however data presented here suggests, again this antibody may not 
be specific for the long isoform of CD21. Additionally, PCR for the CD21 gene within these 
cells, revealed only the short form is present at the mRNA level (Figure 10.3.10C) therefore 
cell surface protein will also be of the short isoform. This observation provides further 
evidence that this antibody clone also recognises the short isoform of CD21.   
Transfected cells were used to investigate R4/23 specificity using flow cytometry. The 
antibody was seen to bind to cells expressing CD21S and CD21L (Figure 10.3.10A); 
therefore R4/23 is not specific for CD21L in a flow cytometry setting. Increased binding of 
the antibody to cells transfected with the long form of CD21 was observed, suggesting the 
antibody may preferentially bind to CD21L, but as this reagent has the capacity to also 
identify CD21S expressing HEK cells, it cannot be said that this reagent is specific for the 
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long isoform. The antibody clone, 7D6, also reported to bind to CD21L, was used to stain the 
transfected cells to test the isoform specificity of this clone. Using this antibody, no CD21+ 
cells were identified; as cells were shown to be CD21+ using Bu32 and R4/23 antibody 
staining, it can be concluded that 7D6 is not suitable for use in flow cytometry to identify 
CD21 expression (Figure 10.3.10A).  
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To further assess isoform preference of the R4/23 antibody, an ELISA was developed using 
this CD21 clone as the capture antibody. Specificity for CD21S and CD21L was assessed 
using supernatants derived from transfected HEK293T cells, specifically expressing the long 
or the short form of CD21. Consequently, supernatants contained either soluble CD21S or 
CD21L, although protein concentrations were not high enough to visualise on western blot. 
Presence of CD21 within reagents was confirmed using a commercial human CD21 ELISA 
(abcam) that detects both the long and short form of CD21 (“total” CD21) (Figure 10.3.11A). 
Standards from the ELISA kit were also run during this assay to determine protein 
concentration within supernatant and confirm the assay was working as expected, detecting 
CD21 specifically. To form the R4/23 ELISA, components from the commercial CD21 ELISA 
were used, replacing the capture antibody with R4/23. HEK derived supernatants and kit 
standards were run using this assay to reveal detection of both CD21S and CD21L using 
R4/23 (Figure 10.3.11B). Interestingly, CD21 standards from the commercial ELISA were not 
detected in this assay, presumably as the protein was in a truncated form, and the epitope 
recognised by R4/23 had been removed. This data further suggested that R4/23 recognises 
both the long and the short form of CD21, but as CD21 within the supernatants could not be 
visualised, to confirm this observation, a standard curve using a recombinant form of CD21 
(R&D systems) was run on the total CD21 and R4/23 ELISA (Figure 10.3.11C). Protein was 
detected in both assays, although signal was slightly reduced in the R4/23 assay, again 
suggesting the antibody may preferentially bind CD21L, but not specifically. As rc-CD21 is 
known to be the short form of CD21, it can be concluded that in an ELISA setting, R4/23 is 
not specific for CD21L and also has the ability to bind CD21S.  
To summarise, the use of CD21S and CD21L HEK293T cells and supernatants derived from 
these cells, revealed that CD21 antibody clone R4/23, although may preferentially bind to 
the long CD21 isoform, is not specific for CD21L and also has binding capacity for CD21S. 
Therefore, there are no CD21L specific reagents readily available to assess protein 
expression in biology.  
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Figure 10.3. 11: R4/23 detects CD21L and CD21S in an ELISA setting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (A) Transfected HEK derived supernatants contain CD21S and CD21L protein, both isoforms of 
this protein are detected by the abcam CD21 ELISA. Standards from the abcam kit are also 
detected using this ELISA. (B) 5 µg/ml R4/23 was used to coat 96 well plates to act as a capture 
antibody in an ELISA. CD21L and CD21S HEK derived supernatants are detected. Abcam 
standards are not detected using R4/23 as a capture antibody. (C) Recombinant CD21, the short 
form of CD21, is detected on both ELISAs.  
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10.3.3 Assessing isoform differential binding functionality using 
transfected HEK293T cells expressing specific CD21 isoforms 
 
As a specific CD21L antibody reagent was not available, to assess the differential C3dg 
binding capacity of CD21 isoforms, transfected HEK293T cells, transiently expressing 
CD21S or CD21L, were utilised (Figure 10.3.8). As with primary cells C3dg binding was 
assessed using C3dg-immune complexes (Figure 10.3.1). CD21+ cells were gated on, 
determined as positive using CD21 isotype antibody stained samples and untransfected 
HEK cells stained with Bu32, the antibody clone of choice for identification of CD21 
expressing cells (Figure 10.3.12).  
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CD21 receptor expression was assessed using Quantibrite-PE beads as described in 
Material and Methods 2.9. Both CD21S and CD21L expressing HEKs were found to express 
~ 15,000 CD21 receptors per cell (Figure 10.3.13A, n=4 independent transfections), as cells 
are expressing similar receptor numbers on their cell surface, any differences observed in 
C3dg binding can be said to be isoform specific, not due to receptor number expression.  
Assays to assess C3dg binding capabilities of each isoform were performed by titrating 
C3dg-immune complexes from a starting concentration of 10 µg/ml C3dg and serially diluting 
3-fold. C3dg was shown to bind to both isoforms in a concentration dependent manner 
(Figure 10.3.13B, n=4 independent transfections), however, as with primary cells (Figure 
10.3.4), saturating concentrations of C3dg were not reached. Increased concentrations were 
not used due to limits to how much protein can be added in an assay. As the concentration 
of C3dg increases, CD21S binds to more of the available ligand. This suggests CD21S has 
a higher binding capacity for C3dg than CD21L.   
Assays using FE8 to block C3dg binding to the two CD21 isoforms were performed by 
preincubating cells with unlabelled FE8 and adding a fixed concentration of C3dg-immune 
complex (1 µg/ml). A higher starting concentration of FE8 was needed to see complete 
blocking of C3dg binding to transfected cells than that used to block binding in primary cells, 
40 nM compared with 13.3 nM respectively. FE8 was shown to block C3dg binding to 
CD21S and CD21L in a concentration dependent manner, the IC50 of each curve was 0.04 
nM and 0.01 nM respectively. As IC50 values are similar for both isoforms, it can be 
concluded that FE8 binds equivalently to each CD21 form. This suggests the binding site of 
C3dg, FE8’s epitope, is not changed between the two isoforms.  
This data suggests that isoforms of CD21 do not differentially bind to C3dg. CD21S binds to 
more C3dg at higher concentrations; therefore it is thought that an increased affinity for 
C3dg is not the cause for antigen transfer between CD21S and CD21L.  
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Figure 10.3. 13: Investigation of C3dg binding capacity of CD21S and CD21L expressing HEK293T 
cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (A) The number of CD21 receptors on the surface of transfected cells was quantified using 
Quantibrite beads (Methods 8.9). Both cell types express an average of ~15,000 receptors per 
cell. n=4 individual transfections, bars represent SD. (B) C3dg titration starting at 10 µg/ml showed 
that C3dg binds to CD21S and CD21L in a concentration dependent manner. CD21S binds 
greater C3dg complexes at high concentrations of C3dg. Saturating concentrations were not 
reached for either isoform. n=4 individual transfections, bars represent SD. (C) Cells were 
preincubated with FE8 CD21 Ab clone at a starting concentration of 40 nM. 1 µg/ml C3dg was 
added to each sample. FE8 blocks C3dg binding to CD21S (IC50 = 0.04 nM) and CD21L (0.01 
nM) in a concentration dependent manner. n=4 individual transfections, bars represent SD, NB: 
data points at 0.002 nM and 0.0006 nM FE8 are n=2.  
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10.3 Discussion: 
The aim of this work was to investigate the C3dg binding functionality of the two CD21 
isoforms, short and long. I hypothesised that unidirectional transfer of C3dg-antigen 
complexes between B cells and FDCs may be due to the differential expression of CD21 
isoforms on each cell type. FDCs are reported to express CD21L, whereas B cells are 
reported to express CD21S (Liu et al., 1997). 
 
Model immune complexes were formed using monobiotinylated-C3dg and fluorescently 
labelled streptavidin (Figure 10.3.1). These complexes of C3dg were assumed as tetramers, 
although this was not confirmed using size exclusion chromatography or other analytical 
methods, but empirically calculated. It has been previously reported that tetrameric C3dg-
complexes are able to bind to B cells and cause improved specific-antibody responses and 
increased activation of cells (Youngkyun et al., 2005), whereas monomeric C3dg-complexes 
have been shown to inhibit these responses (Tsokos et al., 1990). This suggests that C3dg 
can act to both activate and inhibit the immune response depending on which form the 
molecule takes in vivo. Additionally, it has been shown that, binding of monomeric C3dg to 
recombinant CD21 does not occur under physiological conditions (Moore et al., 1989). 
Binding of a monomeric form of C3dg complexes can be visualised under the experimental 
conditions used here, but the signal detected is much lower than that of the tetrameric form 
(Figure 10.3.1B). As this work was assessing binding of C3dg by CD21+ cells, it was 
important to use a tetrameric complex to ensure binding of the ligand to its receptor could be 
easily visualised; the increased valency of the complex subsequently increased the assay 
window for ligand binding assays. This artefact may be due to a low binding affinity of C3dg 
for CD21; suggested by studies using tetrameric complexes of T cell antigen to visualise 
populations of T cells expressing specific TCRs (Altman et al., 1996). These studies 
revealed that tetrameric complexes could be used to visualise weak binding interactions 
between ligand and receptor.  
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C3dg-immune complexes were shown to bind to primary FDCs, T and B cells in a 
concentration dependent manner (Figure 10.3.4). As no data was generated to confirm that 
C3dg was used in a tetrameric form, there is the potential for monomers to be present within 
the assay. As the concentrations used were chosen due to the likelihood of tetrameric 
complex formation, calculated by molar ratios, and the fact that brighter signal was observed 
using these complexes than the “monomeric” complexes (Figure 10.3.1B) suggests any 
monomers present did not dramatically affect the results collected. However, it is true that, 
an increased signal may have occurred if no monomers were present; this may be a reason 
that saturating concentrations of C3dg did not occur on any of the cell types investigated 
(Figure 10.3.4). Increased concentrations of complex were not used due to the occurrence of 
non-specific binding to CD21- cells at high concentrations. C3dg is known to bind to other 
membrane receptors and serum proteins, an action which has been interpolated as the 
molecule acting as a potential universal molecular adjuvant (Karen et al., 2004). These 
additional binding partners could explain the binding of high concentrations of C3dg to CD21- 
cells. As this binding is only observed at high concentrations, it is suggestive that C3dg has 
a higher ligand-receptor affinity with CD21 than with the other receptor interactions on CD21- 
cells. This non-specific signal was not seen at a C3dg-immune complex concentration of 1 
µg/ml; therefore, this was the concentration of complex chosen for subsequent assays. As 
this investigation was focused on binding of C3dg via CD21, it was important to use a 
concentration of the ligand which would bind to CD21 expressing cells and where non-
specific binding was not observed on CD21- cells, allowing all ligand to be bound by the cells 
of interest. 
A monoclonal mouse CD21 antibody clone, FE8, was utilised to further investigate C3dg 
binding on primary human FDCs and B cells. FE8 has previously been shown to block the 
binding of C3dg to human tonsil B cells and infection of these cells with EBV (Wolfgang et 
al., 1998). This study concluded that the antibody blocked binding of CD21 ligands to their 
receptor by occupying an epitope sequence found in the recess formed between SCR1 and 
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SCR2; the ligand binding site. This study did not investigate the effect of this competitive 
antibody clone of C3dg binding on primary human FDCs or B cells derived from the blood. 
Data from the current investigation showed that FE8 was able to block C3dg binding to tonsil 
derived FDCs, B cells derived from tonsil and B cells derived from blood in a concentration 
dependent manner (Figure 10.3.6A). The CD21 antibody clone HB5 was used as a control 
for FE8 blocking ability in the early study, whereas an IgG1 isotype control was used here to 
show blocking was FE8 dependent (Figure 10.3.6B). In addition to blockage of C3dg 
binding, FE8 was also shown to remove C3dg ligands already bound to the CD21 receptor 
(Wolfgang et al., 1998); further supporting the idea that C3dg has a low affinity interaction 
with CD21. Interestingly, the IC50 of FE8 blocking binding of C3dg to FDCs is 6-fold greater 
than that on B cells, 0.4 nM and 0.07 nM, respectively. As FDCs express over 30-fold more 
CD21 receptors on their cell surface, the amount of FE8 needed to block binding of C3dg to 
CD21 on these cells was expected to be higher than 6-fold. Thus, it is possible that CD21L 
on FDCs has a lower affinity for C3dg than CD21S expressed by B cells; this was further 
investigated in subsequent experiments.  
FDCs were confirmed to express the long isoform of CD21 at the mRNA level, whereas B 
cells were shown to express CD21S, detected with total CD21 TaqMan probes (Figure 
10.3.7A). These probes will detect both CD21 and CD21L whereas the SYBR green based 
assay, specifically identifies CD21L mRNA expression (Figure 10.3.7B). Antibodies against 
CD21, Bu32 for example, bind to both the short and the long isoform of CD21 protein. 
However, this investigation revealed that no CD21L specific antibody reagents are currently 
available to detect this isoform at the protein level.  
Antibody staining patterns in tonsil tissue using the antibody clone R4/23 revealed only the 
expression of CD21 on FDCs, an observation previously reported in the literature and the 
primary reason for the conclusion that R4/23 was specific for CD21L protein (Naiem et al., 
1983). Immunohistochemical data presented in results chapter 1 also showed that staining 
secondary lymphoid organ tissue with antibodies against CD21, in this case the antibody 
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clone Bu32, also shows FDC expression of CD21 (Figure 9.3.6). It was concluded that this 
observation was due to the high number of CD21 receptors expressed on the cell surface of 
FDCs compared to B cells (Figure 9.3.16) and it is thought that CD21 expression would be 
observed on B cells in zones devoid of FDCs. Weak binding of R4/23 and 7D6, another 
CD21 Ab clone reported as specific for the long isoform (Liu et al., 1997), was reported 
against B cells outside of the FDC zones, indicating the antibodies do have some capacity to 
bind to CD21S, although their binding preference may be the long isoform. Data using 
antibodies in a flow cytometry setting to identify transfected HEK293T cells further highlight 
the non-specific nature of R4/23. Both CD21S and CD21L expressing cells were shown to 
be transfected to similar levels, around 70% of cells were CD21+ when analysis was carried 
out using the Bu32 antibody clone by flow cytometry (Figure 38). In contrast, an increased 
staining for CD21L expressing cells was seen in comparison with CD21S cells when using 
R4/23 to identify CD21+ cells (Figure 10.3.10). This observation further suggests that R4/23 
preferred CD21L but is not specific for this isoform as both cell populations were detected. 
On the other hand, 7D6 did not identify CD21S or CD21L transfected cells, therefore cannot 
be used in a flow cytometry setting within this study (Figure 10.3.10). Transfected cells were 
shown to express only one form of the protein using both western blot analysis and PCR. 
PCR primers were designed outside of the SCR10a exon boundary which allowed a band of 
273 bp to be formed if the exon was not present in CD21S transcripts, but a larger band of 
413 bp to form when CD21L transcripts were present in the sample (Figure 10.3.10C). Both 
techniques confirmed expression of CD21S or CD21L in the transfected cells. The B cell 
lymphoma cell line, Raji, and total tonsil were used as controls in the PCR assay. Total tonsil 
contained both isoforms, as expected due to the presence of both FDCs and B cells within 
the sample, whereas Raji cells only formed the smaller PCR product, suggesting only 
CD21S is expressed by this cell line. This is interesting as these cells have previously been 
reported to express the long form of CD21 as they were shown to express the 7D6 epitope 
(Liu et al., 1997). Again, the data presented here contradicts these reports, and further 
shows these antibodies are not specific for detection of CD21L. Additional studies using 
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R4/23 as a capture antibody in an ELISA setting and HEK supernatants containing soluble 
CD21S or CD21L confirmed that this antibody could detect both forms of the protein (Figure 
10.3.11B). The antibody could also detect recombinant CD21 (R&D systems) which is 
known to be the short form of the protein (Figure 10.3.11C). This data concludes that no 
specific CD21L antibody reagents are available, therefore to investigate the differential C3dg 
binding potential of CD21S and CD21L, HEK293T cells transfected to transiently express the 
long or short form of CD21 specifically were utilised.  
Transfected HEK cells were shown to express ~15,000 CD21S or CD21L receptors per cell 
(Figure 10.3.13A), which is ~1.5-fold higher than that seen on the surface of B cells and ~10-
fold lower than that expressed on FDCs (Figure 9.3.16). As both transfected cell lines 
averagely expressed similar numbers of receptors, any changes observed in C3dg-binding 
between the two lines is due to the isotype expression. C3dg-immune complexes were 
shown to bind to CD21S and CD21L in a concentration dependent manner (Figure 
10.3.13B). At high concentrations of C3dg, CD21S binds more complex than CD21L. This is 
suggestive of CD21S having a higher affinity for C3dg than CD21L. FE8 blocked C3dg 
binding to CD21S and CD21L with the same affinity, IC50 was found to be 0.04 nM and 0.01 
nM, CD21S and CD21L respectively (Figure 10.3.13C). This experiment only assesses FE8 
affinity for the receptor, not the affinity of C3dg for the two isoforms. To investigate the 
affinity of C3dg for the CD21 receptor isoforms directly, an assay could be designed in which 
C3dg-immune complexes are allowed to pre-bind CD21 receptors before the addition of FE8 
in varying concentrations. If the concentration of FE8 needed to displace the ligand from 
CD21 differed between isotypes, a conclusion of which isoform had the highest affinity to 
C3dg could be more accurately drawn. Previous studies have investigated C3dg 
displacement with FE8, but differential binding capacity of CD21S and CD21L was not 
assessed (Wolfgang et al., 1998). As FE8 binds to the ligand binding site and blocks C3dg, it 
is unlikely that the additional SCR found in CD21L changes the conformation of this site as 
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the antibody binds to each receptor with the same affinity. Thus, it is unlikely that the affinity 
of the receptor for C3dg is changed between isoforms.  
To conclude, data collected in this investigation aimed to investigate the hypothesis that 
unidirectional antigen transfer occurs due to CD21L expression on FDCs having a higher 
affinity for C3dg than CD21S expressed on B cells. The binding capacity for C3dg of CD21S 
vs CD21L was investigated using transiently transfected HEK293T cells that on average 
expressed the same number of CD21 receptors on their cell surface; these experiments 
revealed no considerable differences in C3dg binding between CD21 isotypes. In contrast, 
differences in the ability of FE8 to block C3dg binding was seen in experiments using 
primary FDCs and B cells, which express CD21L and CD21S, respectively. When 
considering the observations discussed above, the differential ability of FE8 to block binding 
of C3dg to CD21 expressed on FDCs and B cells is thought to be due to receptor numbers 
on the cell surface and is not a consequence of the CD21L receptor having a greater affinity 
for C3dg; an increased number of CD21 receptors and size of FDCs results in increased 
FE8 needed to block C3dg binding. As the C3dg binding capacity of B cells and FDCs did 
not differ, saturating concentrations were not reached for either cell types (Figure 10.3.4), it 
is thought that the affinity for C3dg of the CD21 receptors expressed by these cell types also 
does not differ. This mechanism was also suggested after a study investigating antigen 
transport in mice (Phan et al., 2007). FDCs in mice also express higher levels of CD21/35 
than follicular B cells, further supporting this mechanism as an explanation for antigen 
transfer. Heesters et al., (2014) suggested that unidirectional C3dg-antigen complex transfer 
occurs due to cell size. Antigen complexes are presumably opsonised with more than one 
C3dg molecule, therefore FDCs, with their increased size and number of CD21 receptors, 
are able to bind an increased number of the available C3dg molecules on the antigen 
complex than B cells. Contact between FDCs and a B cell during antigen transfer has been 
found to last up to 30 minutes (Suzuki et al., 2009). Within this time, C3dg is likely to 
naturally dissociate from its receptor due to the predicted low affinity of the ligand for CD21. 
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C3dg is thought to bind to CD21 with low affinity, primarily due to the fact tetrameric C3dg 
complexes allow greater visualisation of ligand-receptor binding compared with monomeric 
complexes in these and previously published studies. When the antigen dissociates from its 
receptor, the increased number of contacts the FDC has with the antigen complex allows 
transfer between the B cells and the FDCs. Alternatively, the increased contacts on the 
C3dg-antigen complexes and internalisation of CD21 receptors by FDCs into non-
degradative endosomal compartments, actively pulls the complexes from the B cells and are 
sequestered by the FDCs. C3dg bound CD21 is retained and periodically cycled to the cell 
surface for presentation of antigen to specific B cells (Heesters et al., 2013).  
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The hypothesis of antigen transfer between CD21 receptors on B cell to FDCs was 2-fold. 
The studies detailed in results chapter 1 and 2 investigated whether this phenomenon was 
due to (1) receptor number on the cell surface or (2) CD21L expressed on FDCs having a 
higher affinity for C3dg binding allowing antigen transfer to occur. After reviewing the data 
discussed within these chapters, the following model is proposed (Figure 10.4.1). B cells 
collect C3dg-antigen complexes from SCS macrophages and consequently shuttle the 
antigen bound to CD21 receptors to FDC zones, attached through CXCL13 gradients 
(Figure 10.4.1-1). Contact between C3dg-antigen complexes on B cell CD21 and CD21 on 
FDCs occurs for up to 30 minutes (Figure 10.4.1-2). Within this time, C3dg could naturally 
dissociate from CD21 receptors on B cells and remains bound to those receptors on FDCs 
due to increased number of contacts and receptors on the cell surface. Alternatively, 
receptors are actively internalised, pulling antigen complexes off the B cell CD21 due to 
increased contacts between CD21 receptors on the FDC and the C3dg-opsonised antigen-
complex (Figure 10.4.1-3). CD21 bound antigen is retained in non-degradative endosomal 
compartments and recycled to the cell surface for presentation to antigen-specific B cells 
leading to an increased specific antibody response (Figure 10.4.1-4). 
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11. Results chapter 3: Soluble CD21 in health and disease 
11.1 Introduction 
In addition to the membrane bound form, CD21 also exists in a soluble form found within the 
blood and synovial fluid. There are contradicting reports in the literature discussing the 
isoform of the soluble receptor. The earliest reports suggest that, although both isoforms are 
present, sCD21 is predominantly found as the long isoform (Ling et al., 1998). This study 
utilised the CD21 antibody clone R4/23, reported to be specific for CD21L, however this 
investigation reveals that this claim is incorrect, rendering the conclusions of this data 
questionable. An additional study using western blot analysis, identified two forms of sCD21 
with molecular masses of 135 and 90 kDa, thought to be the long and short isoform 
respectively. The molecular mass of sCD21 is smaller than membrane bound CD21 due to 
the removal of the transmembrane and small cytoplasmic region to create the soluble form 
of the receptor (Figure 11.1.1). It was shown that CD21 can be released by a proteolytic 
cleavage through stimuli including the thiol antioxidants N-acetylcysteine and glutathione, 
and the oxidant pervanadate in murine splenic B cells (Hoefer et al., 2008) but it is currently 
unknown exactly how CD21 is shed from the membrane surface of cells in humans; though it 
is thought to be through the action of a yet unidentified protease. More recently, mass 
spectrometry was used to show that the short form of CD21 is predominantly shed to make 
to pool of sCD21 within the serum (Masilamani et al., 2003).  
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Figure 11.1. 1: Membrane and soluble CD21 receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Membrane bound CD21 is found as a long (16 SCRs) and a short (15 SCRs) isoform. The soluble 
form of CD21 is thought to be of the short isoform and is the extracellular portion of the receptor. 
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11.1.2 The origin of soluble CD21 
 
The origin of sCD21 in humans has not been confirmed; however, a study investigating this 
question showed pre-B cells, peripheral T cells, myeloid, fibroblast and plasmacytoid lines to 
be non-producers of sCD21 (Ling et al., 1991). Additionally, there is published evidence 
towards B cells as major contributors to the sCD21 pool in humans. Soluble CD21 has been 
found in culture media from human T and B cells (Fremeaux-Bacchi et al., 1996) and 
crosslinking of the BCR and CD40 in B cells has been shown to induce shedding of CD21 
paralleled by a decrease in membrane associated CD21 when cells were activated with 
PMA and Ca2+ (Masilamani et al., 2003). Additional observations that further support this 
hypothesis are increased sCD21 levels in patients with B cell chronic lymphocytic leukaemia 
(Lowe et al., 1989), in which B cell numbers in the blood are increased, and decreased 
sCD21 levels in patients with Common variable immune deficiency (CVID) (Ling et al., 
1991), a condition in which patient B cells have been shown to have defects in CD21 
expression.  
 
11.1.3 Functions of soluble CD21 
 
The function of sCD21 in humans has not been fully described. It has been shown to retain 
C3dg and EBV binding capacity (Ling et al., 1991) and to activate monocytes through 
binding of membrane CD23 (Masilamani et al., 2004). Recombinant sCD21 has also been 
shown to inhibit EBV infection of PBMC derived B cells in vitro (Nemerow et al., 1989). A 
(CR2)2-IgG1 chimera was used to demonstrate the ability of sCD21 to bind C3dg within a 
murine model. The study showed that the (CR2)2-IgG1 was able to compete for binding to 
C3dg with cellular CD21 and suppress antibody responses to a T cell-dependent antigen 
when administered to mice at the time of immunisation (Hebell et al., 1991). The same study 
used this model complex to demonstrate how sCD21 can inhibit the primary immune 
response to T-dependent antigen and subsequent isotype switching of murine B cells 
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(Hebell et al., 1991). Another study demonstrated a role for sCD21 in the inhibition of 
sCD23-induced IgE synthesis by IL-4 stimulated human peripheral B cells (Fremeaux-Bacchi 
et al., 1998). Western blot techniques were utilised to show sCD21 could bind to sCD23 in a 
trimeric form, this binding rendered sCD23 unable to induce antibody synthesis by B cells; 
another example of sCD21 dampening the immune response. These observations suggest a 
role for sCD21 in immune response regulation and activation.  
 
11.1.4 Soluble CD21 in disease 
 
It is widely reported that patients with autoimmune diseases have reduced levels of sCD21 
compared with healthy individuals. Patients with Rheumatoid Arthritis (RA) (Masilamani et 
al., 2004), Multiple Sclerosis (Toepfner et al., 2012), Systemic Lupus Erythematosus (SLE) 
(Masilamani et al., 2004), Sjogren’s Syndrome (Masilamani et al., 2004), Systemic Sclerosis 
(Tomita et al., 2012) and progressive Systemic Sclerosis (Masilamani et al., 2004) have all 
reported to have decreased levels of sCD21. Interestingly sCD21 levels have also been 
shown to decrease with pregnancy (Masilamani et al., 2008) and age (Masilamani et al., 
2004) but conclusions as to why this occurs have not been reached.  
In contrast to the decrease in autoimmune diseases, B cell malignancies such as B cell 
chronic lymphocytic leukaemia (Ling et al., 1991), EBV and EBV-associated malignancies 
(Larcher et al., 1995) have higher levels of sCD21 within the serum compared with healthy 
individuals. This is further evidence for B cells as a source of sCD21, as there are increased 
numbers of cells in the circulation and an increased sCD21 concentration.  
As sCD21 levels are affected within disease phenotypes, a role for the soluble receptor in 
disease and regulation of the immune system is implied. Consequently, it has been 
suggested that measurement of sCD21 could serve as a marker for activation of the immune 
system and diseases involving the B cell lymphoid system (Huemer et al., 1993).  
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This investigation focuses on sCD21 levels within Rheumatoid Arthritis patient serum. 
Normal serum sCD21 levels have been reported to range between 100 and 477 ng/ml, 
decreasing with age (Maslamani et al., 2004). A further reduction is reported to levels 
between 50 and 300 ng/ml in patients with RA; this did not differ with age in RA patients in 
this particular study (Masilamani et al., 2004). In addition to the reduction on sCD21 reported 
in RA sera, a further decrease is seen within the synovial fluid of paired patient samples 
(Grottenthaler et al., 2006). The protein content of the synovial fluid is partially derived from 
the pannus tissue and inflammatory cells in the arthritic joint; it has been previously reported 
that expression of CD21 is reduced in synovial fluid compared with blood-derived B cells 
(Illges et al., 2000). This observation could explain the decreased levels of sCD21 within the 
synovial fluid of patients with RA. Blood-derived B cells from RA patients also have 
decreased levels of membrane bound CD21 compared to healthy volunteers, in addition to 
decreased FcγRIIB expression (Prokopec et al., 2010). This decrease of membrane CD21 is 
also observed in patients with SLE (Wilson et al., 1986). An additional study compared CD21 
transcript levels between patients with RA and healthy volunteers and observed a decrease 
in transcript levels within the patient samples (Dash et al., 2016). Further analysis revealed a 
correlation between PBMC-CD21 transcript levels and DAS28 score. Those patients with 
increased DAS28 score (increased disease severity), expressed lower levels of CD21 
transcript. After 6 months of treatment, the levels of CD21 transcript increased within these 
patients, accompanied with a decline in DAS28 scores.  
DAS28 score is a measure of joint pain and is routinely used to classify RA disease severity. 
DAS28 scores above 5.1 are an indicator of more severe disease compared with those with 
scores under 5.1. Other factors on which RA diagnosis is based include; joint involvement, 
serology (rheumatoid factor, RhF, and anti-cyclic citrullinated peptide, anti-CPP), levels of 
acute phase reactants and the duration of the symptoms (Kourilovitch et al., 2014).  
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Figure 11.1. 2: Soluble CD21 levels in disease 
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11.1.5 Treatment of Rheumatoid Arthritis with Rituximab 
 
Rituximab is a clinical formulation of the murine IgG1 monoclonal anti-CD20 antibody 
(Edwards et al., 2001). It was originally used as a therapeutic to treat B cell lymphoma 
however treatment of patients with rheumatoid arthritis in combination with corticosteroid and 
cyclophosphamide resulted in sustained improvement in disease (Edwards et al., 2001). 
This therapeutic antibody depletes all CD20+ B cells, reducing the majority of auto-reactive B 
cells and therefore theoretically inducing the collapse of a pathogenic autoantibody-
generating cycle, leading to remission. Patients treated with mono-therapy frequently relapse 
after finishing the treatment course, however in studies using a combination therapy, 
patient’s B cells returned after treatment without relapse to a disease phenotype after the 
first or second course of treatment (Edwards et al., 2001). In addition, levels of Rheumatoid 
Factor (RhF) fell in all patients within the study. An additional study of 161 patients, revealed 
a greater clinical response in patients treated with Rituximab and a short course of 
corticosteroids in conjunction with methotrexate or cyclophosphamide than those patients 
treated with corticosteroids and methotrexate alone (Shaw et al., 2003). Patients that 
respond to Rituximab treatment have also shown a 75% decrease in anti-cyclic citrullinated 
peptide (CCP) and 60% decrease in RhF antibodies (Cambridge et al., 2003). However, 
follow-up analysis of Rituximab treated patients revealed that most undergo clinical relapse. 
In a study reported by Cambridge et al. (2003) 13 of the 15 patients treated relapsed within 
17 months of B cell repletion, with the additional return of autoantibodies in all but one 
patient. This response is thought to occur through the generation of a new set of naïve B 
cells in the bone marrow.  
Rheumatoid factors (RhF) are autoantibodies specific for the Fc portion of IgG, they can be 
detected in 30% of normal individuals but these RhFs are low affinity and low titre, therefore 
have no significant pathology (Kyburz et al., 1999). A study using mice transgenic for human 
IgM RhF showed that peripheral encounter with soluble human IgG leads to the deletion of 
high-affinity RhF B cells (Tighe et al., 1995). Another study demonstrated how blockade of 
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CD40L-CD40 interactions allowed IgG to delete the RhF precursor cells (Kyburz et al., 
1999); therefore, it was concluded that human RhF production is dependent on CD40 
signalling. This was confirmed by showing activating antibodies to CD40 could substitute for 
T cell help in promoting the survival of RhF precursors and in stimulating RhF synthesis in T 
cell deficient mice (Kyburz et al., 1999). RhF was shown to have no direct pathogenesis in 
RA using the skg mouse model of RA, in which transfer of RF-positive serum into these mice 
was not sufficient to confer disease (Sakaguchi et al., 2003). While RhF alone is not 
sufficient to induce disease, RhF-containing immune complexes may promote synoviocytes 
to induce local release of inflammatory factors and exacerbate the inflammatory cascade.  
RhF has been shown to interfere with antibody-based immunoassays by non-specifically 
binding detection reagents (Todd et al., 2011); therefore, it is important when using RA 
samples to validate the assay in the presence of RhF, ensuring results are not affected by 
the presence of these antibodies. Measures can be taken to prevent interference should it 
occur; reagents such as Heteroblock have been shown to block the activity of heterophilic 
antibodies such as RhF (Olsson et al., 2016).  
 
11.1.6 Pathogenic B cell and cytokine responses in autoimmune 
diseases 
 
In healthy individuals, autoreactive B cells are removed by censoring performed by FDCs. A 
mouse model engineered to conditionally express a membrane-bound self-antigen on FDCs, 
demonstrated how presentation of this antigen by FDCs mediates effective elimination of 
self-reactive B cells at the transitional stage (Yau et al., 2012). It is possible that this effect is 
dependent on the expression level of self-antigen by the FDCs; if expression levels are too 
high, perhaps self-reactive B cells may persist, but this concept has not been investigated at 
present. When the elimination process does not occur, self-reactive B cells persist and 
become pathogenic, resulting in disease.  
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Pathogenic B cells are thought to contribute to RA in several ways. The B cells committed to 
producing IgG RhF can perpetuate their own existence and are known to “bypass” T cell 
help by providing their own antigen complexes with C3dg (Edwards et al., 1999). Subsets of 
these B cells are also thought to induce both articular and extra-articular features of RA by 
generating tumour necrosis factor α (TNFα) through interaction with the IgG Fc receptor 
FcγRIIIa (Abrahams et al., 2000). Additionally, stromal cells from synovial and bone marrow 
compartments may support the survival of these autoreactive B cells and plasma cells 
(Edwards et al., 1997). 
B cell populations which down-regulate CD21 have been reported in SLE (Wehr et al., 
2004), CVID (Warnatz et al., 2002) and RA (Isnardi et al., 2010). These CD21-/low B cells 
express germline autoreactive antibodies, which recognise nuclear and cytoplasmic 
structures and have abnormal BCR signalling, implicating them as pathogenic within these 
diseases. These cells fail to induce tyrosine phosphorylation cascades or increased 
concentration of intracellular calcium upon BCR aggregation, responses known to be 
enhanced by CD21/CD19 co-complex ligation to the BCR. It is thought that chronic BCR 
exposure to self-antigens desensitises BCR signalling abilities (Gauld et al., 2005). 
Transcriptome analysis of CD21-/low B cells from rheumatoid arthritis patients revealed up-
regulation of many genes encoding molecules to increase B cell activation and proliferation 
such as SOX4, TBET and BCL11B (Isnardi et al., 2010). It is feasible to suggest, 
overexpression of these molecules replaces the need for stimulation through the BCR to 
allow proliferation of the CD21-/low B cell subset, and therefore the cells may be contributing 
towards their own survival. These studies also revealed that most Ig genes expressed by 
CD21-/low cells were devoid of somatic hypermutations, indicating that this subset are naïve B 
cells. In addition, the cells were shown to have a specific extracellular surface marker 
phenotype characterised by the down-regulation of receptors that normally favour B cell 
activation, such as BAFF-R. A study using a mouse model expressing mDEL showed that 
provision of excess BAFF does not rescue self-reactive B cells (Yau et al., 2012) further 
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indicating these autoreactive cells are sufficient to maintain their own survival and do not 
require extracellular signals.  
More recently, a B cell subset expressing the IgA receptor FcRL4 has been shown to 
participate in the autoimmune response in patients with rheumatoid arthritis (Amara et al., 
2017). Sequencing of this subset of cells revealed enrichment for the IgA isotype 
immunoglobulin genes; IgA and IgG antibodies heavily make up the autoantibody pool in 
autoimmune disease. FcRL4+ B cells have the capacity to make autoantibodies against 
citrullinated proteins (Amara et al., 2017); this observation further supports their suggested 
role in RA as 60-80% of patients have B cell responses characterised by the production of 
autoantibodies recognising citrullinated proteins, mainly fibrogen, vimentin and α-enolase 
(Klareskog et al., 2014). T cells within lymphoid aggregates of inflamed synovial tissues in 
patients with RA have been shown to be a source of RANKL using immunohistochemistry 
and in situ hybridisation (Quinn et al., 1998); a cytokine that has roles in bone destruction 
and development of lymphoid structures. The FcRL4+ B cell subset was shown to express 
RANKL, further supporting an involvement for these cells in RA autoimmune responses. 
Interestingly, these cells also express low levels of CD21, which could be associated with 
the low level of sCD21 observed in RA patients and the pathogenic responses of CD21-/low B 
cells shown in the investigations discussed above. Taking these observations into account, it 
is possible that these cells are less dependent on CD21 downstream pathways and don’t 
require the co-activation action of the CD19/CD21 complex due to the provision of sufficient 
signals by the cell to promote self-activation.  
Cytokines expressed by B cells, such as IL-6, IL-10 and LTβ, have been implicated in the 
onset of early phase of pathogenesis of rheumatoid arthritis by promoting autoimmunity, 
maintaining chronic inflammatory synovitis and by driving the destruction of adjacent joint 
tissue (Mcinnes et al., 2007). Cytokines involved in B cell survival and activation are also 
found in high levels in ectopic germinal centres that form during RA, further solidifying their 
role in disease. Mature DCs in synovial membranes produce high levels of APRIL (Seyler et 
205 
 
al., 2005) and macrophages and synovial fibroblasts produce BAFF (Ohata et al., 2005), 
molecules with the ability to maintain the survival of autoreactive B cells within these 
structures. Two key proinflammatory cytokines involved in RA are IL-1 and TNFα. TNFα is 
released by synovial macrophages and induces lymphocyte and endothelial-cell activation. 
IL-1 stimulates articular cells to release prostaglandins and metalloproteinases, resulting in 
further inflammation (Henderson et al., 1984). The initial studies implicating these molecules 
within disease involved direct injection of recombinant cytokines directly into the knee joints 
of rabbit and rodents. Subsequent results suggested TNFα was an inflammatory mediator 
and IL-1 was the crucial cytokine responsible for both arthritis and cartilage destruction 
(Henderson et al., 1989). Later studies showed that the development of arthritis in TNF 
transgenic mice could be prevented with antibodies against TNFα but could also be blocked 
using antibodies against the IL-1 receptor (Williams et al., 1992). These investigations lead 
to the conclusion that IL-1 is the secondary mediator responsible for the arthritic changes 
and TNFα alone is neither arthritogenic nor destructive towards the joints but works 
synergistically with IL-1 in pathogenesis. Therapeutic blockade of TNF in RA patients results 
in decreased levels of IL-6, suppression of leukocyte migration, endothelial-cell deactivation 
and recovery of regulatory T-cell function and phenotype in 70% of patients (Nadkarni et al., 
2007), together resulting in an improvement in disease severity.  
 
11.1.7 The role of CD21 in B cell activation 
 
CD21 on the B cell surface co-ligates with CD19 and CD81 to form a protein complex, 
coupling the innate immune recognition of microbial antigens by the complement system to 
the activation of B cells. Put simply, CD21 binds C3dg-opsonised antigen and co-stimulates 
signalling through the antigen receptor, membrane immunoglobulin. Not all CD19 expressed 
by on the B cell surface is in complex with CD21 as at all stages of B cell development CD19 
is in molar excess of CD21 on the cell surface (Fearon et al., 2000). In contrast, CD21 is 
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always complexed with both CD19 and CD81 (Matsumoto et al., 1991) or CD35 on B cells 
(Carter et al., 1991). Upon ligation of CD21 to CD19, the complex is translocated to lipid 
rafts, a cholesterol dependent mechanism, to allow signalling to occur (Cherukuri et al., 
2001). CD19/CD21 complex co-ligation was shown to extend the retention of the BCR within 
lipid rafts, allowing for prolonged signalling (Cherukuri et al., 2001). FDCs have also been 
shown to express CD19, but at levels lower than that seen on B cells (Barrington et al., 
2009), suggesting this protein may not always be in complex with CD21 on the surface of 
this cell.  
It has been shown that crosslinking either CD19 or CD21 to IgM receptors on the B cells 
surface enhances cellular responses 10- to 1000-fold (Carter et al., 1992). Responses 
include elevation of intracellular Ca2+, proliferation and activation of mitogen-activated 
protein (MAP) kinases (Carter et al., 1991); signalling is mediated through the co-ligated 
CD19 molecule. Phenotypes for Cd21-/- and Cd19-/- mice are similar, however Cd19-/- mice 
are more severely immunodeficient than Cd21-/- mice (Engel et al., 1995). CD19 signalling 
couples extracellular ligation to intracellular signalling pathways by tyrosine phosphorylation, 
which may occur following ligation of either membrane IgM or the CD19/CD21 complex 
alone but is increased when they are co-ligated (O’Rourke et al., 1998). Lyn and Fyn, 
members of the src family of tyrosine kinases, have been reported to associate with CD19 
(van Noesel et al., 1993). A phosphorylation cascade occurs (Figure 11.1.3) leading to 
activation of MAP kinases, ERK2, JNK1 and p38. In primary murine B cells, co-ligation of the 
CD19/CD21 complex to membrane IgM caused a 5- to 10-fold increase in activation of all 
three of the MAP kinases, relative to activation through IgM alone (Tooze et al., 1997). 
Enhanced activation of ERK2 has been shown in B cell lines due to the co-ligation of 
membrane IgM and the CD19/CD21 complex (Weng et al., 1997). A study investigating the 
costimulation of enzymes that lead to activation of ERK2 concluded; stimulation of 
membrane IgM alone targets Ras and leads to an intermediate level of ERK activity and the 
addition of signalling by co-ligation of the CD21/CD19 complex to IgM generates a second 
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Figure 11.1. 3: CD21/CD19 signalling pathway 
signal activating MEK1 and inducing an enhanced ERK2 activation (Li et al., 1998). The 
downstream effects of this costimulation signalling pathway are poorly understood, however 
one study described the induction of the anti-apoptotic protein, bcl-2, by co-ligating 
CD19/CD21 with membrane IgM, but not by membrane IgM alone (Roberts et al., 1999). 
This finding suggests a role for CD19/CD21 complex in B cell responses to T-dependent 
antigens, for example in the development or maintenance of memory B cells that exit the 
germinal centre, as bcl-2 expressed by these cells (Bovia et al., 1998). As B cells found in 
the germinal centre express very low levels of this protein (Liu et al., 1991), the CD19/CD21 
complex may not be used for this purpose at this site. Low level expression of bcl-2 in 
germinal centre B cells may be to permit negative selection of autoreactive B cells and 
subsequent apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Bojarczuk et al., 2015 
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11.1.8 B cell development within humanised mouse models 
 
Humanised mice (hu-mice) are considered a valuable tool for studying the human immune 
system. Immunodeficient mouse lines have been used as recipients of CD34+ human 
hematopoietic stem cells in efforts to create a model human immune system. The most 
common mouse lines used include;  
1) Mice that are deficient for recombinant activating gene 2 (Rag2) and common 
gamma chain of the IL2 receptor (IL2Rγ) in the BALB/c background (BRG) 
2) IL2Rγnull, non-obese diabetic (NOD) mice in the NOD/SCID background (NSG) 
3) IL2Rγnull mice in the NOD/Shi- SCID background (NOG). 
Deletion of Rag2 prevents the generation of mature T and B cells and further disruption of 
IL2Rγ produces mice completely deficient for B, T, NK and NKT cells, due to the need for 
signalling through multiple cytokines through this receptor chain to induce cell development 
(Watanabe et al., 2009). Backcrossing an IL2Rγ knockout with mice with NOD background 
and SCID mutations results in mice with almost no functional endogenous immune system. 
Use of these models have allowed for more efficient and stable reconstitution of human 
hematopoietic cells, with varying results in the development of human B cells.  
A study using NOG mice showed development of human B cells was partially blocked and a 
significant number of B cells progenitors were found accumulated in the spleen (Watanabe 
et al., 2009). Those cells that could mature (CD19+IgM+IgD+ human B cells) produced 
antigen-specific IgG in vivo and in vitro, however there was a predominant IgM production 
suggesting only a partial reconstitution of the human adaptive immune system is achieved in 
these mice.  
NSG mice irradiated and injected with human foetal thymus, bone and autologous foetal 
liver-derived CD34+ cells resulted in a balanced and stable development of T and B cells and 
follicular lymphoid structures with functional germinal centres enriched with FDCs and 
activated GC B cells (Chung et al., 2015). Mice also had an increased presence of human 
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plasma cells within these structures, a strong indication of antibody production through class 
switch recombination. After immunisation, mice were shown to produce antigen-specific 
hIgG at comparable levels to those seen in adult humans, compared with previous reports.  
A more recent study was able to restore lymph node (LN) development by inducing 
expression of thymic-stromal-cell-derived lymphopoietin (TSLP) in a Balb/c Rag2-/-Il2rg-/-
SirpaNOD (BRGS) HIS mouse model (Li et al., 2018). TSLP exhibits structural and functional 
homology to IL7 and signals through CD127, a receptor disrupted by removal of the Il2rg 
protein from the model. This molecule requires a ligand-binding TSLP receptor that is 
independent of Il2rg, therefore IL7 signalling can occur with expression of this ligand. This 
model resulted in organised human T and B cell structures within LNs, something that was 
not previously observed. These cells had enhanced antigen-specific responses after 
immunisation.  
Work using a new strain of hu-mice is currently emerging. NSG mice were crossed with 
NOD/SCID-SGM3 mice; the resultant mouse strain has transgenic expression of human 
cytokines SCF, GMCSF and IL-3 (Wunderlich et al., 2009). This strain allows for sustained 
human B cell engraftment and has been shown to have improved B cell maturation and 
antigen-specific antibody responses to dengue virus infection (Jangalwe et al., 2016). This is 
the strain of mice chosen for the hu-mouse serum aspect of this project.  
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11.2 Summary and aims:  
The observation that sCD21 decreases in disease suggests a role for this protein in health 
and disease. I hypothesise that soluble CD21 inhibits C3dg antigen complexes binding to B 
cells, consequently dampening C3dg-mediated immune responses. As sCD21 levels are 
decreased in Rheumatoid Arthritis, this break on the immune system does not occur, 
resulting in pathogenic B cell responses. 
These studies further investigate sCD21 decrease within serum from rheumatoid arthritis 
patients by examination of receptor levels with respect to disease severity, clinical treatment 
and longitudinal clinical effects. Using these observations and a humanised mouse model, 
which were shown to develop human B cells but are devoid of human FDCs, work was 
carried out towards discovery of the origin of the soluble form of this receptor. Additionally, 
the function and role of sCD21 in the immune system was explored using peripheral B cells 
and B cell lines, Raji and Ramos, to determine the effect of sCD21 on C3dg binding and 
activation of these cells, respectively. Therefore, the aims of this chapter are:  
1. Further understand sCD21 levels within healthy volunteer and rheumatoid arthritis 
patient serum, including investigation into age, disease severity, clinical treatment 
and longitudinal effects.  
2. Investigate the origin of human sCD21 using clinical data and serum obtained from 
humanised mouse models.  
3. Investigate the function of human sCD21 using C3dg- and C3dg/anti-IgM-immune 
complexes; specifically, the examination of ability to block C3dg binding to peripheral 
B cells and capacity to block C3dg-dependent activation of B cell lines.  
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11.3 Results 
11.3.1 Measuring sCD21 in healthy volunteer and Rheumatoid Arthritis 
patient serum  
  Validating the human CD21 ELISA for use with human serum  
A commercial human CD21 ELISA kit (abcam) was used to collect the following data, 
however before use, it was important to first validate the assay for use with human serum 
and clinical Rheumatoid Arthritis samples. Pooled human serum from healthy patients 
obtained from the NHS was used (sourced at GSK) for validation experiments.  
Firstly, it was essential to determine whether detection of sCD21 concentration within human 
serum was affected by freeze/thaw cycles. As the RA clinical samples are part of a 
collaborative biobank, many of the samples would have undergone multiple thaws before 
analysis in this assay. Therefore, it was important to confirm this process did not change the 
amount of sCD21 measured within the sample, determining whether the protein was stable 
after the freeze/thaw process. Serum underwent freeze thaw cycles using the following 
process; serum was thawed on ice, allowed to stand for 5 minutes at room temperature 
before refreezing on dry ice. The process was repeated up to 3 times and sCD21 
concentration calculated using the ELISA as described in Method Section 8.17. Results 
confirm sCD21 levels measured do not change within the sample over the course of three 
freeze thaw cycles (Figure 11.3.1A); therefore, the concentration measured within the RA 
serum would not be affected by prior thawing of the clinical samples.  
It is recommended in the manufacturer’s protocol (abcam) that samples be diluted 1in4 
before loading onto the ELISA plate. To determine if sCD21 concentration within human 
serum could be measured at this dilution and the linearity of dilution of the samples within 
this assay, a dilution series of healthy pooled human serum was undertaken starting with 
neat serum and diluting 2-fold until the lowest concentration of 1in8 was reached. CD21 
concentration was interpolated from the standard curve and multiplied by the dilution factor 
to calculate the neat concentration of sCD21 within the sample. The absorbance measured 
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for 1in8 diluted samples was too low to interpolate from the standard curve, therefore these 
samples were not analysed further, and it was concluded that this dilution was too low to 
accurately interpolate CD21 concentration from serum. Interpolation of sCD21 concentration 
within 1in2 and 1in4 diluted serum determined that serum can be diluted and concentration 
of sCD21 within the samples accurately interpolated in a linear manner (Figure 11.3.1B). 
The decision to use the recommended dilution of 1in4 for samples within the assay was due 
to the smaller volume of clinical sample that needed to be available to run samples in 
duplicate. 
Next, whether human serum caused matrix interference in the assay was assessed. 
Standard curves were made using rc-CD21 (R&D Systems) within assay buffer and human 
serum diluted 1in4 and 1in8 in assay buffer. Standard curves made within diluted human 
serum have a greater absorbance than the curve made within assay buffer (Figure 11.3.1C); 
therefore, human serum causes matrix interference within the assay. In order to overcome 
this problem, all subsequent standard curves were made within 1in4 diluted serum and 
background absorbance (1in4 diluted serum only) subtracted from measured absorbances of 
all samples, ensuring remaining absorbance is from sCD21 only and there is no matrix 
contribution within the final result.  
It has been reported that Rheumatoid factor (Rhf) also interferes with assays such as 
ELISAs (Todd et al., 2011). Because Rhf could be present within the RA serum samples, it 
was important to determine whether this protein interfered with the human CD21 ELISA 
(abcam). Standard curves were made using rc-CD21 (R&D Systems) within 1in4 diluted 
serum. Four standard curves were made from; serum only, serum plus 125 IU/ml Rhf, serum 
plus 150 µg/ml heteroblock and serum plus heteroblock and Rhf, 125 IU/ml and 150 µg/ml, 
respectively. Rhf concentrations were chosen according to the concentrations likely present 
in patient samples and concentrations of heteroblock chosen according to reports of use in 
the literature (Olsson et al., 2016). Heteroblock has been confirmed to block interference 
from Rhf (Olsson et al., 2016) and therefore could be used within the assay if interference 
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was measured. Addition of this reagent to the standard curve alone allows confirmation 
heteroblock itself does not cause matrix interference within the assay. Addition of both 
heteroblock and Rhf to the standard curve determines whether any effect Rhf has on the 
assay is neutralised by the presence of heteroblock. Standard curves were not affected by 
the addition of either reagent (Figure 11.3.1D). At the lower concentration of CD21 within the 
curve plus heteroblock, there is a slight shift in absorbance, however as the other curves are 
not affected this can be said to be due to human error or natural variation within the assay. 
Therefore, as Rhf was shown to have no effect on sCD21 measurement, heteroblock was 
not included in the final assay.  
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It is important while running clinical samples that the assay is reliable and reproducible. As 
multiple plates were run assessing sCD21 concentration with healthy volunteer and RA 
patient serum, it was essential to run quality control samples on each plate, assessing the 
performance of each individual assay. These samples were made by spiking rc-CD21 into 
neat human serum at 4x the final concentration to interpolate. Human serum was then 
diluted 1in4 in assay buffer and loaded in duplicate to each plate. Final concentrations of 
sCD21 measured were 20ng/ml, 50ng/ml and 100ng/ml; concentrations were chosen to 
ensure CD21 concentration could be accurately calculated close to the lower limit of 
quantitation of the assay (9.3 ng/ml, Figure 11.3.2) and at points within the standard curve 
where sCD21 concentrations within RA patient samples were predicted to fall. The 
concentration of rc-CD21 within the serum was interpolated from the standard curve from 
each respective plate (Figure 11.3.3). The controls confirm that sCD21 concentration was 
being accurately interpolated reproducibly on each plate run.  
Together, these validation experiments confirm that the sCD21 ELISA (abcam) can be used 
to measure the concentration of protein within human serum, producing reliable, accurate 
and reproducible results. 
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Figure 11.3. 2: Quality control samples confirm the assay is reproducible and CD21 can be 
detected above background absorbance 
Figure 11.3. 3: Example standard curve for healthy volunteer and RA clinical sample CD21 ELISA 
data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For each assay plate run with clinical samples, recombinant CD21 was spiked into neat serum 4x 
final concentration and diluted 1in4 in the final assay. Concentrations of original spike into neat 
serum were; 80, 200 and 400 ng/ml.. n=9, bars represent SD. 
Standard curve was made in 1in4 diluted human serum and background absorbance subtracted 
from measured absorbance values. Lower limit of detection = 0.15, lower limit of quantitation = 9.3 
ng/ml, samples below this limit were considered 0. Each point on the standard curve is done in 
duplicate for each plate run.  
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Measuring sCD21 levels in healthy volunteer and Rheumatoid Arthritis 
serum samples  
In addition to disease, sCD21 concentration has been reported to decrease with age 
(Masilamani et al., 2004). The average age group of the initial RA cohort (30 patients) was 
between 45 and 70 years old; therefore, healthy volunteer blood samples were obtained 
from the blood donation unit (20 samples, 10 male, 10 female) at GSK from individuals 
within this age range. Samples from volunteers under the age of 25 were also obtained (20 
samples, 10 male, 10 female) and serum extracted from each cohort. sCD21 concentration 
was measured within these samples following the protocol detailed in Method Section 8.17. 
Concentration of sCD21 was interpolated from standard curves made in 1in4 diluted serum, 
with a lower limit of quantitation of 9.3ng/ml; any samples with sCD21 concentrations 
measured below this value were considered 0 (Figure 11.3.4). Results confirmed the 
observation that sCD21 decrease in the 45-70yrs age group, with an average sCD21 
concentration of 257.1 ± 25.39 ng/ml, compared with the >25yrs group, which has an 
average sCD21 concentration of 474 ± 47.02 ng/ml (Figure 11.3.4). Due to this observation, 
it was essential that the healthy volunteer samples were age-matched to the average age of 
the rheumatoid arthritis cohort and conclusions of sCD21 levels between health and disease 
were drawn between these two cohorts.  
Subsequently, sCD21 levels were measured within 80 baseline RA serum samples, obtained 
from the University of Birmingham as part of the Beacon Cohort. Samples were diluted 1in4 
and protocol performed as detailed in Method Section 8.17. Analysis revealed sCD21 
concentration decreased in RA samples compared to healthy volunteer samples aged 
between 45-70yrs (Figure 11.3.4). The average sCD21 concentration decreased from 257.1 
± 25.39 ng/ml in healthy volunteers to 85.33 ± 10.3 ng/ml in RA patients; this data confirms 
observations made in the current literature. Additional observations about the role of sCD21 
in RA were made by exploring correlations between age, disease severity and sCD21 
concentration within these patients.  
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Figure 11.3. 4: sCD21 concentration in the serum decreases with age and Rheumatoid Arthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy volunteer >25 yrs, n=20, 10 male, 10 female. Healthy volunteer 45-70 yrs, n=20, 10 male, 
10 female. RA, n=80, 50 female, 30 male. Samples were run in duplicate and the average 
interpolated concentration represented on the graph. Bars represent SD. LLOQ = 9.3 ng/ml, 
concentrations detected lower than this were considered 0. Results are significant with an 
unpaired t-test. Test was done between >25 yrs and 45-70 yrs group and 45-70 yrs and RA group.  
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As sCD21 concentration decreases with age in healthy volunteers (Figure 11.3.4), it is 
interesting to also investigate whether this phenomenon occurs within RA patients. When 
sCD21 concentration in the serum and the age of the patient at the time of sample collection 
were compared, no correlation was observed (Figure 11.3.5); showing the age of the patient 
does not affect the sCD21 concentration, unlike in healthy volunteers. Therefore, the age of 
the patient does not dictate the sCD21 concentration in disease. Additionally, the age of the 
patient was shown to have no effect on the severity of the disease phenotype, determined 
through the lack of correlation of DAS28 score and age (Figure 11.3.6). However, when 
sCD21 concentration within patient serum was compared to DAS28 score, a correlation 
between disease severity and sCD21 measured within the serum was observed (Figure 
11.3.7, r2=0.077); patients with a higher DAS28 score, therefore presenting with more severe 
disease, have a lower concentration of sCD21 present within their serum. This suggests that 
the concentration of sCD21 within the serum may be a modulator of disease; patients with 
lower sCD21 concentrations have a greater disease phenotype, suggesting a role for sCD21 
in protection from disease, a mechanism that is further supported by the observed reduction 
in sCD21 between healthy and disease samples (Figure 11.3.4).  
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Figure 11.3. 5: Age does not affect sCD21 concentration in Rheumatoid Arthritis patients 
Figure 11.3. 6: Age does not affect disease severity in Rheumatoid Arthritis patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy volunteer >25 yrs, n=20, 10 male, 10 female. Healthy volunteer 45-70 yrs, n=20, 10 male, 
10 female. RA, n=80, 50 female, 30 male. Samples were run in duplicate and the average 
interpolated concentration represented on the graph. 
n=80, samples were run in duplicate and average interpolated sCD21 concentration represented 
here. There is no correlation between the age of the patient and the severity of their disease.  
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Figure 11.3. 7: Increased disease severity correlates with decreased sCD21 concentration in RA 
patient serum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=80, samples were run in duplicate and average interpolated sCD21 concentration represented 
here. Patients with higher DAS28 scores have lower sCD21 concentrations within the serum. 
Rsquared = 0.077, p value = 0.013 
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Analysis of 10 patients over the course of 12 months after diagnosis was carried out, 
measuring sCD21 concentration within the serum of these patients at baseline (day 1 in the 
clinic), 6 months after diagnosis and 12 months after diagnosis. All patients were treated with 
methotrexate, a commonly used immune system suppressant, along with steroid treatment 
in many cases. After 6 months of treatment, the average sCD21 concentration of the cohort 
increased from 15.15 ng/ml ± 3.811 to 40.46 ng/ml ± 10.64 (Figure 11.3.8A, significant using 
unpaired t test). After 12 months of treatment, the average sCD21 concentration increased 
further still to 47.49 ng/ml ± 9.91 (Figure 11.3.9B, significant using unpaired t test). In 
addition to these observations, when patient’s disease severity scores were tracked over 
time, generally disease phenotype decreased (Figure 11.3.9C). These data further suggest a 
role for sCD21 concentration in disease severity and disease modulation; as sCD21 
concentration increases over time with treatment of disease, disease severity decreases 
(Figure 11.3.7), therefore the increase in sCD21 within the serum may be acting to modulate 
the immune response, dampening pathogenic immune responses leading to the resulting 
decrease in disease phenotype.  
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Figure 11.3. 8: Disease severity of patients with Rheumatoid Arthritis decrease upon diagnosis and 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=10 patients in each group, patients had samples taken upon arrival at the clinic (baseline), 6 
months and 12 months after arrival. All patients had been treated with methotrexate, among other 
drugs. sCD21 concentrations increase over time, with treatment of disease. Significance of data 
analysed using unpaired t tests. Bars represent SD. (A) sCD21 concentrations increase overtime 
after RA diagnosis. (B) Disease severity decreases overtime in RA patients. (C) Disease severity 
vs sCD21 concentration over time. 
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Although treatment of patients with topical steroids and immune suppressants was shown to 
increase sCD21 concentration within the serum (Figure 11.3.8), serum from patients treated 
with rituximab were shown to have a further decrease in sCD21 concentration post-
treatment (Figure 11.3.9). Rituximab is a human CD20 monoclonal antibody which depletes 
B cells, thereby improving the condition of patients by removing a disease modulator. This 
data suggests that B cells could be implicated as a producer of sCD21, as removal of these 
cells lead to a further decrease in the concentration of this protein. Interestingly, DAS28 
scores were observed to first raise after the initial treatment (Year 3) before falling below the 
initial score at first measurement (Year 1) (Figure 11.3.9 B). This data also suggests that 
removal of pathogenic B cells leads to a less severe disease phenotype.  
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Patient serum was taken at two time points before treatment with Rituximab (Year 1 and 2) 
and a further twice after the course of treatment (Year 3 and 4) had been undertaken. 
Samples were taken within a year of each other. (A) sCD21 levels were measured with 
CD21 ELISA revealing a decrease in sCD21 concentration in samples taken post treatment 
compared with those taken before administration of the drug. Pre1 was set at 100% and % 
change calculated from this value for the other time points from respective patients. (B) After 
treatment DAS28 score first increased before falling rapidly to below original diagnostic 
score.  n=2 
Figure 11.3. 9: Rituximab treatment further reduces sCD21 concentration in Rheumatoid Arthritis 
serum 
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To further investigate B cells as an origin of sCD21, CD21 receptor number was determined, 
using Quantibrite-PE beads (Materials and methods section 8.9), on the surface of PBMC 
derived B cells from the healthy volunteers, whose sCD21 concentrations had been 
measured previously. As sCD21 levels were shown to decrease with age (Figure 11.3.4), the 
number of receptors on B cells within the two age groups, >25 and 45-70 yrs, was 
investigated. This analysis revealed no significant difference between the number of surface 
CD21 receptors on B cells from either age group (Figure 11.3.10A, n=20 in each group). 
However, when the number of surface CD21 molecules was compared with the sCD21 
concentration measured in each of the volunteers, a correlation between higher sCD21 
concentrations and higher cell surface receptors on B cells was observed (Figure 11.3.10B, 
n=20, r2=0.059). This further supports B cells as an origin of the soluble protein, as subjects 
with a greater number of membrane bound receptors have more sCD21 present in their 
serum suggesting these B cells are able to produce more soluble protein.  
In summary, measurement of sCD21 concentrations within serum from patients with RA 
confirmed observations within the literature that sCD21 decreases in age and further still in 
disease. Additional information was added to these observations by investigating sCD21 
concentration relative to disease severity (DAS28), revealing a correlation between a lower 
sCD21 concentration and a greater DAS28 score, indicating a greater disease phenotype. 
Samples taken from patients over a 12-month time period revealed that upon treatment with 
conventional drugs administered to treat RA, sCD21 concentration increases, accompanied 
by a decrease in disease severity scores. Additionally, patients treated with Rituximab were 
shown to have a further decrease in sCD21 levels after administration of the drug, 
implicating B cells as a source of this protein.  
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Figure 11.3. 10: Expression of CD21 surface receptor number does not change with age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=40, samples were run in duplicate, bars represent SD. (A) Quantibrite beads were used to 
receptor numerate CD21 receptors on blood derived B cells. Receptor number did not change 
between age groups, was not significant using t-test. (B) There is a correlation between surface 
receptor number and concentration of soluble CD21. n=20, rsquared= 0.059, p value = 0.13 
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11.3.2 The origin of sCD21 – measuring human sCD21 within 
humanised mouse serum  
 
With the aim to further investigate the origin of sCD21, serum from a humanised mouse 
model was utilised. 4-week old female NSG-SGM3 mice were irradiated and reconstituted 
with approximately 35,000 human CD34+ cord blood cells for 98 days before +/- 
schistosome infection (70 cercariae). Infection was allowed to persist for 7 weeks and the 
mice harvested at d147 post-reconstitution (d49 post-infection). These mice were part of a 
study independent from the projects detailed in this thesis, therefore work was carried out by 
another lab and thus methods are not detailed here; serum and secondary lymphoid organs 
were kindly donated to this study from the Hitchcock and Hewitson lab (University of York).  
Firstly, expression of human immune cells by these mice was confirmed using RNA derived 
from the hu-mouse thymus and qPCR for human cell markers. Wild-type mouse thymus and 
human tonsil mRNA were used as negative and positive controls respectively. Wild-type 
mice were negative for all genes investigated, as expected, confirming the primers were 
specific for human cell markers and expression of these genes in hu-mice was determined 
relative to expression levels measured in the human tonsil samples. Humanised mice 
expressed hCD19, hCD21 and hCD3 (Figure 11.3.11B, C and F respectively). This suggests 
mice had developed human T and B cells upon reconstitution with human derived 
haemopoietic cells. No expression of hCD35, hCXCL13 or hCCL21 was detected within 
these mice, suggesting an absence of human stromal cells, i.e. no human FDCs or FRCs 
(Figure 11.3.11A, D and F respectively).  
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Presence of human immune cells was further investigated using immunohistochemical 
analysis of hu-mouse spleen. Co-staining with hCD3 and hCD21 reveals the presence of 
human T cells within the hu-mice spleen but shows that these cells are not responsible for 
the expression of hCD21 as staining for these markers does not overlap (Figure 11.3.12). No 
hCD21 is seen within the T cell zone (determined with hCD3 presence) of the human tonsil 
tissue. This is due to proper organisation of the SLO microarchitecture, resulting in the 
absence of B cells within T cell zones and vice versa (Figure 11.3.12C). The observation of 
hCD21 staining in the presence of human T cells suggests disorganisation of the SLO’s 
within this hu-mice model. Antibodies were determined to be specific for human CD21 and 
CD3 using wild-type mouse spleen. Staining is negative for both antibodies in these sections 
using the same microscope settings to acquire images (Figure 11.3.12B), therefore there is 
no cross reactivity for mouse CD3 or CD21 and confirming the origin of these cells within hu-
mice to be human.  
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Figure 11.3. 12: hu-mice spleen contains human T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images are reprehensive of 3 independent uninfected animals, multiple sections were stained from 
each animal. (A) (i) hu-mouse spleen stained for hCD3 (green-A488) and hCD21 (red-A647). 
Magnification x63, scale bar 50 µm (ii) hCD3 alone – green channel only (iii) hCD21 alone – red 
channel only. (B) wild-type mouse spleen stained for hCD3 (green-A488) and hCD21 (red-A647). 
Magnification x63, scale bar 50 µm. No staining seen, human antibodies do not cross react with 
mouse proteins (ii) hCD3 alone – green channel only (iii) hCD21 alone – red channel only. (C) 
human tonsil tissue stained for hCD3 (green-A488) and hCD21 (red-A647). Magnification x63, 
scale bar 50 µm. No CD21 staining is seen due to CD3 staining in a T cell zone (ii) hCD3 alone – 
green channel only (iii) hCD21 alone – red channel only. (D) (i) human tonsil tissue stained with 
hCD3 (A488-green) and hCD21 secondary antibody (A647-red). Magnification x63, scale bar 50 
µm (ii) hCD21 secondary antibody only – red channel only. (E) human tonsil tissue stained with 
hCD3 (A488-green) and IgG1 isotype antibody (A647-red). Magnification x63, scale 50 µm (ii) 
isotype antibody only – red channel only. 
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Hu-mice spleen co-stained with hCD19 and hCD21 revealed the presence of human B cells 
within the spleen which express hCD21 (Figure 11.3.13A). Within the human tonsil, CD21 
expression is only observed on FDCs (Figure 11.3.13C) due to the high receptor number 
expression by these cells, however as human FDCs appear absent from the hu-mice model 
system, suggested by qPCR data for FDC markers, hCD21 expression is detected on the B 
cells. Absence of human FDCs in hu-mice was confirmed using staining for hCD35 (Figure 
11.3.14A). Sections costained with hCD19 and hCD35 would identify human B cells and 
FDCs respectively. Human B cells were present, but no hCD35 staining was observed in hu-
mice or wt. mice (Figure 11.3.14A and C). Together with the qPCR data discussed above, it 
can be concluded that these humanised mice do not develop human FDCs. CD35 is 
detected within human tonsil, confirming the antibody can detect the presence of hFDCs 
(Figure 11.3.14C).  
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Figure 11.3. 13: hu-mice spleen contains human B cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images are representative of 3 independent uninfected animals, multiple sections were stained 
from each animal sample. (A) (i) hu-mice spleen stained for hCD19 (A488-green) and hCD21 
(A647-red). Magnification x20, scale bar 200 µm (ii) hCD19 alone – green channel only (iii) hCD21 
alone – red channel only. (B) wildtype mouse spleen stained with hCD19 (A488-green) and 
hCD21 (A647-red). Magnification x63, scale bar 50 µm. No staining is seen confirming human 
antibodies are species specific (ii) hCD19 alone – green channel only (iii) hCD21 alone – red 
channel only. (C) Human tonsil tissue stained with hCD19 (A488-green) and hCD21 (A647-red). 
Magnification x63, scale bar 50 µm. (ii) hCD19 alone – green channel only (iii) hCD21 alone – red 
channel only. 
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Figure 11.3. 14: hu-mice spleen do not develop human FDCs 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Images are representative of 3 individual uninfected animals, multiple sections were stained and 
analysed from each animal. (A) hu-mice spleen stained for hCD19 (green-A488) and hCD35 (red-
A647). Magnification x63, scale bar 50 µm. No staining for hCD35 is present (ii) hCD19 alone – 
green channel only (iii) hCD35 alone – red channel only (B) wildtype mouse spleen stained for 
hCD19 (green-A488) and hCD35 (red-A647). Magnification x63, scale bar 50 µm. No signal is 
seen, therefore antibodies are species specific (ii) hCD19 alone – green channel only (iii) hCD35 
alone – red channel only. (C) human tonsil tissue stained with hCD19 (green-A488) and hCD35 
(red-A647). Magnification x63, scale bar 50 µm. (ii) hCD19 alone – green channel only (iii) hCD35 
alone – red channel only. 
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Costaining for hCD19 and hCD3 revealed human T and B cells in the hu-mice spleen within 
the same region of the organ (Figure 11.3.15A). Within human tonsil, these two cell subsets 
are organised into isolated T and B cell zones (Figure 11.3.15C and D), however within 
these mice it is evident that proper microarchitectural organisation of secondary lymphoid 
organs has not occurred and the human T and B cells present are interspersed within the 
spleen. Proper organisation of T and B cells into specified zones within murine SLO’s was 
demonstrated using wild-type mouse spleen. This tissue was first co-stained with mCD19 
and mCD21/35, coexpressed as one gene in mice, to identify B cells and FDCs. Staining 
revealed bright mCD21/CD35 signal on stromal cells, likely to be mouse FDCs (Figure 
11.3.16A). Expression of CD21/CD35 on mouse FDCs is also known to be higher than that 
on mouse B cells and may be the cause of brighter staining of FDC expressed CD21 than 
that of B cells. It is presumed that if FDCs were not present then the lower level of CD21 
expression on B cells would be detected, as seen in the humanised mouse spleen (Figure 
11.3.13A). mCD19 staining is within the same zone as mCD21/CD35 staining, suggesting 
this structure is a germinal centre (Figure 11.3.16A). Antibody specificity was confirmed by 
staining of human tonsil tissue; no signal was detected using the same acquisition settings, 
therefore antibodies are specific to mouse proteins (Figure 11.3.16B). Costaining with mCD3 
and mCD21/35 identified T cells and FDCs within wildtype mice. Staining revealed 
mCD21/CD35 was contained to the germinal centre/B cell zone, whereas mCD3 staining is 
specific to a distinct section within this tissue, the T cell zone (Figure 11.3.17A). Human 
tonsil tissue was also stained with these antibodies, confirming species specificity as no 
staining was observed (Figure 11.3.17B). These data allow comparison of the true 
organisation of mouse SLO’s to that observed in the humanised mouse model; confirming 
within this hu-mouse model these organs are not organised in the proper manor. This is 
likely to be due to the absence of human FDCs and hCXCL13, both of which have been 
shown as essential for development of SLO and germinal centres. Insufficient development 
of these structures may have an impact on the functionality of the cells within this model 
system.  
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Figure 11.3. 15: hu-mice spleen are highly 
organised 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image is representative of 3 individual uninfected 
animals, multiple sections were stained from each 
animal. (A) hu-mouse spleen stained for hCD3 
(green-A488) and hCD19 (red-A647). Magnification 
x63, scale bar 50 µm (ii) hCD3 alone – green 
channel only (iii) hCD19 alone – red channel only. 
(B) wt-mouse spleen stained for hCD3 (green-A488) 
and hCD19 (red-A647). Magnification x63, scale bar 
50 µm (ii) hCD3 alone – green channel only (iii) 
hCD19 alone – red channel only. (C) Human tonsil 
tissue, B cell zone, stained with hCD3 (green-A488) 
and hCD19 (red-A647), Magnification x63, scale bar 
50 µm (ii) hCD3 alone – green channel only (iii) 
hCD19 alone – red channel only. (D) Human tonsil 
tissue, T cell zone, stained with hCD3 (green-A488) 
and hCD19 (red-A647). Magnification x63, scale bar 
50 µm (ii) hCD3 alone – green channel only (iii) 
hCD19 alone – red channel only.  
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Figure 11.3. 16: wildtype mice have organised germinal centre structures within the spleen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images are representative of 3 individual uninfected animals, muliple sections were stained and 
several images taken from each section and animal. (A) wildtype mouse spleen stained with 
mCD19 (A488-green) and mCD21/35 (A647-red). Magnification x63, scale bar 50 µm (ii) mCD19 
alone – green channel only (iii) mCD21/35 alone – red channel only. (B) human tonsil tissue 
stained with mCD19 (A488-green) and mCD21/CD35 (A647-red). Magnification x63, scale bar 50 
µm. No signal is obtained confirming antibodies are species specific. (ii) mCD19 alone – green 
channel only (iii) mCD21/35 alone – red channel only.  
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Figure 11.3. 17: wildtype mice have distinct T cell zones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images are representative of 3 individual uninfected animals, multiple sections were analysed from 
each animal. (A) Wildtype mouse spleen stained with mCD3 (A488-green) and mCD21/35 (A647-
red). Magnification x63, scale bar 50 µm (ii) mCD3 alone – green channel only (iii)  mCD21/35 
alone – red channel only. (B) human tonsil tissue stained with mCD3 (A488-green) and mCD21/35 
(A647-red). Magnification x63, scale bar 50 µm. No signal is seen confirming antibodies are 
species specific. (ii) mCD3 alone – green channel only (iii) mCD35/21 alone – red channel only. 
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This analysis determined hu-mice have human B cells but are devoid of human FDCs. 
Therefore, when investigating the presence of human sCD21 within hu-mice serum, any 
protein detected can be assumed to be derived from the human B cells, the only cell present 
in the model expressing human CD21.  
Before serum was analysed on the human CD21 ELISA (abcam), used previously in the RA 
study, it was important to determine there was no cross reactivity between mouse serum and 
the assay. Standard curves were made using human rc-CD21 within assay buffer, human 
serum and wildtype mouse serum. Serum was diluted 1in4, a concentration determined by 
previous validation of the assay (Section 11.3.1). Assays were run, and data processed 
according to the protocol detailed in Methods Section 8.17. Standard curves made within 
assay buffer and mouse serum showed no significant differences in the detection of rc-CD21 
using this assay (Figure 11.3.18A). This confirms that mouse serum does not cause any 
matrix interference with the human CD21 ELISA. Human serum has previously been shown 
to cause matrix interference with the assay and therefore a shift in the standard curve is 
observed (Figure 11.3.18A), however this is not the case with mouse serum. Spike recovery 
of human sCD21 was also tested within mouse serum. Human rc-CD21 was spiked into neat 
mouse and human serum 4-fold higher than the final concentration to be detected. A low 
(final concentration 50 ng/ml), mid (final concentration 100 ng/ml) and high (final 
concentration 200 ng/ml) concentration of rc-CD21 was chosen to spread a range of 
concentrations that could be present when measuring levels within the hu-mice serum 
samples. Serum was then diluted 1in4 in assay buffer and the concentration of sCD21 
interpolated using standard curves made in respective species serum. Human sCD21 
concentration was accurately detected within both mouse and human serum, determining 
both that the assay can measure sCD21 reliably and that human sCD21 concentration can 
be accurately detected above mouse serum background absorbance (Figure 11.3.18B). 
These experiments conclude mouse serum does not cross-react with the human CD21 
ELISA and human sCD21 can accurately be detected within mouse serum, therefore this 
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Figure 11.3. 18: Mouse serum does not cross-react with human CD21 ELISA (abcam) 
assay can be used to investigate the presence of human CD21 within humanised mouse 
serum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Standard curves made in assay buffer, human or mouse serum with recombinant CD21 
revealed mouse serum does not cause matrix interference with the ELISA unlike human serum. 
Assay is specific for human protein. (B) recombinant CD21 was spiked into human and mouse 
serum and concentration interpolated using standard curve made in respective species serum. 
Human CD21 can be accurately detected above mouse serum background absorbance. Samples 
were run in duplicate.  
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Mouse serum was diluted 1in4 and samples were run in duplicate. This dilution was chosen 
due to the small volume of serum available and the final sample volume needing to be 100 
µl. Additionally, this dilution was the chosen concentration in all previous assays using this 
ELISA kit (abcam). A standard curve of human rc-CD21 was performed as before and 
absorbances measured in the mouse serum interpolated to find the concentration of sCD21 
within the samples. Samples from six mice were investigated, three naïve and three infected, 
in all cases the absorbance measured for each repeat was below the lower limit of detection 
for the assay (data not shown). This result suggests the humanised mouse model used here 
do not produce human soluble CD21, however as only a small volume of sample was 
available the dilution made in to run the assay may have reduced the concentration of 
protein within the sample to undetectable levels. Alternatively, B cells within this model may 
not be producing sCD21 due to other factors such as altered development and gene 
expression due to disorganised SLO structures, which were not investigated here.  
In summary, this data show that within this humanised mouse model, human T and B cells 
develop in the SLOs but human stromal cells, FDCs and FRCs, are absent. CD21 is 
expressed within the cells in this model, predominately by the B cells, as shown by IHC 
(Figure 11.3.13). Although these SLOs contain human immune cells, proper organisation of 
the organs fails to develop (Figure 11.3.12), therefore suggesting that the cells may not be 
producing the relevant factors, potentially leading to the absence of sCD21 in this mouse 
model.  
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11.3.3 The function of sCD21 – blocking C3dg binding in peripheral B 
cells and activation in B cell lines 
 
The current observations made in the literature suggest sCD21 may have a role in disease 
and control of the immune system, therefore it is important to further understand the role of 
human sCD21 in biology.  
Investigating the ability of sCD21 to block C3dg model immune 
complex binding to B cells  
A recombinant form of sCD21 has previously been shown to bind C3dg (G. Nemerow et al., 
1989); in this investigation recombinant CD21, full length receptor, and SCR1/2, the ligand 
binding site of CD21, were used to demonstrate the ability of soluble CD21 to block binding 
of C3dg to peripheral B cells. B cells were identified using CD19 antibody staining and C3dg 
binding assessed on this population (Figure 11.3.19) in the presence of varying sCD21 
concentrations, the highest concentration being 144 nM.  
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Before assessing blockage of binding, the concentration of C3dg-immune complexes was 
first optimised to find an assay window in which this may be observed. As the concentration 
of sCD21 reagents that could be added to the assay was the limiting factor in this 
investigation, a low concentration of C3dg-immune complex must be used. Investigations 
into binding of monomeric and tetrameric complexes were undertaken; in previous 
experiments a tetrameric complex was used as a greater assay window is achieved when 
using these complexes, thought to be due to weak ligand-receptor interactions (Altman et al., 
1996). Comparing monomeric and tetrameric complex binding confirmed that a greater 
signal is achieved by using tetrameric complexes (Figure 11.3.20) but binding could still be 
visualised with the monomeric form. Blocking C3dg binding with sCD21 (144 nM) revealed 
that it was easier to prevent binding of monomeric C3dg-complexes to peripheral B cells 
than tetrameric complexes; this may be due to the C3dg being more diffusely spread over 
Strep-APC molecules when in a monomeric form than in the tetramer (Figure 11.3.20Aii and 
66Bii). For this reason, monomeric C3dg complexes were used. At concentrations lower 
than 0.02 µg/ml monomeric C3dg-complexes, binding could not be visualised, and the assay 
window lost, therefore this was the final concentration of C3dg-complexes used in the 
subsequent experiment.  
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Figure 11.3. 20: Blocking monomeric vs tetrameric C3dg-streptavidin complex binding to 
peripheral B cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orange= plus FE8, Blue= plus sCD21, Red= complex alone. (A) (i) 0.02 µg/ml monomeric 
C3dg-StrepAPC complexes bind peripheral B cells; binding can be blocked using CD21 Ab 
clone FE8 (120nM) and sCD21 (144nM) (ii) C3dg molecules are spread over Streptavidin 
molecules to create monomers. (B) (i) 0.02 µg/ml tetrameric C3dg-StrepAPC complexes bind 
peripheral B cells; binding can be blocked using CD21 Ab clone FE8 (120nM) and sCD21 
(144nM) (ii) C3dg molecules are bound to form a tetramer on Streptavidin molecules. 
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Experiments in which monomeric C3dg-complexes were preincubated with varying 
concentrations of rc-CD21 before addition to cells, revealed that sCD21 has the ability block 
C3dg binding to peripheral B cells in a concentration dependent manner. Interestingly, full 
length CD21 (recombinant CD21) is able to block C3dg binding to B cells at lower 
concentrations than the ligand binding site alone (SCR1/2). The IC50 for rc-CD21 was 
calculated at 3.94 nM, whereas the IC50 for SCR1/2 is 5-fold higher at 19.2 nM (Figure 
11.3.21, n=3). This result was surprising as it was assumed addition of the C3dg binding site 
alone would have a higher binding affinity for the C3dg immune complexes, however these 
results suggests the whole protein provides the receptor with a greater affinity to C3dg, 
perhaps due to conformational differences in the ligand binding site in the full-length protein. 
Physiological levels of sCD21 within healthy volunteers were shown to be ~400 ng/ml, 
equivalent to 2.75 nM (Figure 11.3.4). At these concentrations, C3dg binding to B cells is 
blocked by rc-CD21 but not SCR1/2 (Figure 11.3.21). The physiological levels of C3dg are 
unknown, and as the distribution of the protein at any given time is difficult to determine, it is 
reasonable to conclude that sCD21 blocks C3dg binding to B cells at physiological 
conditions.  
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Figure 11.3. 21: Soluble CD21 can block C3dg-immune complex binding to peripheral B cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3. sCD21 (recombinant CD21 or SCR1/2) was titrated at a starting concentration of 144 nM and 
shown to block the binding of 0.02 µg/ml C3dg in a concentration dependent manner. sCD21 and 
C3dg-APC immune complexes were preincubated prior to the addition to PBMCs. RC-CD21 has 
an IC50 of 3.94 nM and SCR1/2 has an IC50 of 19.42 nM. Physiological levels of sCD21 is 
approximately 2.75 nM. 
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Figure 11.3. 22: Stimulation complex used for B cell line activation pERK assays 
Investigating B cell line activation using anti -IgM/C3dg model 
immune complexes  
As C3dg binding to CD21/CD19 complexes allows for co-activation of B cells, sCD21’s 
ability to block this response by preventing this interaction was investigated. Cells were 
stimulated using an immune complex composed of biotinylated Fab2 anti-IgM and 
biotinylated C3dg which are co-ligated together using neutravidin to form a tetramer, 
calculated empirically (Figure 11.3.22). Anti-IgM stimulates membrane bound IgM receptors 
on B cells and C3dg stimulates the cells through binding CD21 in the CD21/CD19 co-
complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stimulation complexes are composed of biotinylated Fab2 anti-IgM and biotinylated C3dg which 
are co-ligated together using neutravidin. The complex is a tetramer, the ideal complex ratio is 3 
C3dg: 1 neutravidin: 1 anti-IgM, however this is dependent individual reagent concentration.  
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For these experiments B cell lines were utilised due to lack of success developing a robust 
and reliable signalling assay in primary B cells. To determine which cell lines were suitable 
for use in the activation assay, expression of IgM and CD21 was assessed on Raji, Daudi 
and Ramos B cell lines. Ramos cells were shown to be CD21- and IgM+ (Figure 11.3.23), 
therefore can only be activated by anti-IgM stimulation and thus act as a negative control in 
the assay. Daudi cells express both CD21 and IgM (Figure 11.3.23) and Raji are also CD21+ 
but express IgM at low levels (Figure 11.2.23). Raji cells were used in the assay due to their 
low IgM expression as this cell line was thought to be a model more similar to primary B 
cells, which were also shown to express lower IgM levels on their cell surface than that 
observed in the Daudi cell line (Figure 11.2.23). The number of CD21 receptors was 
quantified on the surface of the chosen cell lines using Quantibrite-PE beads, using the 
methods detailed in Methods Section 8.9. Cells were stained with 1 µg/ml CD21-PE (Bu32) 
and the number of receptors calculated. Raji cells were found to express an average of 
21,000 CD21 receptors on the surface of each cell. This expression is 2.5-fold higher than 
primary B cells (Figure 11.2.23C, n=3), which were found to express an average of 8,000 
CD21 receptors per cell. Increased CD21 receptor number on the Raji cells line may explain 
why an assay window for C3dg activation could be successfully developed in B cells lines 
but not in primary cells.  
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Firstly, anti-IgM concentration was titrated, plus and minus C3dg (0.3 µg/ml and 1 µg/ml), 
starting at a concentration of 10 µg/ml, to show that anti-IgM activated B cell lines, Raji and 
Ramos, in a concentration dependent manner (Figure 11.3.25, n=3). The neutravidin 
concentration (1 µg/ml) was kept constant in all complexes in this particular experiment. 
Addition of C3dg to the stimulation complex, enhanced activation of CD21+ Raji cells (Figure 
11.3.25A, n=3). This effect was also concentration dependent; addition of 0.3 µg/ml C3dg 
decreased the EC50 of anti-IgM stimulation alone 12.5-fold from 0.51 µg/ml to 0.06 µg/ml. 
The addition of 1 µg/ml C3dg to the anti-IgM titration further decreased the EC50 to 0.04 
µg/ml. At low concentrations (0.3 µg/ml), C3dg alone does not activate cells, however at 
higher concentrations (1 µg/ml), 13.8% of CD21+ B cells are pERK+ve due to stimulation 
with C3dg alone. As these experiments were investigating the co-activation response of 
C3dg, for the rest of the investigation, C3dg was used at the concentration of 0.3 µg/ml. 
Ramos cells confirm the enhanced activation with C3dg was CD21 dependent as no co-
activation response is seen in these CD21- cells with the addition of this reagent (Figure 
11.3.25B, n=3). A small increase in EC50 was observed with the addition of C3dg, from 0.12 
µg/ml to 0.23 µg/ml and 1.3 µg/ml with 1 µg/ml and 0.3 µg/ml C3dg respectively. This effect 
may be due to the inclusion of C3dg within the stimulation complex potentially causing steric 
hinderance and preventing anti-IgM from binding IgM receptors on the cell surface.  
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Figure 11.3. 25: C3dg lowers the threshold for activation of CD21+ve Raji B cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3 individual assays. Anti-IgM concentrations start at 10 µg/ml and complexes are formed by the 
addition of 1 µg/ml neutravidin. C3dg is added at concentrations of 1 µg/ml and 0.3 µg/ml. (A) anti-
IgM activates Raji cells (CD21+ve) in a concentration dependent manner. Addition of C3dg 
increases activation (%pERK positive cells), this increase is concentration dependent, 1 µg/ml 
C3dg increases activation further than 0.3 µg/ml C3dg. (B) anti-IgM activation Ramos cells (CD21-
ve) in a concentration dependent manner. Addition of C3dg has no effect on activation status of 
these cells.  
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In addition to C3dg lowering the threshold for activation of CD21+ B cell lines, it was shown 
that C3dg acts synergistically with low anti-IgM concentrations to activate cells to levels 
equivalent to high anti-IgM stimulation (Figure 11.3.26A, n=3). Cells stimulated with C3dg 
alone (0.3 µg/ml) or low anti-IgM concentrations (0.03 µg/ml) do not become activated, 
however when the two reagents are added together complexed with neutravidin, co-
stimulation occurs and 12% of cells become pERK+ve. Stimulation of Raji cells with high 
concentrations of anti-IgM (1 µg/ml) also caused 11% of cells to become pERK+ve, 
therefore C3dg lowers the concentration of anti-IgM required to activate cells. Again, Ramos 
cells demonstrate this effect is CD21 dependent as co-stimulation with C3dg (0.3 µg/ml) and 
low anti-IgM concentrations (0.03 µg/ml) result in the same response as stimulation with low 
anti-IgM concentrations alone (Figure 11.3.26B, n=3). When these cells are stimulated with 
a high anti-IgM concentration (1 µg/ml), activation increases from 2.1% pERK+ve (low anti-
IgM stimulation) to 35.7% pERK+ve.  
 
 
 
 
 
 
 
 
 
 
 
255 
 
Figure 11.3. 26: C3dg acts synergistically with low anti-IgM concentrations to activate CD21+ve Raji B 
cell lines to levels of high anti-IgM stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3 individual assays, significance measured using ANOVA test, bars represent SD. 
Concentrations of reagents in data shown: 0.3 µg/ml C3dg, 0.03 µg/ml anti-IgM, 1 µg/ml 
neutravidin. (A) C3dg and low anti-IgM concentrations (0.03 µg/ml) do not activate Raji cells alone; 
when added together synergy between the two reagents is seen to cause activation to levels of 
high anti-IgM stimulation (1 µg/ml). (B) Low anti-IgM concentration (0.03 µg/ml) and C3dg alone do 
not activation Ramos cells, together synergy does not occur but high anti-IgM concentrations (1 
µg/ml) alone activate the CD21-ve cells.  
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Stimulation complexes were made with and omitting neutravidin (1 µg/ml). These 
experiments demonstrated the need for co-ligation of anti-IgM and C3dg to induce the co-
activation response seen in CD21+ cells (Figure 11.3.27). The concentration dependent 
activation of cells with anti-IgM is not affected by the presence or absence of neutravidin 
(Figure 11.3.27, n=3); however, for the co-stimulation with C3dg to occur, neutravidin must 
be present. Removal of this reagent from the stimulation results in a response equivalent to 
anti-IgM stimulation alone (Figure 11.3.27, n=3). Therefore, to get a C3dg-dependent 
activation response from CD21+ cells, all three components of the stimulation complex, 
C3dg, anti-IgM and neutravidin, are needed (Figure 11.3.27A). This observation suggests 
that in biology opsonisation of antigen with both anti-IgM and C3dg is needed to cause the 
co-activation response in B cells. The presence of neutravidin has no effect on the activation 
of Ramos cells (Figure 11.3.27B, n=3), as they do not respond to C3dg stimulation. 
During assay optimisation, neutravidin concentration was decreased from 1 µg/ml, used 
previously, to 0.2 µg/ml in order to further understand how the molar ratios of reagents within  
the complex affects activation of the cells with hope this would lead to insight into which 
complex should be used in the final blocking assay. Cells were activated with complexes 
containing 0.3 µg/ml C3dg, 0.2 µg/ml neutravidin and varying anti-IgM concentrations 
(starting at 10 µg/ml and diluted 3-fold to create a titration). Lowering the concentration of 
neutravidin does not affect activation responses of Ramos cells at high anti-IgM 
concentrations as C3dg inclusion within the stimulation complexes does not affect activation 
status of this cell line (Figure 11.3.28B, n=3). However, when concentrations of anti-IgM 
reached above 0.1 µg/ml in this assay, co-activation with C3dg was lost within Raji cells 
(Figure 11.3.28A, n=3). This can be explained by considering the molar ratios of the 
reagents within the complex. For example, within the complex containing 0.3 µg/ml C3dg 
(7.5 nM), 3 µg/ml anti-IgM (20 nM) and 0.2 µg/ml neutravidin (3 nM), the theoretical complex 
would contain a molar ratio of approximately 1:2.5:7M neutravidin:C3dg:anti-IgM 
respectively. Therefore, at these concentrations, complex formation would be inefficient and 
257 
 
preferentially contain only anti-IgM molecules. This explains the observed loss of C3dg-
dependent co-activation at high concentrations of anti-IgM (Figure 11.3.28A, n=3). A 
reduction in activation is also seen when using neutravidin at concentrations of 1 µg/ml (14.7 
nM) when complexes are formed using 10 µg/ml anti-IgM (66 nM) and 0.3 µg/ml C3dg (7.5 
nM) (Figure 11.3.28A, n=3). Using these molar concentrations, complexes would form with a 
molar ratio of 1:0.5:5 neutravidin:C3dg:anti-IgM respectively. Again, there is now an excess 
of anti-IgM within this complex, causing the majority of complexes to form containing only 
anti-IgM molecules. Consequently, loss of co-activation is seen when reagents are added at 
these concentration. These investigations conclude that molar ratios of reagents within the 
complex are an important factor in the activation of CD21+ Raji cells.   
To summarise, these experiments show that CD21+ Raji cells can be activated in a 
concentration dependent manner with the stimulation complex, and that C3dg lowers the 
threshold for activation in these cells, but not in CD21- Ramos cells. Investigations continued 
to explore the roles of sCD21 in blocking this co-activation through its ability to bind to C3dg. 
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Figure 11.3. 27: Co-ligation of C3dg and anti-IgM is needed for C3dg-dependent activation of 
CD21+ve Raji cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3 independent experiments, bars represent SD. (A) Removal of neutravidin from stimulation 
complexes results in loss of C3dg-dependent activation in CD21+ve Raji cells. (B) Removal of 
neutravidin from stimulation complexes has no effect on activation of CD21-ve Ramos cells 
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Figure 11.3. 28: Low neutravidin and high anti-IgM concentrations leads to insufficient complex 
formation to cause C3dg-dependent activation of CD21+ve Raji cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3 independent experiments, bars represent SD. (A) Lowering the concentration of neutravidin to 
0.2 µg/ml is insufficient to make complexes at high anti-IgM concentrations, resulting in loss of 
C3dg-dependent co-activation of Raji cells. (B) Decreasing neutravidin concentration has no effect 
on activation of CD21-ve Ramos cells.   
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Investigating a role for sCD21 in blocking C3dg-dependent 
activation in CD21+ B cell lines  
As the molar ratios of reagents within the stimulation complex is important for the activation 
response in CD21+ cells (Figure 11.3.28), the percentage of pERK+ve cells after stimulation 
with different complexes was assessed to determine which complex should be used in the 
final blocking assay (See Figure 11.3.29 for respective reagent concentrations). In all cases, 
0.3 µg/ml anti-IgM was used in the complex as this concentration was shown to be the 
lowest anti-IgM concentration to cause an activation response (Figure 11.3.25); therefore, 
creating the largest assay window for additional activation seen due the coactivation 
response with C3dg. For all complexes, all 3 reagents in the stimulation complex were 
required to achieve C3dg-dependent co-activation (Fgure 76). Complexes formed to the 
molar ratio of 1:3:1 neutravidin:C3dg:anti-IgM respectively, could be described as the “ideal” 
complex shown in Figure 11.3.22. Under these conditions, 3 C3dg molecules and 1 anti-IgM 
molecule would be bound to each neutravidin. Although this is the “ideal” complex for 
activation, it may prove challenging to block with sCD21 as there are 3-C3dg molecules per 
complex. In contrast, when the neutravidin concentration is increased from 0.2 µg/ml to 1 
µg/ml within in this complex, the molar ratio of the complex is changed to 5:2.5:1 
neutravidin:C3dg:anti-IgM respectively, and the C3dg becomes more diffuse over the 
increased amounts of neutravidin available. Although complexes may not be fully formed, 
stimulation with this complex results in 16.5% of cells becoming pERK+ve, the greatest 
activation window compared with other complexes considered. Additionally, activation using 
this complex may be easier to block using sCD21 as C3dg will more widely distributed. 
Complexes containing a lower concentration of C3dg were also considered for use in the 
blocking assay; complexes contained a molar ratio of 5:1:1 and 1:1:1 neutravidin:C3dg:anti-
IgM respectively. Activation with these complexes resulted in a response of 6.93% and 
10.62% pERK+ve respectively (Figure 11.3.31, n=3). Although a lower concentration of 
C3dg would be easier to block with sCD21, stimulation with lower concentrations of this 
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Figure 11.3. 29: Concentrations and molar ratios of stimulation complexes 
reagent result in a smaller assay window of activation compared with low anti-IgM alone (0.3 
µg/ml), which results in 5.24% of cells becoming pERK+ve (Figure 11.3.31, n=3). For these 
reasons, the complex containing 0.3 µg/ml C3dg, 0.3 µg/ml anti-IgM and 1 µg/ml neutravidin 
was chosen to use in subsequent blocking experiments.   
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Figure 11.3. 30: C3dg, neutravidin and anti-IgM are required for synergistic activation of CD21+ Raji 
cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3, bars represent SD (A) Complex has a calculated molar ratio of 5:2.5:1 neutravidin:C3dg:anti-
IgM respectively. Concentrations of reagents within the complex are 1µg/ml neutravidin, 0.3µg/ml 
C3dg and 0.3µg/ml anti-IgM. (B) Complex has a calculated molar ratio of 5:1:1 
neutravidin:C3dg:anti-IgM respectively. Concentration of reagents within the complex are 1µg/ml 
neutravidin, 0.1µg/ml C3dg, 0.3µg/ml anti-IgM. (C) Complex has a calculated molar ratio of 1:3:1 
neutravidin:C3dg:anti-IgM respectively. Concentration of reagents within the complex are 0.1µg/ml 
neutravidin, 0.36µg/ml C3dg and 0.3µg/ml anti-IgM. (D) Complex has a calculated molar ratio of 
1:1:1 neutravidin:C3dg:anti-IgM respectively. Concentration of reagents within the complex are 
0.2µg/ml neutravidin, 0.1µg/ml C3dg and 0.3µg/ml anti-IgM. 
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Figure 11.3. 31: Complex with ratio 5:2.5:1 (neutravidin:C3dg:anti-IgM) has the greatest assay 
window over anti-IgM stimulation alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3, bars represent SD. Complex with 5:2.5:1 molar ratio was chosen for stimulation in 
activation blocking assays. 
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In the final assay, the capacity of CD21 blocking antibody clone, FE8 (starting concentration 
120 nM), and a recombinant form of sCD21 (starting concentration 1250 nM) to block 
CD21/C3dg-dependent activation was investigated. The two assays differ in their method of 
blocking the receptor-ligand interaction; FE8 will block by binding to the ligand binding site of 
membrane bound CD21; blocking ligand binding to the receptor, whereas sCD21 will bind 
the ligand C3dg and prevent it binding to membrane bound CD21. These reagents were 
added to cells stimulated with the chosen anti-IgM/C3dg complex (0.3 µg/ml C3dg, 0.3 µg/ml 
anti-IgM and 1 µg/ml neutravidin) and the effect on activation observed.   
Both reagents were shown to block activation of CD21+ Raji cells in a concentration 
dependent manner (Figure 11.3.32, n=3), these data further confirm the C3dg-dependence 
of the co-activation response. FE8 has an IC50 of 0.12 nM (Figure 11.3.32A, n=3), whereas 
the isotype antibody control does not cause a blocking response at any concentration, 
confirming results are due to FE8 specific actions. Ramos cell activation status is not 
affected by FE8 or isotype antibody. sCD21 blocks activation of Raji cells at a concentration 
of 132.9 nM (IC50) (Figure 11.3.32B, n=3). sIL7R acts as a control for the addition of high 
concentrations of protein to the assay; no effect on activation is seen with the addition of this 
protein, confirming blocking effect of sCD21 is specific to the action of this protein. Again, no 
effect is seen with either protein on the activation status of Ramos cells. Physiological levels 
of sCD21 were shown to be ~2.75 nM; in this experiment this concentration of sCD21 is not 
sufficient to block activation of the Raji B cell line. However, sCD21 may still have the 
capacity to block activation of B cells in vivo. B cells are predominantly activated within the 
Germinal Centre and it is not known how much C3dg is present within these microstructures, 
if C3dg levels are lower than that used in this assay, lower concentrations of sCD21 would 
be needed to block B cell activation. This assay used the lowest concentration of C3dg (0.3 
µg/ml) sufficient to observe an assay window for activation, therefore the assay is working at 
the limits of detection and lower concentrations of this reagent could not be used. 
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Additionally, the germinal centre is a closed system which could result in local 
concentrations of sCD21 having a greater impact on activation status of B cells than within 
the current assay.  
It was shown that within this system, C3dg and low anti-IgM concentrations synergistically 
stimulated Raji cells to levels equivalent of stimulation with high anti-IgM concentrations 
(Figure 11.3.26). In this experiment cells were also stimulated with high anti-IgM (1 µg/ml) 
and, to further demonstrate that sCD21 and FE8 block through the C3dg-dependent co-
activation mechanism, FE8 (120 nM) and sCD21 (1250 nM) were added to this stimulation. 
Activation of Raji cells with high anti-IgM concentrations was not blocked by either reagent 
(Figure 11.3.33A), cells remain around 13% pERK+ve, similar to stimulation with the 
activation complex (0.3 µg/ml C3dg, 0.3 µg/ml anti-IgM and 1 µg/ml neutravidin). The same 
is true of activation of Ramos cells with high anti-IgM concentrations alone, however a 
difference is noted in the levels of activation seen between high anti-IgM stimulation and 
stimulation with the activation complex (0.3 µg/ml C3dg, 0.3 µg/ml anti-IgM and 1 µg/ml 
neutravidin). As Ramos cells do not respond to co-activation with C3dg, cells activated with 
the complex are ~20% pERK+ve, whereas cells activated with high anti-IgM are ~80% 
pERK+ve (Figure 11.3.33B); this is due to cells responding only to anti-IgM stimulation.  
These data sets reveal a role for sCD21 in binding C3dg and blocking B cell activation which 
could act as a mechanism to control the immune response to C3dg-dependent stimulation.  
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Figure 11.3. 32: sCD21 and FE8 block CD21+ Raji B cell line activation in a concentration dependent 
manner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3 individual experiments, bars represent SD. (A) FE8 blocks CD21 positive cell activation in a 
concentration dependent manner. IC50= 0.12nM. FE8 has no effect on CD21 negative Ramos 
cells. No response to isotype antibody concentrations is seen with either cell type. (B) sCD21 
blocks activation of CD21 positive cells in a concentration dependent manner. IC50= 132.9nM. 
sCD21 has no effect on activation of CD21 negative Ramos cells. sIL7R protein has no effect on 
activation in either cell type. 
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11.4 Discussion:  
This chapter focuses on the role of the soluble form of the CD21 receptor in health and 
disease. It is well documented in the literature that sCD21 is decreased in many autoimmune 
diseases such as Rheumatoid Arthritis (Masilamani et al., 2004). These reports lead to the 
hypothesis that sCD21 inhibits C3dg antigen complexes from binding to B cells, 
consequently preventing activation of these cells and thus dampening C3dg-mediated 
immune responses. Therefore, it is possible that a decrease in sCD21 concentration results 
in pathogenic B cell responses and disease as this break on the immune system is depleted 
in these systems.  
The first aim of this work was to further investigate this decrease in sCD21 in disease using 
serum samples from RA patients and age-matched healthy volunteers. Age-matching the 
healthy samples to that of the RA serum samples was important as sCD21 levels have been 
shown to decrease with age (Masilamani et al., 2004); an observation that was mirrored in 
this data (Figure 11.3.4). As the majority of RA patients are between the ages of 45-70yrs, 
and in healthy volunteers sCD21 is decreased compared to subjects of ages >25yrs, this 
natural decrease may be a reason why age is a risk factor of development of RA, however 
when sCD21 concentration in RA patients was compared with their age, no correlation to 
suggest older patients have less sCD21 than younger patients were observed (Figure 
11.3.5). Analysis of sCD21 concentration within the serum from RA patients revealed a 
further decrease compared to levels found in healthy volunteers (Figure 11.3.4).  
To further investigate these findings, sCD21 concentration in RA patients was considered in 
relation to disease severity (DAS28 score). Results revealed that an increase in disease 
severity correlated with a decrease in sCD21 concentrations (Figure 11.3.7). This 
observation implicates sCD21 as a marker of disease severity and a contributor to 
manifestation of RA.  
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Additional evidence to add to the observation that lower sCD21 concentration lead to an 
increased disease phenotype comes from analysis of longitudinal patient data. sCD21 
concentration was shown to increase in patients after treatment with methotrexate and 
various topical steroids 6 months after entering the clinic (baseline) and increase further still 
after 12 months of treatment (Figure 11.3.8A). Disease severity (DAS28 score) was also 
shown to decrease over the time points measured in these patients (Figure 11.3.8B). These 
data suggest there is a correlation between the increase in sCD21 concentrations and the 
decrease in disease severity.  
Serum samples taken from patients pre- and post-rituximab treatment revealed a further 
decrease in sCD21 levels after treatment (Figure 11.3.9). As rituximab is a depleting 
monoclonal antibody against CD20, it can be assumed that these patients are deficient or 
have decreased number of B cells, excluding plasma cells which do not express CD20. 
Thus, these results give indication of the origin of sCD21; as sCD21 concentrations 
decrease upon B cell depletion it is reasonable to suggest these cells as a source of sCD21. 
Data from this study has suggested that lower sCD21 concentrations further increases the 
severity of disease, however as B cell subsets are known to be pathogenic within RA 
(Abrahams et al., 2000), depletion of these cells removes a major mediator of disease, 
allowing resolution and improvement of symptoms independent of sCD21 concentrations.  
The source of sCD21 was further investigated using a hu-mouse model. NSG-SGM3 mice 
reconstituted with human CD34+ cells were shown to express human cell surface markers for 
T and B cells (CD3 and CD19 respectively) (Figure 11.3.11), but did not express human 
CD35, CXCL13 or CCL21, suggesting that human stromal cells, FDCs and FRCs, were not 
present within these mice (Figure 11.3.11). Human CD21 however was detected in splenic 
mRNA, presumably from expression by human B cells as FDCs were thought to be absent. 
Immunohistochemical analysis further confirmed these observations, revealing positive 
staining for hCD3 (Figure 11.3.12), hCD19 (Figure 11.3.13) and hCD21 (Figure 11.3.13) and 
an absence of hCD35 staining (Figure 11.3.14). Thus, this humanised mouse model 
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develops human T and B cells but not FDCs. As FDCs do not develop from the 
haematopoietic lineage, this was expected after reconstitution by the chosen method. This 
analysis also revealed that the secondary lymphoid organs were disorganised, potentially an 
indication that development of human cells was not complete and cells may not respond in 
the same ways as in human SLOs.  
When investigating the presence of sCD21 within the serum of the humanised mouse model, 
levels of this protein were not detected, suggesting these mice do not produce the soluble 
version of this protein. However, this result may be due to the low concentration of serum 
used; only a small volume of serum was available which was required to be diluted 1in4 in 
order to run the assay in duplicate, therefore this may have diluted the sample too far to 
detect the presence of sCD21 within the samples. Alternatively, B cells within this model do 
not secrete sCD21. This could be due to a number of reasons; the development of the cells 
may not be correct within the mouse model, expression of other factors such as IgG levels 
were not measured within these mice therefore it is hard to say if the B cells were 
responding in the correct manner. If development was not correct, perhaps expression of the 
signalling pathways or cleavage factors to produce sCD21 is not expressed within these 
cells. Additionally, as the SLO’s in this model were shown to be disorganised (Figure 
11.3.12); this could affect sCD21 production as the correct signals to produce the soluble 
protein may not be received within this environment. Therefore, this result does not rule out 
B cells as a source of sCD21 within humans.  
B cell populations which down-regulate CD21 have been reported in RA (Isnardi et al., 
2010). Data from the current study suggests B cells as a source of sCD21 production; 
therefore, if B cells in disease down-regulate CD21 on their surface, it is also plausible that 
less sCD21 is produced by these cells. Thus, CD21-/low may have another pathogenic 
response not yet explored. As sCD21 has been shown to have the ability to bind to C3dg 
and prevent binding to B cells in this and previous studies (Ling et al., 1991), this decrease 
would subsequently cause an increase in the number of C3dg-immune complexes available 
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to bind to and activate these and other autoreactive B cells. This is an alternative 
mechanism in which these CD21-/low cells could be contributing to the development and 
manifestation of autoimmune disease. Data presented in this investigation also showed that, 
in healthy volunteers, the number of CD21 receptors expressed on the cell surface of 
peripheral B cells, correlates with increased sCD21 concentration measured within the 
serum, again suggesting that sCD21 may be produced by these cells.   
Additional evidence supporting B cells as an origin for sCD21 is the increased concentration 
of this protein within patients with B cell malignancies such as B cell chronic lymphocytic 
leukaemia (Ling et al., 1991) and EBV/EBV-associated malignancies (Larcher et al., 1995) 
compared with healthy individuals. As these diseases are characterised by an increase in 
the number of circulating B cells, it is probable that the increase in sCD21 correlates to this 
phenotype.  
Next, the function of sCD21 was further investigated using C3dg-immune complexes. In the 
first experiment assessing function, the C3dg-strepavidinAPC complex was utilised to 
understand whether sCD21 can block the binding of C3dg to peripheral B cells. When 
binding was previously assessed in results chapter 2, a tetrameric C3dg complex was used 
to enable greater visualisation of binding on the cells of interest. In these experiments the 
concentration of sCD21 it was possible to add to the assay to block binding was a limiting 
factor, therefore exploration of the use of monomeric C3dg-strep complexes was further 
investigated. Theoretically, using a monomeric complex would result in a lower concentration 
of sCD21 required to block all C3dg molecules binding to membrane bound CD21 than that 
needed to block C3dg in a tetrameric form. Using monomers decreased the signal observed 
upon binding to cells compared with tetrameric complexes (Figure 11.3.20), but signal was 
still sufficient to allow visualisation of the ligand-receptor interaction. The decrease in signal 
when using monomeric complexes has been well studied (Altman et al., 1996); data showed 
that when weak ligand-receptor interactions occur, visualisation of these interactions can be 
observed by using tetrameric complexes. Complexes were blocked with high sCD21 
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concentrations (144 nM), resulting in complete blockage of binding of monomeric C3dg-
complexes to B cells, similar to that of FE8 blocking (Figure 11.3.20). Partial blockage of 
tetrameric complex binding occurred when using the same sCD21 concentration (Figure 
11.3.20). This confirmed that monomeric complexes were easier to block using sCD21 than 
tetrameric complexes, and since sCD21 concentration was the limiting factor in this assay, 
monomeric complexes were chosen for these experiments. Previous studies had reported 
that monomeric C3dg was unable to bind to rc-CD21 (Moore et al., 1989), however 
observations made in this investigation contradict this result. Experimental differences may 
be the cause of this discrepancy as the published study used sedimentation analyses to 
assess binding, which could not be observed under physiological conditions, but low levels 
of binding were seen at low ionic strength, whereas this study assessed binding in an in vitro 
flow cytometry assay. Other publications have shown tetrameric C3dg to augment B cell 
activation, whereas monomeric C3dg inhibits these responses (Bohnsack et al., 1988). It is 
possible that within this study, binding of monomeric C3dg-complexes to peripheral B cells 
caused inhibition of activation, but as this particular experiment was investigating sCD21’s 
ability to block C3dg binding to CD21 on the surface of B cells, the resultant activation 
response was not of interest.  
sCD21 was shown the block C3dg binding to peripheral B cells in a concentration dependent 
manner. Interestingly, full-length rc-CD21 was able to block binding more effectively than the 
ligand binding site only, SCR1/2, shown by the reagents having IC50 values of 3.94 nM and 
19.42 nM, respectively (Figure 11.3.21). Surface plasmon resonance studies investigating 
interactions between CD21 and C3dg reported Kd values for binding of C3dg to SCR1/2 and 
SCR1-15 (full length protein) as 22.4 nM and 27.1 nM, respectively (Ling et al., 1991). These 
binding kinetics suggest that the full-length protein has an increased affinity for C3dg than 
the binding site alone, as C3dg both associated and dissociated 10-fold slower from SCR1-
15 and SCR1-2. These results correspond to the observation of increased binding of C3dg 
by full length sCD21 compared with SCR1/2 alone in this study. Together these results imply 
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that the full-length protein affects the kinetics of C3dg binding and hence improves the 
affinity for its ligand.  
Physiological levels of sCD21 in healthy volunteers were found to be around 400 ng/ml; this 
is equivalent to 2.75 nM. At these concentrations, full length rc-CD21 can block binding of 
0.02 µg/ml C3dg to peripheral B cells. It is unknown at what concentrations C3dg is found 
within physiology as C3dg specific reagents are limited. However, this data suggests that 
physiological levels of sCD21 can bind C3dg and therefore prevent the binding of immune 
complexes to B cells, preventing downstream C3dg-dependent pathways. It is possible that 
sCD21-C3dg complexes are then cleared using an unknown mechanism, and hence sCD21 
acts as a break on the immune system. It is known that C3d levels are increased in RA and 
SLE (Morrow et al., 1983). As C3d is a precursor to C3dg, it is reasonable to suggest that 
this molecule is also increased in these diseases, although this has not been studied in the 
published literature. Interestingly this study showed that increased C3d levels were 
proportional with worsening disease activity in RA (Morrow et al., 1983). Together these data 
sets propose a mechanism in which a decreased sCD21 concentration in RA disease allows 
for increased availability of C3dg-immune complexes, as they are no longer bound by 
sCD21. These complexes are then able to bind to B cells causing activation of potentially 
pathogenic cells resulting in an increase in disease prevalence. This mechanism would 
explain an increase in disease severity with a further decrease in sCD21, as the lower 
concentration of sCD21 present in the serum allows more C3dg to activate B cells.  
To further develop this model, experiments investigating the ability of sCD21 to block B cell 
activation were undertaken. For these studies B cell lines were utilised due to the 
inconsistent and unreliable results generated using primary B cells. Raji cells were chosen 
as the CD21+ B cell line as they expressed IgM receptors at a similar level to that of primary 
B cells in comparison to the other CD21+ cell line considered for these experiments, Daudi 
(Figure 11.2.23). CD21- Ramos cells were used as a negative control, to ensure that 
responses seen were CD21-dependent.  
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For these experiments’ cells were activated using a stimulation complex composed of C3dg, 
anti-IgM and neutravidin. This complex will activate cells through membrane bound IgM 
receptors and the CD21/CD19 complex. This co-activation has previously been reported to 
lower the threshold for activation of B cells (Carter et al., 1992), data which is reproduced in 
the CD21+ Raji cell line (Figure 11.3.25A). Activation with the stimulation complexes was 
shown to be synergistic in that, although C3dg (0.3 µg/ml) and low anti-IgM (0.3 µg/ml) do 
not activate cells individually, together they activate CD21+ cells to levels similar to 
stimulation with high anti-IgM (1 µg/ml) (Figure 11.3.26A). Interestingly, high concentrations 
of C3dg alone (1 µg/ml) cause activation of CD21+ cells, but again co-activation occurs with 
anti-IgM. This was also reported by Tsokos et al., (1990), whom first suggested that 
crosslinking CD21 and IgM ligand would further increase B cell responses compared to 
multivalent C3dg only. These observations are CD21/C3dg-dependent as these effects were 
not seen in CD21- Ramos cells, which were only activated with anti-IgM in a concentration 
dependent manner (Figure 11.3.26B).  
It was shown that co-ligation of C3dg and anti-IgM using neutravidin was essential for this 
co-activation effect to occur (Figure 11.3.27). In the absence of neutravidin, activation only 
occurs through anti-IgM stimulation. In the absence of neutravidin, C3dg is most likely to be 
in a monomeric form. It is reported in this study that monomeric C3dg is able to bind to 
CD21, whereas other studies have published conflicting data using monomeric C3dg (Moore 
et al., 1989), reporting an inability of monomeric C3dg to bind to rc-CD21. As the same batch 
of biotinylated-C3dg was used in these experiments as in C3dg binding experiments, it is 
assumed that monomeric C3dg is able to bind CD21 in these experiments, but B cell 
activation is not enhanced when this occurs. The absence of an activation response using 
monomeric C3dg is supported by previously published data reporting inhibition of B cell 
activation when using monomeric C3dg-complexes (Ling et al., 1991). Within the same 
study, stimulation with tetrameric complexes augmented activation responses. The 
stimulation complex used in these experiments mimics an C3dg-antigen complex found in 
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physiology; neutravidin acting as the antigen which would be bound with antibody, anti-IgM, 
and C3dg. Therefore in vivo C3dg-antigen complexes are able to bind to membrane bound 
IgM and CD21 simultaneously, causing increased Lyn recruitment and subsequent activation 
of cell signalling pathways leading to increased MEK activation which phosphorylates ERK 
leading to B cell activation, proliferation and development (Bojarczuk et al., 2015). Taken 
together, these results suggest that if monomeric C3dg (i.e. not within complex with antigen 
and antibody) binds CD21, B cells do not respond. This could be a potential mechanism to 
prevent over-activation of B cells in the presence of free-C3dg; in addition to sCD21 
preventing C3dg binding membrane bound CD21.  
A stimulation complex containing the final molar ratios of 5:2.5:1 neutravidin:C3dg:anti-IgM 
revealed the greatest assay window for stimulation compared with activation with low anti-
IgM (Figure 11.3.31) so was determined as the most suitable for blocking experiments with 
sCD21 and CD21 blocking antibody clone, FE8. Both sCD21 and FE8 were shown to block 
activation of CD21+ B cell lines in a concentration dependent manner (Figure 11.3.32A and 
Figure 11.3.32B, respectively). FE8 binds to the receptor on the cell surface to block binding 
of C3dg, and hence co-activation of B cells. The IC50 for this blocking effect is 0.12 nM, 
previous experiments using this antibody to block the binding of C3dg to primary B cells 
revealed 0.06 nM FE8 is needed to block the binding of C3dg tetrameric complexes to these 
cells. Receptor numeration revealed Raji cells express 2.5-fold more CD21 receptors on 
their cell membrane than primary B cells, ~20,000 and ~8,000 receptors, respectively 
(Figure 11.3.23C). This increase in receptor number is responsible for the increased FE8 
needed to block binding and subsequent C3dg-dependent activation. sCD21 blocks 
activation by binding to the ligand, C3dg. The IC50 of sCD21 is 132.9 nM, which is much 
higher than that found in physiology, 2.75 nM. Therefore, under these conditions, 
physiological concentrations of sCD21 do not block activation of CD21+ B cell lines. As this B 
cell line expresses 2.5-fold more CD21 receptors than primary B cells, it is assumed less 
sCD21 would be needed to block activation of B cells in vitro. As the concentration of C3dg 
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within the germinal centre, where most of B cell activation occurs, has not been measured, it 
is hard to determine what concentration of sCD21 is needed to block C3dg-dependent 
activation responses. Additionally, within these systems, blockage of all C3dg-responses 
would cause defects in the immune response; therefore it is likely that in physiology C3dg is 
in excess to sCD21. The sCD21 that is present is acting to ensure over activation of B cells 
does not occur, binding some but not all C3dg-immune complexes, again acting as a brake 
on the immune system.  
Blockage of activation using FE8 and sCD21 was shown to be C3dg/CD21-dependent as no 
effect was observed on activation of Ramos cells (Figure 11.3.24B). Additionally, activation 
with high anti-IgM concentrations could not be blocked with these reagents on either cell 
type (Figure 11.3.24).  
To summarise, data presented in this chapter shows that sCD21 concentrations decrease 
with age and further in autoimmune disease, in this case RA (Figure 11.3.4). sCD21 
concentration directly correlates to disease severity (Figure 11.3.7) and increasing sCD21 
concentration upon treatment of disease also correlate with a decrease in disease 
phenotype, suggesting a role for sCD21 in pathology. Rituximab treatment further decreases 
sCD21 concentration in RA patients (Figure 11.3.9), suggesting B cells are a source of 
sCD21. The function of sCD21 was further investigated and was shown to have the ability to 
block C3dg binding to peripheral B cells and block the activation of CD21+ B cell lines.  
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Taking these observations into account, the following model for sCD21’s role in health and 
disease is proposed. In health, sCD21 is produced by B cells at concentrations sufficient to 
allow C3dg-complexes to bind antigen-specific B cells and produce specific antibody 
responses, but still block excessive C3dg-mediated activation, therefore acting as a break on 
the immune system. In autoimmune disease phenotypes, such as Rheumatoid Arthritis, 
autoreactive B cell downregulate CD21 expression and can self-regulate through multiple 
different pathways; the decrease in CD21 expression by these cells leads to a decreased 
production of sCD21. A decrease in sCD21 allows all C3dg-immune complexes to activate 
autoreactive B cells, resulting in autoantibody production and pathogenic B cell responses, 
manifesting itself as disease. Therefore, the lower the concentration of sCD21, the more 
severe the disease, as a greater immune response can be elicited with the removal of 
sCD21 acting as a break on B cell activation responses (Figure 11.4.1).  
This mechanism and the data presented here supports the hypothesis of this work, 
suggesting that sCD21 can inhibit C3dg-mediated immune responses and decreased sCD21 
levels remove this break on the immune system, resulting in pathogenic B cell responses 
and disease.  
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12. General Discussion 
 
12.1 Thesis hypothesis and aims  
 
This thesis focused on exploring the roles of CD21 in the germinal centre as a membrane 
bound receptor and within the periphery as a soluble protein.  
As the essential function of CD21 in the GC response relies on the transfer of C3dg-
opsonised antigen transfer from CD21 on B cells to FDCs, it was important to further 
investigate how this unidirectional transfer may occur between the two cell types. A clear 
mechanism for this transfer is not currently described within the literature, and most studies 
are carried out within murine models. These studies lead to suggestions that unidirectional 
transfer of antigen could occur due to cell size (Heesters et al., 2014) or increased receptor 
numbers on FDCs compared to that on B cells (Phan et al., 2007). These observations, 
together with the differential expression of CD21 isoforms by these two cell types, lead to the 
following hypothesis; C3dg-opsonised antigen transfer between human FDCs and B cells is 
due to (1) CD21 receptor number on the cell surface and/or (2) the CD21L isoform 
expressed by FDCs having a higher affinity for C3dg than CD21S, expressed by B cells.  
This work further investigated the functions of the soluble form of the CD21 receptor by 
analysing the potential mechanisms of the decrease in sCD21 levels observed in serum from 
patients with autoimmune disease. Due to the observation of decrease sCD21 in disease, I 
hypothesised: a key function of sCD21 is to act as a break on the immune system preventing 
C3dg-mediated immune responses. The decrease in sCD21 levels in disease, removes this 
break on the immune system and therefore, overactivation of pathogenic B cells and the 
immune response can occur, subsequently resulting in disease phenotypes. 
These hypothesise lead to the following thesis aims:  
1) Isolate and characterise human FDCs from human tonsil. Assess CD21 absolute 
receptor number on FDCs (tonsil derived), T and B cells (tonsil and blood derived).  
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2) Assess C3dg binding capacity of CD21 on FDCs (tonsil derived) and B cells (tonsil 
and blood derived), investigating potential functionality differences between CD21S 
and CD21L isoforms.  
3) Further understand the function and role of sCD21 in healthy volunteers and disease 
patients.  
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12.2 Summary of results and significance  
 
12.2.1 Unidirectional transfer of C3dg-opsonised antigen complexes between 
B cells and FDCs 
 
12.2.1.1 CD21 receptor number expression on FDCs and B cells  
Histological studies on human tonsil and lymph node tissue, confirmed cell specific 
expression of known markers as well as cellular interactions within the germinal centre 
microarchitecture. These data allowed identification of FDCs as CD35+CD21+CXCL13+ cells 
(Figure 9.3.1, 15 and 12 respectively) and B cells as CD19+ cells (Figure 9.3.1). It is known 
that B cells also express CD21 on their cell surface, confirmed using qPCR (Figure 9.3.11) 
and flow cytometry analysis (Figure 9.3.13). However, in alignment with other published 
studies (Naiem et al., 1983), these cells were not found to be CD21+ within FDC zones using 
immunohistochemistry techniques. This was the first indication within this study that CD21 
receptor number expression may differ between FDCs and B cells; resulting in a masking of 
the CD21 staining on the B cells by the high expression of membrane bound CD21 receptors 
on FDCs. CD21 antibody clones, R4/23 (Naiem et al., 1983) and 7D6 (Lui et al., 1997), have 
been reported as FDC specific antibodies and, therefore, CD21L specific, with weak 
reactivity to B cells outside of FDC zones. Results from these studies were interpreted as 
FDC specificity rather than considering possible differences in receptor number expression 
or relative affinities of the antibody clones. Results within this study confirmed that R4/23 
was able to recognise CD21S expressing cells (Figure 10.3.10), therefore was not specific 
for the long form of CD21. Additional experiments staining human tonsil B cells in areas 
devoid of FDCs using the antibody clones Bu32 and R4/23, utilised within this study, to 
confirm identification of CD21 expression on these cells in the absence of FDCs, would 
further support this concept.  
These studies also showed that CD19 expression could be visualised on B cells using IHC, 
however, FDCs appear negative for this marker (Figure 9.3.1). In contrast with these 
observations, a low level of CD19 expression has been reported at the mRNA level within 
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FDCs within these studies (Figure 9.3.11) and previously published data (Barrington et al., 
2009). As with the lack CD21 staining visualised on B cells, the reason for these 
discrepancies is thought to be due to the high number of CD19 receptors expressed by B 
cells and this consequently masks CD19 staining of the receptor on the FDC surface. The 
role of CD19 on FDCs remains unclear. On the B cell surface, CD19 is expressed in molar 
excess to CD21 and therefore it is thought that all CD21 receptors are contained within the 
CD19/CD21 complex (Fearon et al., 2000) acting to lower the threshold for activation of the 
B cell (Carter et al., 1992). As CD21 is expressed in excess of CD19 in FDCs, the majority of 
the CD21 receptors will not be contained within the CD19/CD21 complex; these 
observations suggest that the role of CD19 on FDCs is unlikely to be cell activation. 
Interestingly, CD81, the tetraspanin molecule involved in anchoring the CD19/CD21 complex 
in B cells, is highly expressed by murine FDCs (Rodda et al., 2018), therefore it is possible 
that the CD21 receptor and this protein are still in close association on the FDC, but this has 
not been investigated at present. As CD81 has been shown to traffic CD19 along the 
secretory pathway, it is possible that together these proteins have a role in the internalisation 
and recycling of CD21 receptors to the FDC cell surface, although there is no evidence at 
present to suggest this be the case.  
There are limited protocols available within the literature for the isolation of human FDCs. 
Replication of available methods proved unreliable and results were not reproducible using 
human tonsil tissue. Therefore, a robust isolation method of human FDCs from human tonsil 
tissue was developed to enable further assessment of CD21 functionality on this cell 
population. The method detailed in Materials and Methods Section 8.2 produces replicable 
results for the isolation of human FDCs from tonsil tissue and this protocol was successfully 
utilised to allow the following investigations on human FDCs and CD21 receptor biology. 
To address the hypothesis that transfer of C3dg-immune complexes from B cells to FDCs 
occurs due to receptor number, absolute CD21 receptor number on the cell surface was 
determined on isolated human FDCs (tonsil derived), T and B cells (tonsil and blood 
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derived), something that has not previously been reported in the current literature. Results 
revealed that FDCs express over 30-fold more CD21 receptors on their cell surface than B 
cells, ~150,000 versus ~8000 receptors (Figure 9.3.16). As FDCs are ~10-fold larger than B 
cells, the density of CD21 receptors on these cells is around 3-fold greater than that on B 
cells. Therefore, it is possible that the increased size of these cells, along with the high 
receptor number on the cell surface, allows for unidirectional transfer to occur as a result of 
increased binding of CD21 receptors to available C3dg ligands on the immune complexes. 
Spacing of antigen complexes, and hence CD21 receptors, on the FDC membrane has been 
studied using electron microscopy (Shikh et al., 2010). Antigen complexes were spaced 
periodically 200 to 500 Angstroms apart on the FDC cell membrane; this spacing was 
thought to be optimal for FDC-immune complexes to engage multiple BCRs simultaneously. 
In terms of antigen transfer, this spacing suggests that FDCs can bind to multiple C3dg 
molecules on opsonised immune complexes, creating greater contracts with the complex 
than that by the B cell. Increased interactions between the cell and the complex could lead to 
transfer of the complex through dissociation of the ligand off the B cell surface and/or 
internalisation of CD21 receptors, leading to the removal of complexes from CD21 on B 
cells.  
Investigations using murine B cells and FDCs, lead to suggestions that unidirectional 
transfer of C3dg-antigen complexes could occur due to cell size (Heesters et al., 2014) 
and/or, CD21/35 receptor number (Phan et al., 2007). This study showed that murine FDCs 
expressed higher numbers of CD21/35 receptors than B cells; although absolute receptor 
number quantification was not reported. Together with the data presented here, these 
observations suggest antigen transfer likely occurs due to the increased density of CD21 
receptors on the surface of FDCs, leading to increased interactions between the cell and 
C3dg-opsonised immune complexes. Therefore, these interactions may be important in the 
successful competition with migrating B cells for the capture and retention of noncognate 
immune complexes.  
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12.2.1.2 C3dg binding functionality of CD21 on FDCs and B cells  
 
The second part of the transfer hypothesis regards the differential expression of CD21 
isoforms on FDCs and B cells. FDCs are known to express the long form of CD21 and B 
cells express the short form (Figure 10.3.7). The short form of the receptor is made of 15 
SCR protein units, whereas the long isoform has an additional SCR in the middle of the 
protein (Figure 10.1.2), bringing the whole protein to a total of 16 SCRs. It is possible that 
these two isoforms have differential binding affinities for their ligand, C3dg, consequently 
leading to unidirectional transfer between the short isoform on the B cells to the long isoform 
on FDCs.  
To investigate ligand binding by CD21 receptors, a C3dg immune-complex was used, 
consisting of mono-biotinylated C3dg complexed to a Streptavidin-APC molecule to form a 
tetramer (Figure 11.3.20). The use of tetrameric complexes in these experiments suggests 
that the interactions between receptor and ligand are of low affinity; an artefact that was 
demonstrated using tetrameric complexes of T cell antigen to visualise weak ligand-receptor 
interactions on a population of T cells expressing specific TCRs (Altman et al., 1996). 
Interestingly, previous studies have shown that monomeric C3dg does not bind to 
recombinant CD21 under physiological conditions (Moore et al., 1989), although this was not 
the case in this investigation (Figure 11.3.20). Monomeric C3dg was shown to have the 
ability to bind to CD21 in flow cytometry experiments, however it was still important to use a 
tetrameric complex for binding assays due to the increased assay window created by the 
increased valency of the complex and thus increased binding of membrane bound receptors 
(Figure 10.3.1B).  
This C3dg immune complex was shown to bind the FDCs, T and B cells in a concentration 
dependent manner (Figure 10.3.4). As only ~20% of T cells express very low levels of CD21, 
~200 receptors per CD21+ cell (Figure 9.3.16), these cells were no longer investigated as 
part of this work as the expression of this receptor is unlikely to be physiologically relevant.  
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The hypothesis of differential ligand binding affinity by receptor isoforms was assessed by 
investigating C3dg binding to CD21 in the presence of a blocking CD21 antibody clone, FE8, 
which was shown to prevent binding of C3dg to CD21 receptors (Figure 10.3.5) and is 
known to bind to an epitope spanning SCR1/2 (Wolfgang et al., 1998), the ligand binding site 
of this receptor. This antibody was shown to block binding of C3dg immune-complexes to 
FDCs (tonsil derived) and B cells (tonsil and blood derived) in a concentration dependent 
manner (Figure 10.3.6). Blockage of C3dg binding to CD21 on human tonsil derived B cells 
using FE8 has been previously reported (Wolfgang et al., 1998), but experiments using 
human FDCs and B cells derived from the periphery had not been undertaken. The IC50 of 
FE8 blocking C3dg binding to FDCs was shown to be 6-fold higher than that of B cells, 
which was the same in cells derived from tonsil and blood, 0.4 nM, 0.06 nM and 0.07 nM, 
respectively. This increase in IC50 was predicted due to the increased receptor number on 
the surface of FDCs, therefore more antibody is needed to block the binding sites of C3dg. 
However, receptor numeration experiments revealed FDCs express over 30-fold CD21 
receptors on their surface than B cells (Figure 9.3.16), therefore a 6-fold increase in IC50 is 
surprisingly low in relation to the increased number of receptors FE8 needs to bind to 
prevent C3dg immune complex binding to all receptors on the FDC surface. This data may 
imply that CD21L expressed on FDCs has a lower affinity for its ligand, C3dg.  
To further investigate these results, a specific CD21L antibody was needed to ensure the 
results were due to isoform expression. Clones, such as Bu32, recognise total CD21; 
therefore bind to an epitope present in both the long and the short isoform of CD21. The 
CD21 antibody clone, R4/23, was reported to bind specifically to FDCs and therefore said to 
recognise the long isoform of this receptor (Naiem et al., 1983). Antibody staining patterns in 
tonsil tissue using this CD21 antibody clone revealed only the expression of CD21 on FDCs, 
like the published report (Figure 10.3.8). However, staining with the CD21 antibody Bu32 
also reveals the same staining pattern, in that CD21 expression on B cells are not detected 
(Figure 9.3.6) due to an increased number of CD21 molecules expressed on the surface of 
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FDCs compared to B cells, not differential isoform expression. Therefore, high CD21 
receptor numbers on FDCs leads to a bright staining pattern that masks signal from CD21 
stained B cells. Further investigations using the R4/23 antibody revealed that, although the 
antibody may preferentially bind CD21L, it is not specific for this isoform. Using the antibody 
clone R4/23, CD21S or CD21L isoforms derived from transfected HEK293T cells both in a 
membrane bound form using flow cytometry (Figure 10.3.10) and as a soluble protein by 
ELISA (Figure 10.3.11). Therefore, reports that these CD21 antibody clones are specific for 
FDCs and the CD21L isoform are not correct.  
Due to the lack of available isoform specific CD21 reagents and therefore the ability to 
determine specific protein isoform expression on the cell surface of FDCs and B cells by flow 
cytometry, the transiently transfected HEK293T cells expressing CD21 were utilised to 
further investigate C3dg immune complex binding by the two CD21 isoforms. On average, 
the transfected cell lines expressed similar numbers of CD21 receptors (~15,000 receptors 
per cells, Figure 9.3.16), any changes observed in C3dg-binding between these cell lines 
can be said to be due to the isotype expression. C3dg was shown to bind in a concentration 
dependent manner to both receptor isoforms; however, cells expressing the CD21S protein 
bound an increased amount of C3dg at higher complex concentrations (Figure 10.3.13B). 
This could suggest that the short isoform has a higher affinity for its ligand than the long, but 
further experiments to confirm this were beyond the scope of this work. Previously published 
experiments using surface plasmon resonance have been undertaken comparing the affinity 
of the ligand binding site, SCR1/2, and the full-length receptor, SCR1-15, for C3dg (Ling et 
al., 1991), revealing the full-length protein has an increased affinity for its ligand. To date, 
comparisons between the affinity of the short and the long isoforms for C3dg have not 
explored in this manner. Although the data presented here suggests little difference between 
the binding affinities of the two CD21 isoforms, it would be important to consider the off rates 
of C3dg to each of the receptors, and hence the stability of ligand-receptor interactions, 
before eliminating this mechanism as a possible method of antigen transfer altogether.  
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The CD21 antibody clone, FE8, was used to block the binding of C3dg immune complexes 
to these isoform specific cells (Figure 10.3.13C). Data showed that there was no change in 
IC50 for the blockage of ligand binding by FE8 to either isoform; this confirms that the 
additional SCR added in the long isoform of CD21 does not change the binding site, 
SCR1/2, as FE8 is able to bind to both receptors with equal affinity. Thus, it is unlikely that 
the affinity for the receptor for C3dg is changed between isoforms, potentially disproving the 
hypothesis that differential isoform expression is responsible for unidirectional transfer of 
antigen between B cells and FDCs.  
 
 12.2.2 The function of sCD21 in health and disease 
 
  12.2.2.1 sCD21 levels decrease in autoimmune disease  
 
It is known that sCD21 levels change in disease; in autoimmune diseases, for example 
Rheumatoid Arthritis, sCD21 levels decrease. Data presented here confirmed this 
observation, firstly demonstrating that age matched healthy donors must be used due to a 
decrease in sCD21 levels with age and secondly, repeating observations from the literature, 
confirming that sCD21 levels decrease in RA (Figure 11.3.4). A correlation between sCD21 
levels and disease severity, assessed by DAS28 score revealed that lower sCD21 
concentrations are found in patients with more severe disease (Figure 11.3.7), therefore 
suggesting a role for sCD21 in disease modulation. This relates to the hypothesis that 
sCD21 acts as a break on the immune system, preventing C3dg-antigen complex binding to 
B cells, consequently dampening C3dg-mediated immune responses. As sCD21 levels are 
decreased in RA, this break on the immune system does not occur, allowing pathogenic B 
cell responses to occur.  
Interestingly, further supporting this hypothesis, when following the treatment of RA patients 
over time, sCD21 concentrations increase followed by a decrease in disease severity upon 
treatment with steroids and other conventional drugs. 
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Further investigation of RA patients treated with Rituximab, a human CD20 depleting 
monoclonal antibody resulting in the removal of B cells upon administration, revealed a 
further decrease in sCD21 concentration in the serum after treatment (Figure 11.3.9). This 
data suggests B cells may be the source of sCD21, as removal of these cells decreases the 
concentration of protein detected. Further investigations were carried out using a humanised 
mouse model which was shown to express CD21 at the mRNA level and develop human B 
cells but not FDCs (Figure 11.3.11). The presence of sCD21 within the serum of these mice 
was investigated as if this protein was detected this would further suggest that the B cells 
are an origin of the soluble form of CD21. Unfortunately, sCD21 was not detected within the 
serum of these mice, however this does not rule out B cells as the source of the protein as 
SLO’s within these mice were highly disorganised (Figure 11.3.12), suggesting the human T 
and B cells within these animals were not properly developed, a factor that could also be 
affecting the production of sCD21 by these cells.  
Within the published literature, there is evidence for B cells as the source of sCD21, but this 
is not currently confirmed. Analysis of culture media from human T and B cells revealed the 
presence of sCD21 (Fremeaux-Bacchi et al., 1996) showing these cells have the ability to 
release this protein from their cell surface in vitro. B cells have also been induced to shed 
membrane bound CD21 by crosslinking the BCR and CD40 (Masilamani et al., 2003). As 
CD21 expression is lost during differentiation of B cells into B-blastoid cells, a role for CD21 
shedding and sCD21 in the initial steps of B cell activation during the immune response is 
suggested. This observation further adds to the work demonstrated here. As cells become 
activated during the immune response, sCD21 is shed from the B cell surface, thereby 
potentially preventing the overactivation of the immune response by modulation of C3dg-
mediated responses by this addition sCD21.  
Clinical observations of increased sCD21 levels in diseases with increased B cell numbers 
(Lowe et al., 1989) and decreased levels of sCD21 in patients with defective CD21 
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expression on B cells (Ling et al., 1991), also provide strong evidence that these cells are 
the source of sCD21.  
Of course, as it is known that B cells depletion in mice leads to loss of FDCs in mice (Anolik 
et al., 2008), FDCs cannot be disregarded as a potential source of sCD21. In this model, the 
removal of B cells by treatment with rituximab would lead to a subsequent loss in FDCs and 
a resultant decrease in sCD21 concentration. FDCs have not been confirmed as a source of 
sCD21 in current published literature as culture of human FDCs for long periods of time is 
very difficult and without standardised protocols. Additionally, as T cells were shown to 
produce sCD21 (Ling et al., 1991), and the soluble protein can be detected with the culture 
media of these cells in vitro (Fremeaux-Bacchi et al., 1996), these cells may be responsible 
for the shedding of sCD21. Although this is a possible mechanism, it is not very probable 
due to the low CD21 receptor number expressed on T cells. Data presented in the current 
study revealed only ~20% of T cells (tonsil and blood derived) express CD21 and these cells 
were seen to have only ~200 receptors per cell; much lower than that of B cells and FDCs 
(Figure 9.3.16) and therefore these cells are unlikely to be the sole source of sCD21.    
Publications have also reported a B cell population which down-regulate CD21 expression 
within patients with RA (Isnardi et al., 2010). As data from this study suggests B cells are a 
source of sCD21 production, downregulation of CD21 expression on the surface of these B 
cells may lead to a decreased concentration of sCD21 within the serum of these patients as 
sCD21 is thought to be cleaved from the cell surface by an unknown protease (M. 
Masilamani et al., 2003).  
12.2.2.2 sCD21 blocks binding of C3dg to peripheral B cells 
 
To further understand the role of sCD21 in health and disease, functional assays were 
undertaken, firstly using the C3dg immune-complex used in FE8 blocking assays. For these 
experiments a monomeric form of the complex was used; as the aim of the assay was to 
block C3dg binding to peripheral B cells, blockage of a monomeric form of C3dg would 
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theoretically need less sCD21 to prevent binding of ligand to CD21 receptors on the surface 
of B cells, and therefore it was more likely that a larger assay window would be observed for 
blockage of binding using the complex in this form. It has previously been reported that 
monomeric C3dg is unable to bind to rc-CD21 (Moore et al.,1989), however binding using 
the monomeric form of C3dg was observed to CD21 receptors on the surface of B cells in 
the current study. As the previous study used sedimentation analyses under physiological 
conditions to assess binding, whereas this data was generated using in vitro flow cytometry 
assays, differences in assay design may be the cause of this discrepancy and therefore 
perhaps binding of monomeric C3dg does not occur in physiology.  
sCD21 was shown to block C3dg binding to peripheral B cells in a concentration dependent 
manner (Figure 11.3.21). It is published in the literature that C3d levels are increased in RA 
and SLE (Morrow et al., 1983), suggesting, as C3d is a precursor to C3dg, this molecule 
may also be increased within these diseases, although this is not published within the 
current literature. Exploration into the C3dg levels with the RA serum samples used in this 
report would have shed light onto this unanswered question, but due to the lack of C3dg-
specific ELISA reagents commercially available, this was not investigated in the present 
study. The published study showed that increased C3d levels were proportional with 
increased disease activity in RA (Morrow et al., 1983), suggesting a mechanism in which the 
decrease in sCD21 within these patients leads an increased number of C3dg-immune 
complexes available to bind and activate cells as less C3dg is cleared by sCD21, resulting in 
worsened disease. This mechanism would explain the observation that decreased sCD21 
levels correlate with an increased disease severity observed within the patients investigated 
within this study (Figure 11.3.7). Interestingly, C3dg is reported to have a plasma half-life of 
4 hours (Teisner et al., 1983) and the estimated half-life of sCD21 is approximately 20 hours 
(Ciechanover et al., 1989). As sCD21 has the ability to bind to this protein, it is feasible to 
suggest that this action affects the half-life of C3dg by binding and clearing it from the 
system. If this were to be true, the half-life of C3dg within patients with lower sCD21 levels 
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would increase, leading to the increased levels found in the plasma and an increase C3dg-
mediated immune response; another mechanism in which decreased levels of sCD21 could 
lead to increased pathology symptoms.  
A recent publication reported that a fibroblast subset, characterised by the expression of 
podoplanin, THY1 membrane glycoprotein and cadherin-11, but lacking CD34, is expanded 
in patients with RA compared with those with osteoarthritis (Mizoguchi et al., 2018). These 
cells were shown to be proliferative and to secrete proinflammatory cytokines, therefore are 
thought to have a pathogenic role in the development of the RA disease phenotype, 
subsequently shown to be inflammatory sublining layer fibroblasts (Croft et al., 2019). It is 
known that an increase in synovial lining fibroblasts correlates with disease severity (DAS28 
score) and disease duration (Izquierdo et al., 2011). Single cell analysis of synovial 
fibroblasts in both human and mice show that C3 is produced by the sublining inflammatory 
fibroblasts in the joint of both RA patient biopsies and in mice (Croft et al., 2019). The 
precursors C2 and C4 producing the C3 convertase are also expressed by fibroblasts. 
These results further suggest that there could be an increased concentration of C3dg 
produced within the joint of RA patients leading to a microenvironment for activation of 
pathogenic joint B cells. As sCD21 concentration is decreased within these patients and has 
been shown to have the ability to prevent the binding of C3dg to B cells, the “brake” is 
removed from the system and therefore this increase in C3dg is not removed and 
overactivation of the immune system can occur. These data further support the hypothesis 
that sCD21 could have an important role in the modulation of the immune response.  
Two forms of sCD21 were used in experiments investigating the proteins ability to block 
C3dg binding to B cells; full length rc-CD21 and the ligand binding site only, SCR1/2. 
Interestingly, the full-length receptor blocks binding of C3dg more efficiently than SCR1/2, 
IC50 3.94 nM and 19.42 nM, respectively (Figure 11.3.21). These results reflect published 
surface plasmon resonance studies investigating interactions between CD21 and C3dg (Ling 
et al., 1991). These studies showed that the Kd value for C3dg binding to SCR1/2 was lower 
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than that of the full-length protein, SCR1-15, 22.4 nM and 27.1 nM, respectively. This data 
also suggests that the full-length protein has a higher affinity for C3dg than the binding site 
alone, mirroring the data within this report. This is important as blockage of binding can still 
occur at physiological concentrations, ~2.75 nM sCD21, using full length receptor but does 
not occur at this concentration using the binding site alone.  
12.2.2.3 sCD21 blocks activation of CD21+ B cell lines  
 
As it was shown that physiological concentrations of sCD21 can block binding of C3dg to its 
receptor, the next step in this investigation was to understand if the soluble receptor could 
block activation of B cells by disrupting C3dg-receptor interactions. It has been shown in the 
literature that C3dg lowers the threshold for activation of B cells (Carter et al., 1992), data 
which was replicated in this study (Figure 11.3.25). Experiments used a stimulation complex 
consisting of anti-IgM and C3dg, co-ligated with a neutravidin molecule (Figure 11.3.22). 
This co-ligation was shown to be essential to the co-activation action of C3dg (Figure 
11.3.27). These studies, using B cell lines Raji and Ramos, CD21+ and CD21- respectively 
(Figure 11.3.23A), showed that activation with anti-IgM occurs in a concentration dependent 
manner and that stimulation with anti-IgM/C3dg complexes causes increased activation of 
CD21+ Raji cells (Figure 11.3.25A). This response was confirmed as CD21-dependent, as 
the addition of C3dg to the stimulation complex had no effect on CD21- Ramos cells, which 
are only activated by anti-IgM (Figure 11.3.25B). C3dg (0.3 µg/ml) was shown to 
synergistically activate CD21+ Raji cells with low anti-IgM concentrations (0.03 µg/ml) (Figure 
11.3.26A). Stimulation with these reagents alone had no effect on activation status of the 
cell, however together activation was observed at levels similar to stimulation with high 
concentrations of anti-IgM (1 µg/ml), therefore confirming that C3dg lowers the threshold for 
activation of CD21+ B cells. This synergistic response was not seen in CD21- Ramos cells 
(Figure 11.3.26B).  
Soluble CD21 and the CD21 blocking antibody, FE8, were then used to investigate whether 
blockage of B cell activation could be a role of sCD21, something that has not been 
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previously reported in human studies. Both reagents were shown to block activation of 
CD21+ Raji cells in a concentration dependent manner using the chosen stimulation complex 
(1 µg/ml neutravidin, 0.3 µg/ml C3dg and 0.3 µg/ml anti-IgM) (Figure 11.3.31). Activation 
was not blocked in CD21- Ramos cells or cells stimulated with high anti-IgM concentrations 
alone (1 µg/ml) using these reagents, confirming the response was CD21- and C3dg-
dependent.  
Together these experiments support the hypothesis that sCD21 can block activation of B 
cells by binding to C3dg-opsonised immune complexes and preventing them from binding to 
membrane bound CD21 expressed by these cells. As these data have shown that sCD21 
has the ability to bind C3dg, thereby preventing binding to CD21 (Figure 11.3.21) and co-
activation of B cells (Figure 11.3.33), a decrease in sCD21 levels, seen in RA patient serum 
(Figure 11.3.4), would subsequently cause an increase in the number of C3dg-immune 
complexes available to bind to and activate these cells and other autoreactive B cells. 
Therefore, the lower the concentration of sCD21 within the system, an increased number of 
potentially harmful B cells can be activated; supported by the correlation between lower 
sCD21 concentrations in patients with more severe symptoms in RA (Figure 11.3.7). As this 
decrease in sCD21 could be due to a reduced expression of CD21 on B cells, the CD21-/low 
B cell population may have another pathogenic response that has not yet been explored. 
Together with observations that CD21-/low B cell populations fail to induce tyrosine 
phosphorylation cascades or increased concentrations of intracellular calcium upon BCR 
aggregation, both responses known to be enhanced by CD21/CD19 co-complex ligation to 
the BCR, the loss of CD21 and therefore the CD21/CD19 complex could lead to defects in B 
cell activation. Coligation of the CD21/CD19 complex to membrane IgM has been shown to 
lower the threshold for activation of B cells in this and previous studies (Carter et al., 1992), 
however, it has been reported that CD21-/low B cells up-regulate genes encoding molecules 
to increase B cell activation and proliferation (Isnardi et al., 2010) and are known to “bypass” 
T cell help in activation pathways by providing their own antigen complexes with C3dg 
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(Edwards et al., 1999). Due to these observations, it is feasible to suggest that, the CD21-/low 
B cell subset replaces the need for co-activation with CD21 and even stimulation through the 
BCR to allow proliferation, therefore the cells may be contributing towards their own survival.  
 
12.3 Remaining questions and future work 
12.3.1 Unidirectional transfer of C3dg-opsonised antigen between CD21 
expressed on B cells and FDCs 
 
The data presented in this study suggests that it is higher CD21 receptor number expression 
on FDCs compared to B cells that allows for unidirectional antigen transfer to occur rather 
than the differential expression of the long isoform of CD21 by FDCs.  
Although FDCs were shown to express over 30-fold more CD21 receptors on their cell 
surface than B cells and the receptor density was predicted to be ~3-fold greater on these 
cells; experiments to confirm receptor density were not undertaken. Therefore, this remains 
a question to answer to further validate this mechanism of antigen transfer.  
Results from experiments using FE8 to block binding of C3dg immune complexes to CD21 
receptors on FDCs and B cells, as well as transiently transfected HEK293T cells expressing 
CD21S or CD21L, suggest that the CD21L isoform does not have higher affinity ligand 
interactions than that of CD21S, therefore this may not be the reason for unidirectional 
transfer of antigen complexes. To further expand on these observations, competition assays 
between C3dg and FE8 in which C3dg is pre-bound to CD21 receptors on the surface of the 
cell and FE8 is used to compete for binding of the ligand binding site could be undertaken. 
Previous studies have demonstrated that FE8 can remove prebound ligands from the CD21 
receptor in B cells derived from human tonsil (Wolfgang et al., 1998), however the 
comparison between CD21 receptors on FDCs and B cells, and hence the two isoforms, has 
not been undertaken at present. These experiments would shed further light towards a 
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conclusion about potential differential affinity of the CD21 receptor for its ligands on FDCs 
and B cells.  
Additionally, experiments to further investigate the differential affinity of C3dg binding 
between the long and the short isoform directly would include using immobilised long and 
short specific CD21 protein, SCR1-16 and SCR1-15 respectively, and surface plasmon 
resonance techniques. This has been done previously using the receptor binding site alone, 
SCR1-2, and the full-length receptor, SCR1-15, revealing the full-length receptor has a 
higher affinity for its ligand than the binding site alone (Ling et al., 1991). These experiments 
would further confirm binding affinity however it is also important to consider the Koff rate of 
C3dg from the different isoforms of CD21. It is possible that the long form of CD21 is able to 
bind to its ligand for a longer time period than CD21S and therefore the interactions between 
CD21L and its ligand may be more stable than that of CD21S. This could be another 
potential mechanism responsible for unidirectional transfer of C3dg between B cells and 
FDCs.  
If this work was to be undertaken, the hypothesis that receptor number is responsible for 
unidirectional transfer, presented here, would be further solidified.  
 
12.3.1 The function of sCD21 in health and disease 
 
The remainder of the work in this thesis focused on the function of the soluble form of CD21. 
Data presented here suggests a role for sCD21 in the modulation of the immune response 
through binding C3dg-opsonised immune complexes to prevent activation of B cells.  
pERK activation experiments were undertaken using B cell lines Raji and Ramos, due to the 
lack of replicable data obtained using primary B cells within these assays. To add further 
relevance to this data, and if additional time had been available, modifications could be 
made to the current protocol to allow assays to be undertaken in primary B cells that result in 
the production of more reliable data.  
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This report reproduced data from the literature, showing how sCD21 concentration 
decreases in the serum of RA patients compared to age-matched healthy volunteers (Figure 
11.3.4). Additional observations were added to what is already know by assessing disease 
severity, which revealed a correlation between lower concentrations of sCD21 and a more 
prevalent disease phenotype (Figure 11.3.7). In contrast to the decrease in sCD21, it is 
known that C3d levels are increased in RA (Morrow et al., 1983), suggesting that C3dg may 
also be increased in these diseases. The increase in C3d and decrease in sCD21 suggests 
a lack of clearance of complement components may occur. It would be interesting to explore 
the concentration of C3dg within the RA patient samples used within this study and compare 
C3dg and sCD21 levels. This would confirm whether a decrease in sCD21 leads to the 
increase in complement found in RA. As no specific C3dg reagents are available at present, 
a C3dg-specific ELISA would need to be developed to investigate this question and measure 
protein levels within the serum.  
Data from patients treated with Rituximab suggest B cells as a source of sCD21. In disease, 
populations of CD21-/low B cells are found, which could be a mechanism leading to the 
decrease in sCD21 in these pathologies. Further experiments would be needed to confirm 
this response; these could include measuring the amount of sCD21 produced in vitro by 
CD21-/low B cells and CD21+ B cells. Additionally, culture and measurement of sCD21 
produced by B cells derived from patients with RA compared to healthy controls would also 
provide additional evidence that these cells produce less soluble protein in disease 
phenotypes. 
At present the mechanism for production of sCD21 is only speculative. It is thought to be 
cleaved from the cell surface but no direct evidence for this has been published to date. To 
address this further, as well as further investigating B cells as a source of sCD21, the effect 
of proteases and protease inhibitors could be assessed by measuring the sCD21 
concentration of cell cultures. Increases in sCD21 concentration within culture media, 
assessed by ELISA, and decreased in membrane CD21 receptors on the surface of the 
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cells, assessed by flow cytometry, would indicate a role for that protease in cleavage of the 
protein to form sCD21. In contrast, a decrease in sCD21 production and an increase in 
CD21 receptors on the surface upon addition of a protease inhibitor would imply a function 
for that protease in the release of the protein. Of course, it is possible that sCD21 is not 
released from the cell surface by proteatic cleavage at all, but as the protein is identical to its 
membrane bound form minus the transmembrane and intracellular domain, cleavage by a 
membrane protease is a very likely mechanism for protein release.  
12.4 Thesis synopsis 
The first hypothesis of this work addressed the unidirectional transfer of C3dg-opsonised 
antigen complexes between CD21 receptors on B cells and CD21 receptors on FDCs. The 
hypothesis was two-fold, first investigating whether this transfer was due to receptor number 
on the cell surface of the different cell types and the secondly investigating differential ligand 
binding abilities by CD21S and CD21L expressed on B cells and FDCs, respectively. As 
data collected here suggests that CD21L does not have a higher affinity for C3dg than 
CD21S, the following mechanism for unidirectional transfer of antigen is proposed (Figure 
12.4.1). 
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B cells collect C3dg-antigen complexes from SCS macrophages and shuttle the antigen 
bound to their CD21 cell surface receptors to FDCs zones. Interaction between these cells 
occurs through the binding of CD21 on the FDC to C3dg on the immune complex. As FDCs 
express an increased number of CD21 receptors on their cell surface compared to B cells, a 
greater number of interactions between the FDC and the opsonised immune complex 
occurs. C3dg may naturally dissociate from CD21 receptors on the B cell surface due to 
weak ligand-receptor interactions, and due to the increased interactions on FDCs remains 
bound to this cell and is subsequently internalised by the cell. Alternatively, as antigen bound 
CD21 receptors are actively internalised by FDCs, antigen complexes are pulled off the B 
cells due to the high number of interactions between membrane bound CD21 receptors on 
FDCs compared with that of B cells, if dissociation has not already occurred. CD21 bound 
antigen is retained in non-degradative endosomal compartments and recycled to the cell 
surface for presentation to antigen-specific B cells leading to an increased specific antibody 
response.  
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The second hypothesis investigated as part of this work concerned the soluble form of CD21 
and its role in health and disease. The hypothesis was derived from the observation that 
sCD21 concentrations decrease in autoimmune diseases, therefore this protein may be 
acting as a break on the immune system to dampen C3dg-mediated immune responses, a 
mechanism that is removed in diseases with decreased sCD21 concentrations, 
consequently leading to pathogenic immune responses that result in disease phenotypes. 
Results presented in this investigation show that sCD21 levels in RA patients treated with 
Rituximab have further decreased sCD21 levels, suggesting B cells as an origin of this 
protein. Additionally, sCD21 was shown to have the ability to prevent C3dg binding to B cells 
and prevent co-activation of B cells with anti-IgM/C3dg stimulation complexes. Taken 
together these results point to the following mechanism for the role of sCD21 in health and 
disease.  
In health, sCD21 is produced by CD21+ B cells at a concentration allowing the balance of 
activation of B cells by C3dg immune complexes and blockage of the binding of these 
complexes to CD21 receptors on B cells to prevent over activation of the immune response. 
In disease, a population of pathogenic B cells which are CD21low/- are described. As these 
cells express lower levels of CD21, and B cells are thought to be the origin of sCD21, this 
could be a reason for decreased sCD21 production within patients with autoimmune disease 
(Figure 12.4.2). Pathogenic fibroblast subsets, expanded in RA, produce increased C3 levels 
(Mizoguchi et al., 2018), potentially leading to increased C3dg within the serum. The low 
sCD21 concentration is unable to prevent binding of this C3dg and opsonised immune 
complexes to B cells, therefore resulting in the overactivation of the immune response and 
pathogenic B cell responses. 
Together this data has provided additional insight into the mechanism of antigen transfer in 
germinal centres and suggested a potential mechanism for autoimmune disease 
development through investigating the functions of CD21 in the germinal centre as a 
membrane bound receptor and periphery as a soluble protein. 
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